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1. INTRODUCTION and BACKGROUND 
 
IL-2 is a potent immunomodulator whose major function is the activation of various cells of the 
immune system including T cells, B cells, NK cells and macrophages. 
Its receptor is expressed at low levels on around 5% of resting peripheral blood mononuclear 
cells but is rapidly transcribed and expressed upon cell activation and is implicated in the 
generation of effector cells from antigen stimulated T cells. 
Interestingly it has been shown to be expressed constitutively by a small population of regulatory 
T cells, which have a suppressive activity. 
 
Given the potent immunomodulatory effect of IL-2 on T cells and the fact that the IL-2 receptor 
(in particular IL-2Rα also known as CD25 antigen) has been found to be highly expressed by T 
cells in some autoimmune diseases, a monoclonal antibody designed to bind with high affinity 
the CD25 antigen has the potential to prevent at least some of the biological activities of IL-2.  
However, it is difficult to foresee which sub population of CD25+ cells will be most inhibited by 
anti-CD25 blocking antibodies in vivo and such differential effects would impact the potential 
clinical use since the key to successful anti- CD25 therapy is to elicit the correct balance between 
effector and regulatory T cells. 
 
The therapeutic antibody presented herein designated as Anti- CD25 mAb is a fully human IgG1k 
monoclonal antibody (mAb) against IL-2Rα generated using transgenic mice containing an 
unrearranged human antibody repertoire in which endogenous murine antibody expression has 
been knocked out. Mice were then immunized with soluble and cell-bound CD25. Hybridoma 
cell cultures originating from the fusion of murine splenocytes and a human myeloma cell line 
were then established for the production of anti-CD25 monoclonal antibodies.  
Among the different monoclonals obtained, the drug candidate antibody was selected based on 
its ability to inhibit the binding of IL-2 to IL-2Rα in comparison to two commercially available 
products (a humanized anti- IL-2R and a chimeric human and mouse anti- IL-2R). 
The potential competitive advantages of Anti- CD25 mAb are 3-5 times higher affinity for human 
CD25 than competitors and the fact that it is a fully humanised mAb, potentially less 
immunogenic, leading to longer duration of therapeutic effect. 
 
A number of potential therapeutic indications were then envisaged for Anti- CD25 mAb 
including rheumatoid arthritis (RA), multiple sclerosis (MS), scleroderma, skin disorders like 
psoriasis and atopic dermatitis, ulcerative colitis, asthma, type 1 diabetes and heart transplant 
rejection. Among those, it is felt that the great therapeutic promise could in the clinical setting of 
different forms of MS. 
Hence, Anti- CD25 mAb is presented with a potential therapeutic application in T cell mediated 
diseases and with primary indication of Multiple Sclerosis (MS). 
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1.1 CD25 (Interleukin-2 receptor) and autoimmune diseases 
 
1.1.1 CD25 / TAC: α-chain of IL-2 receptor 
 
CD25 / TAC is the unique α-chain of the IL-2 receptor (IL-2Rα). 
 
IL-2 is a key regulator of normal immune functions, acting on T cells, B cells and natural killer 
cells. CD25 is highly expressed on activated T cells and is a clinically validated target for the 
development of novel mAb therapies that block IL-2R function inhibiting, in turn, T cell 
proliferation. 
 
CD25-specific mAb therapies have proven efficacy in the treatment of a number of T cell 
mediated diseases, including organ transplant rejection and autoimmune disease, such as 
multiple sclerosis (MS) and uveitis. 
 
1.1.1.1 Structure and function of the IL-2 receptor 
 
The high-affinity interleukin-2 receptor (IL-2R) consists of three subunits: the α-chain (IL-2Rα; 
also known as CD25), the β-chain (IL-2R β; also known as CD122) and the common cytokine-
receptor γ-chain (γ c; also known as CD132). It is thought that in the absence of IL-2, these 
subunits are not pre-assembled on the surface of an IL-2R-expressing T cell. The concomitant 
expression of the all three chains is indispensable for IL-2 signaling to be executed [1]. 
 
 
 
Fig. 1: IL-2 receptor (IL-2R) subunits: α- (CD25), β- (CD122) and γ-chains (CD132) 
 
 
The binding of IL-2 to IL-2Rα drives the association of this subunit with IL-2R β and the γ chain 
to form a stable heterotrimer, which then leads to the initiation of signal transduction. 
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Fig. 2: IL-2 activation pathway 
 
Janus activated kinase 3 (JAK3) molecules that are associated with the γ c, and JAK1 molecules that are associated 
with IL-2R β, phosphorylate key tyrosine residues in the cytoplasmic tail of IL-2R β, the γ c and the JAK molecules 
themselves. This amplifies the association of these tyrosine kinases and induces the association of the adaptor SHC 
(SRC-homology-2-domain-containing transforming protein C), and either signal transducer and activator of 
transcription 5 (STAT5) or STAT3, with the cytoplasmic tail of IL-2R β. The complexed SHC allows activation of the 
mitogen-activated protein kinase (MAPK)- and phosphatidylinositol 3-kinase (PI3K)–AKT-signalling pathways. 
Tyrosine residues in STAT5 are also phosphorylated, leading to the dimerization of STAT5 and its translocation to 
the nucleus where it regulates STAT5-responsive genes. GRB2, growth-factor-receptor-bound protein 2; SOS, son 
of sevenless homologue. 
 
The common γ-chain is shared by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 and 
its mutation causes severe combined immunodeficiencies [2]. The β - and γ chain without the α-
subunit build the β -/γ- complex, a form of the IL-2R with intermediate affinity, which also binds 
IL-15. Therefore, both cytokines (IL-2 and IL-15) compete for binding to the β -/γ- complex. 
This intermediate affinity IL-2R is present on NK cells and resting T cells [3]. Different α-chains 
for the IL-2 receptor, together with the β -/γ- complex, complete the high-affinity form of each 
receptor [4]. Upon activation, expression of the α-chain (CD25) is rapidly up-regulated on the 
cell surface [5]. Activated T cells, regulatory T cells (Tregs) [1] and NK cells [6] express high 
levels of CD25 and expression of the high-affinity IL-2R is mostly limited to these cell 
populations. Isolated expression of the α-chain (CD25) is not sufficient to trigger the IL-2 
signaling pathway because CD25 by itself displays the low-affinity form of the IL-2R that is 
non-functional with respect to IL-2 internalization and signaling due to its short cytoplasmic tail 
[5]. CD25 is mainly involved in IL-2 binding thereby stabilizing a secondary binding site for the 
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β-chain and recruiting γ-chain to the cell surface [7]. Despite the absolute requirement for the γ-
chain in IL-2 signaling, the signal transduction itself does not act via its cytoplasmic tail. The 
majority of known pathways are linked to the receptor via the β -chain, generally through 
phosphorylated cytoplasmic tyrosine residues that recruit various non-receptor-type protein 
tyrosine kinases (PTKs), which trigger an intracellular signaling cascade [8]. Furthermore, it has 
been demonstrated that the IL-2R complex is linked to at least three distinct signaling pathways 
leading to the induction of the target genes c-fos/c-jun, c-myc and bcl-2 [9]. All these pathways 
are essential for IL-2- mediated proliferative signaling and co-operate with each other to ensure a 
full-scale signal transduction [8]. 
 
In contrast to β- and γ-chains, CD25 also exists in a soluble form that  not the product of a 
unique post-transcriptional splicing event [10] but is most likely derives from proteolytic 
cleavage of surface CD25 [11] rather than originating from a unique post-transcriptional splicing 
event [10]. The soluble form of CD25 binds IL-2 efficiently [12] but with lower affinity than the 
β-/γ complex, with a dissociation constant similar to that of surface CD25 [13]. 
 
Signaling via IL-2R mediates multiple biological processes in various cell populations, e.g. 
proliferation and differentiation of B cells [14] and NK cells [15]. However, T cells remain the 
major target of IL-2 [16]. IL-2 is secreted after encounter of the TCR/MHC-complex (the antigen 
presenting cell and T cell receptor interaction is required for antigen recognition by T 
lymphocytes), binds autocrine to the high affinity IL-2R on the T-cell surface and thereby allows 
entrance into the cell cycle and clonal expansion of activated T cells [3]. IL-2 is produced 
primarily by activated CD4+ T cells and CD8+ T cells [17]. 
 
Interestingly, involvement of IL-2 signaling in the homeostasis of CD25high Tregs has been 
described [1]. Treg cells are a minor subpopulation of T cells that develop in the thymus and 
migrate to the periphery, where their main role is to suppress self-reactive T cells that escape 
negative selection in the thymus. Treg cells not only prevent autoimmunity but also control a 
broad range of T-cell-dependent immune responses in vivo [18]. So, functionally Treg cells also 
inhibit the rejection of transplants, prevent the induction of antitumour responses and regulate 
the immune response to infectious diseases. Although much remains to be learned about the 
basis of Treg -cell generation, specificity and inhibitory activity, there is increasing evidence that 
points to a mandatory role for IL-2–IL-2R signalling in the development and peripheral activity 
of Treg cells [19]. 
 
1.1.1.2 IL -2 and T –Cell response 
 
The idea that IL-2 is an essential cytokine for the production of Treg cells is based on recent data. 
However, the importance of IL-2 as a potent T-cell growth factor has been recognized for more 
than 20 years. 
Three key findings, which have been well-documented in in-vitro studies, led to a widely held 
view that IL-2 is an essential cytokine for both generating and then limiting T-cell-dependent 
immune responses [20]. 
 
First, IL-2 has potent T-cell growth-factor activity [21]. The genes that encode IL-2 and the 
subunits of the IL-2R, especially IL-2Rα, are among the immediate early genes that are activated 
in T cells as a consequence of signalling through the TCR. After either CD4+ or CD8+ T cells 
have been activated, exogenous IL-2 levels are sufficient to induce a more than 1000-fold clonal 
expansion of these cells. Other cytokines have also been reported to function as T-cell growth 
factors, notably those with receptors that contain the γc [22]. 
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However, IL-2 is the most potent T-cell growth factor and the main γc-dependent cytokine that is 
secreted when T cells are initially activated in vitro. 
 
Second, T-cell proliferation and function in vitro can be substantially inhibited using monoclonal 
antibodies specific for either IL-2 or the IL-2R [23]. This finding provides the strongest support 
for a crucial role for IL-2 in the generation of an immune response. Furthermore, the ability to 
block many such responses supports the view that TCR ligation (signal 1) and co-stimulatory-
receptor(s) engagement (signal 2) induces the production of IL-2 and the expression of the IL-
2R; the subsequent IL-2–IL-2R interaction is then responsible for the proliferation of antigen-
activated T cells. Indeed, when the precursor frequency of the responding T cells is relatively 
low, such as for cells specific for antigen or alloantigen, blockade of the IL-2–IL-2R interaction 
abrogates T-cell proliferative responses. 
 
However, after strong stimulation through the TCR, such as that induced by mitogens or CD3-
specific antibody, T-cell proliferation is sometimes only partially inhibited by IL-2- or IL-2R-
specific antibodies [24]. 
It was argued that the failure to block these responses resulted from limitations of the inhibitory 
activity of the monoclonal antibodies. To block these responses, IL-2-specific or IL-2R-specific 
antibodies must substantially inhibit most of the IL-2–IL-2R interaction for a considerable time, 
under conditions in which the affinity of IL-2 for its receptor is 2–3 orders of magnitude higher 
than the monoclonal antibody binding to these proteins. Nevertheless, the high concentration and 
potency of the antibodies used were such that more substantial inhibition of proliferation would 
be anticipated if proliferation was driven by IL-2. More-recent data clearly indicate that some T-
cell proliferation occurs in vitro in an IL-2R-independent manner. This has best been shown 
using IL-2- or IL-2R-deficient mice, in which substantial proliferation to mitogen, CD3-specific 
antibody or specific antigen has been reported — although these responses were always reduced 
compared with those of control mice. The ability of T cells that are deficient in the IL-2–IL-2R 
pathway to respond to stimulation was not the result of an abnormal T-cell response occurring as 
a consequence of autoimmunity, because T-cell proliferation of IL-2- or IL-2R-deficient T cells 
occurred after the prevention of autoimmunity in these mice. Prevention of autoimmunity can be 
accomplished either by breeding TCR-transgenic mice onto IL-2-/- or IL-2Rα -/- genetic 
backgrounds so that the mice only express TCRs of a single defined specificity and therefore do 
not have autoreactive T cells, or it can be achieved by providing Treg cells to such mice. It is 
important to note that when IL-2- or IL-2R-deficient T cells from mice that are free from 
autoimmunity are activated to proliferate in vitro, these T cells are markedly deficient in effector 
functions, such as cytokine secretion and cytotoxic T lymphocyte (CTL) activity [25]. 
 
This finding indicates that a failure in effector function is not due to a lack of T-cell growth. 
Therefore, the simplest interpretation of these findings is that engagement of the TCR and co-
stimulatory molecules is sufficient to induce several rounds of T-cell proliferation in vitro, but 
more-extensive clonal expansion and differentiation into effector cells depend on IL-2. The 
molecular basis by which IL-2 controls effector-cell differentiation has not been extensively 
investigated, but recent studies indicate that IL-2 stabilizes the accessibility of the IL-4 gene, 
thereby influencing IL-4 secretion [26]. 
 
The third key activity of IL-2, which was also determined using in vitro studies, is its ability to 
sensitize activated T cells to undergo apoptosis or activation-induced cell death (AICD) by FAS- 
and tumour-necrosis factor (TNF)-dependent pathways [27]. AICD occurs when the TCR is 
engaged by antigen after substantial clonal expansion in response to IL-2 in vitro. It is thought 
that AICD is an important mechanism that greatly reduces the number of antigen-specific T cells 
and limits the immune response. A failure in AICD of autoreactive T cells was postulated to 
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account for the lymphoproliferation and lethal autoimmunity that is associated with IL-2-
deficiency and IL-2R-deficiency. Other γc-dependent cytokines, notably IL-4 and IL-7, also 
sensitize T cells to undergo AICD, but not as efficiently as IL-2 [28]. So, all of these in vitro 
studies place IL-2 in a central role for T-cell responses, by controlling the magnitude of clonal 
expansion, the development of effector cells and the subsequent contraction of the antigen-
specific T cells. 
 
1.1.1.3 IL -2 as a “signal 3” T –Cell immunity 
 
On the basis of the above information, it was proposed a model to account for the distinct 
requirements for IL-2 during T-cell-dependent immune responses in vitro and in vivo (Figure 3 - 
[1]). 
 
 
Fig. 3: IL-2 as a "signal 3" T-Cell immunity 
A naive T cell is activated after ligation of its T-cell receptor (TCR) (signal 1) and engagement of the co-stimulatory 
molecules CD28 and CD40 ligand (CD40L) (signal 2) during antigen presentation by a dendritic cell (DC). This is 
sufficient to induce several rounds of T-cell proliferation; however, this interaction is not sufficient for an effective 
T-cell-dependent immune response. Signal 3 is a crucial checkpoint for substantial clonal expansion of antigen-
specific T cells and development into effector cells. In tissue culture, engagement of the interleukin-2 receptor (IL-
2R) is the main mechanism of passing the signal 3 checkpoint. However, there are several sources of signal 3 
in vivo. It is probable that redundancy in the molecules that provide signal 3 is not limited to other common 
cytokine-receptor –γ chain (γc)-dependent cytokines. 
 
Engagement of the TCR (signal 1) and co-stimulatory molecules (signal 2) is sufficient to induce 
limited clonal expansion of T cells in vitro, but extensive amplification of these T cells and their 
differentiation into effector cells requires signals through the IL-2R (signal 3). This activity of 
IL-2 might be viewed as a crucial checkpoint that is required for a productive T-cell response. 
 
However, during in vivo T-cell-dependent immune responses in the absence of IL-2, 
considerable T-cell clonal expansion occurs, but effector-cell responses are impaired to a 
variable extent. Nevertheless, a protective immune response still ensues. In the absence of IL-2 
in vitro, one prediction of this model is that providing additional signals should restore one or 
more aspects of impaired T-cell activity. Supplementing cultures of IL-2- or IL-2R-deficient T 
cells with exogenous IL-4, IL-6 or TNF improved T-cell growth and effector activity [29]. So, 
both inflammatory and T-cell-derived cytokines might provide signal 3. Several members of the 
TNF-receptor superfamily, such as 4-1BB (also known as CD137), OX40 (also known as 
CD134) and CD27, are induced during T-cell activation and strongly enhance T-cell responses. 
These might also be candidates for signal 3 in vivo. Regardless of which molecule(s) can bypass 
IL-2 in vivo, its activity is more effective in reconstituting T-cell proliferation than effector 
activity, because defects in effector function were more commonly observed in IL-2-deficient 
and IL-2R-deficient mice. This also indicates that signal 3 is complex, because normal clonal 
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expansion of T cells is not always accompanied by a normal effector response. One simple 
explanation that could account for IL-2-independent T-cell clonal expansion in vivo is that other 
γ c-dependent cytokines provide this function. In some cases, this might be sufficient, because a 
JAK3-specific inhibitor has been shown to prolong survival of heart and kidney transplant [30]. 
 
However, when γc-deficient TCR-transgenic CD4+ T cells are challenged with antigen, 
substantial clonal expansion of these T cells readily occurred, showing that T cells clonally 
expand in response to antigen in vivo in the absence of signalling induced by any of the six 
cytokines that depend on the γc as a receptor subunit [31]. 
 
 
1.1.1.4 Clinical implications 
 
Mouse studies indicate that in vivo IL-2 is crucial for the differentiation of Treg cells and 
therefore for the maintenance of peripheral T-cell tolerance that it is required for the generation 
of effective T-cell-mediated immunity. This concept should now be considered when targeting 
IL-2 or the IL-2R in clinical settings, because CD4+ Treg cells (highly expressing CD25) and a 
functional role for IL-2 have also been identified in humans [32] [33]. A mutation in the CD25 
gene that leads to a lack of CD25 expression as well as of the high affinity IL-2R has been 
reported  in humans. This patient had anaemia, lymphadenopathy and multi-organ inflammatory 
infiltrates [34], symptoms that are similar to those of mice that are deficient in IL-2 or the IL-2R. 
Given this information and our new appreciation for the important contribution of IL-2 to the 
production of Treg cells, targeting IL-2 and/or the IL-2R in clinical settings is not synonymous 
with directly targeting the clonal expansion and development of effector T cells. 
 
IL-2 is being used in clinically to boost immunity in individuals who are infected with HIV and 
patients with AIDS, and also in patients with cancer, especially those with metastatic melanoma, 
acute myelogenous leukaemia or metastatic renal-cell carcinoma [35] [36]. Although IL-2 might 
boost an effector response, it might be prudent to consider whether this might also increase the 
number or potency of Treg cells. Such an effect could diminish immune responses, which would 
be undesirable if the goal of therapy is to augment immunity. The presence of Treg cells is also 
crucial for the maintenance of homeostasis of both peripheral CD4+ and CD8+ T cells, partly by 
preventing unwanted autoantigen-dependent T-cell activation and by controlling CD8+ memory 
T cells [37]. So, the capacity of IL-2 to reset an imbalanced immune compartment, as observed 
in HIV/AIDS patients [38], might be attributed partly to restoring Treg cells, rather than solely to 
boosting effector T cells. Consistent with this hypothesis, recent data show that treatment of HIV 
patients with IL-2 leads to decreased proliferation of CD4+ T cells while increasing the number 
of both naïve and memory T cells [39]. Interestingly, these changes were found to be associated 
with a clonal expansion of CD4+CD25+ T cells. However, it is still to be investigated if these 
cells are Treg cells. 
 
Investigational CD25-specific antibodies have been reported to transiently deplete peripheral Treg 
cells in mice [40]. Another class of agent that is potently cytotoxic for IL-2R+ cells is IL-2–
diphtheria toxoid fusion proteins, and these have been used clinically to target IL-2R+ 
lymphomas [41]; however, they could also target Treg cells. More- broadly acting drugs that 
potentially antagonize the action of IL-2, such as rapamycin, or drugs that suppress IL-2 
production, such as cyclosporin, might also affect Treg cells. Such outcomes might result in 
unwanted augmentation of immunity or induction of an autoimmune response, rather than 
inhibition of the undesirable immune response. 
 
By contrast, this inhibition of IL-2 or depletion of CD25+ T cells, which might reduce the 
Page 14 
number and function of Treg cells, could be beneficial for tumour immunity, because in this 
situation, the main goal is to increase self-reactivity towards tumour-associated antigens. 
Examples of enhanced tumour immunity have been reported in mouse models after depletion of 
Treg cells [42], and increased numbers of Treg cells have been detected in human cancer patients 
[43], raising the possibility that these cells might suppress the host immune response. However, 
to determine whether current interventions that target the IL-2R actually interfere with Treg -cell 
activity needs to be evaluated in patients undergoing therapy with CD25-specific antibodies or 
other agents that target IL-2 production. Because this is a serious issue, it also necessitates a 
better assessment of whether IL-2 is essential for the maintenance and homeostasis of peripheral 
Treg cells. In this regard, if the function of IL-2 is crucial only during thymic development, then 
redundant pathways might be sufficient to maintain the number and function of peripheral Treg 
cells, even when IL-2 is blocked in an immunocompetent individual. Consistent with this idea, it 
was reported that thymic reconstitution of the IL-2R was sufficient to correct the severe 
autoimmune syndrome that in mice is associated with IL-2Rβ -/- phenotype, even though the 
resulting peripheral Treg - cell pool does not express a functional IL-2R [44]. However, more 
studies are required to establish the contribution of IL-2 to peripheral mouse and human Treg 
cells. 
 
In clinical settings, IL-2R blockade has shown some efficacy in graft vs host disease, including 
transplant rejection and autoimmune diseases [45] [46]. The mechanism by which IL-2R-specific 
antibodies suppress these responses has not been precisely established, but these antibodies are 
thought to inhibit the activity of IL-2 on activated T cells. It might be relevant that CD25-
specific monoclonal antibodies are often used in combination with, or directly after, other 
immunosuppressant  that more-broadly target T-cell activation. To achieve a clinically relevant  
inhibitory response, the utility of targeting the IL-2R together with other aspects of T-cell 
activation is consistent with the observation, in mouse models, of an operational redundancy for 
the effective T-cell immune responses even when IL-2R function is absent. 
There is now evidence that the impaired production of Treg cells is sufficient to account for the 
lethal autoimmunity that is associated with IL-2-, IL-2Rα- and IL-2Rβ – deficiency in mice. 
Therefore, the main function of IL-2 seems to be the production of Treg cells and the maintenance 
of peripheral T-cell tolerance. One of the most important unanswered questions is what the 
outcomes of signalling through the IL-2R are for the development, homeostasis and functional 
activity of Treg cells. Furthermore, in therapeutic settings, manipulation of Treg -cell number or 
function might be accomplished by targeting IL-2 or the IL-2R. Conceptually, this is counter-
intuitive to the past emphasis on IL-2 as a driver of immune responses. But consistent with this 
hypothesis, challenge of IL-2- or IL-2R-deficient mice that have been rendered free of 
autoimmunity clearly shows that effective T-cell immunity is generated in the absence of IL-2. 
Therefore, although IL-2 is a dominant signal 3 for the generation of T-cell responses in vitro, 
there must be sufficient redundancy in vivo to compensate for the lack of IL-2. So, enhanced 
understanding of the nature of signal 3 in vivo, at both the immunological and molecular levels, 
might lead to better defined targets that can be used to inhibit both T-cell clonal expansion and 
effector responses. 
Page 15 
1.2 The Guideline ICH S6 (R1): Preclinical Safety Evaluation of Biotechnology – 
Derived Pharmaceuticals 
 
The ICH S6 guidance has been issued to provide general principles for designing scientifically 
acceptable preclinical safety evaluation programs, and may offer useful background in 
developing new biopharmaceuticals. 
 
The preclinical safety evaluation is needed to support clinical development and marketing 
authorization. 
 
The primary goals of preclinical safety evaluation are: 
 
1. to identify an initial safe dose and subsequent dose escalation schemes in humans; 
2. to identify potential target organs for toxicity and for the study of whether such toxicity is 
reversible; 
3. to identify safety parameters for clinical monitoring. 
 
This guidance is intended primarily to recommend a basic framework for the preclinical safety 
evaluation of biotechnology-derived pharmaceuticals. It applies to products derived from 
characterized cells through the use of a variety of expression systems including bacteria, yeast, 
insect, plant, and mammalian cells. The intended indications may include in vivo diagnostic, 
therapeutic, or prophylactic uses. The active substances include proteins and peptides, their 
derivatives, and products of which they are components; they could be derived from cell cultures 
or produced using recombinant deoxyribonucleic acid (DNA) technology, including production 
by transgenic plants and animals. Examples include but are not limited to: Cytokines, 
plasminogen activators, recombinant plasma factors, growth factors, fusion proteins, enzymes, 
receptors, hormones, and monoclonal antibodies. 
 
The principles outlined in this guidance may also be applicable to recombinant DNA protein 
vaccines, chemically synthesized peptides, plasma derived products, endogenous proteins 
extracted from human tissue, and oligonucleotide drugs. 
 
This document does not cover antibiotics, allergenic extracts, heparin, vitamins, cellular blood 
components, conventional bacterial or viral vaccines, DNA vaccines, or cellular and gene 
therapies. 
 
1.2.1 Specification of the Test Material 
 
Safety concerns may arise from the presence of impurities or contaminants. 
It is preferable to rely on purification processes to remove impurities and contaminants rather 
than to establish a preclinical testing program for their qualification. In all cases, the product 
should be sufficiently characterized to allow an appropriate design of preclinical safety studies. 
 
There are potential risks associated with host cell contaminants derived from bacteria, yeast, 
insect, plants, and mammalian cells. The presence of cellular host contaminants can result in 
allergic reactions and other immunopathological effects. The adverse effects associated with 
nucleic acid contaminants are theoretical but include potential integration into the host genome. 
For products derived from insect, plant, and mammalian cells, or transgenic plants and animals, 
Page 16 
there may be an additional risk of viral infections. 
 
In general, the product that is used in the definitive pharmacology and toxicology studies should 
be comparable to the product proposed for the initial clinical studies. 
 
The comparability of the test material during a development program should be demonstrated 
when a new or modified manufacturing process is developed or other significant changes in the 
product or formulation are made in an ongoing development program. Comparability can be 
evaluated on the basis of biochemical and biological characterization (i.e., identity, purity, 
stability, and potency). In some cases, additional studies may be needed (i.e., pharmacokinetics, 
pharmacodynamics and/or safety). The scientific rationale for the approach taken should be 
provided. 
 
1.2.2 Preclinical Safety Testing 
 
The objectives of the preclinical safety studies are to define pharmacological and toxicological 
effects not only prior to initiation of human studies but throughout clinical development. Both 
in vitro and in vivo studies can contribute to this characterization. Biopharmaceuticals that are 
structurally and pharmacologically comparable to a product for which there is wide experience in 
clinical practice may need less extensive toxicity testing. 
 
Preclinical safety testing should consider: 
1. Selection of the relevant animal species; 
2. age; 
3. physiological state; 
4. the manner of delivery, including dose, route of administration, and treatment regimen; 
5. stability of the test material under the conditions of use. 
 
Toxicity studies are expected to be performed in compliance with Good Laboratory 
Practice(GLP); however, it is recognized that some studies employing specialized test systems, 
which are often needed for biopharmaceuticals, may not be able to comply fully with GLP. In 
some cases, lack of full GLP compliance does not necessarily mean that the data from these 
studies cannot be used to support clinical trials and marketing authorizations. 
 
Conventional approaches to toxicity testing of pharmaceuticals may not be appropriate for 
biopharmaceuticals due to the unique and diverse structural and biological properties of the latter 
that may include species specificity, immunogenicity, and unpredicted pleiotropic activities. 
 
1.2.2.1 Biological activity / Pharmacodynamics 
 
Biological activity may be evaluated using in vitro assays to determine which effects of the 
product may be related to clinical activity. Due to the species specificity of many biotechnology-
derived pharmaceuticals, it is important to select relevant animal species for toxicity testing. 
In vitro cell lines derived from mammalian cells can be used to predict specific aspects of in vivo 
activity and to assess quantitatively the relative sensitivity of various species (including human) 
to the biopharmaceutical. The combined results from in vitro and in vivo studies assist in the 
extrapolation of the findings to humans. In vivo studies to assess pharmacological activity, 
including defining mechanism(s) of action, are often used to support the rationale of the 
proposed use of the product in clinical studies. 
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For monoclonal antibodies, the immunological properties of the antibody should be described in 
detail, including its antigenic specificity, complement binding, and any unintentional reactivity 
and/or cytotoxicity towards human tissues distinct from the intended target. Such cross-reactivity 
studies should be carried out by appropriate immunohistochemical procedures using a range of 
human tissues. 
 
1.2.2.2 Animal species / Model selection 
 
The biological activity together with species and/or tissue specificity of many biotechnology 
derived pharmaceuticals often preclude standard toxicity testing designs in commonly used 
species (e.g., rats and dogs). Safety evaluation programs should include the use of relevant 
species. A relevant species is one in which the test material is pharmacologically active due to 
the expression of the receptor or an epitope (in the case of monoclonal antibodies). Knowledge 
of receptor/epitope distribution can provide greater understanding of potential in vivo toxicity. 
 
Relevant animal species for testing of monoclonal antibodies are those that express the desired 
epitope and demonstrate a similar tissue cross-reactivity profile as for human tissues. This would 
optimize the ability to evaluate toxicity arising from the binding to the epitope and any 
unintentional tissue cross-reactivity. 
 
Safety evaluation programs should normally include two relevant species. However, in certain 
justified cases one relevant species may suffice (e.g., when only one relevant species can be 
identified or where the biological activity of the biopharmaceutical is well understood). 
 
Toxicity studies in non-relevant species may be misleading and are discouraged. When no 
relevant species exists, the use of relevant transgenic animals expressing the human receptor or 
the use of homologous proteins should be considered. While useful information may also be 
gained from the use of homologous proteins, it should be noted that the production process, 
range of impurities/contaminants, pharmacokinetics, and exact pharmacological mechanism(s) 
may differ between the homologous form and the product intended for clinical use. Where it is 
not possible to use transgenic animal models or homologous proteins, it may still be prudent to 
assess some aspects of potential toxicity in a limited toxicity evaluation in a single species, e.g., 
a repeated dose toxicity study of < 14 days duration that includes an evaluation of important 
functional endpoints (e.g., cardiovascular and respiratory). 
 
In recent years, there has been much progress in the development of animal models that are 
thought to be similar to the human disease. These animal models include induced and 
spontaneous models of disease, gene knockout(s), and transgenic animals. These models may 
provide further insight, not only in determining the pharmacological action of the product, 
pharmacokinetics, and dosimetry, but may also be useful in the determination of safety (e.g., 
evaluation of undesirable promotion of disease progression). In certain cases, studies performed 
in animal models of disease may be used as an acceptable alternative to toxicity studies in 
normal animals. The scientific justification for the use of these animal models of disease to 
support safety should be provided. 
 
1.2.2.3 Number / Gender of animals 
 
The number of animals used per dose has a direct bearing on the ability to detect toxicity. A 
small sample size may lead to failure to observe toxic events due to observed frequency alone 
regardless of severity. The limitations that are imposed by sample size, as often is the case for 
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nonhuman primate studies, may be in part compensated by increasing the frequency and duration 
of monitoring. Both genders should generally be used or justification given for specific 
omissions. 
 
1.2.2.4 Administration / Dose Selection 
 
The route and frequency of administration should be as close as possible to that proposed for 
clinical use. Consideration should be given to pharmacokinetics and bioavailability of the 
product in the species being used and to the volume which can be safely and humanely 
administered to the test animals. Consideration should also be given to the effects of volume, 
concentration, formulation, and site of administration. The use of routes of administration other 
than those used clinically may be acceptable if the route must be modified due to limited 
bioavailability, limitations due to the route of administration, or to size/physiology of the animal 
species. 
 
Dosage levels should be selected to provide information on a dose-response relationship, 
including a toxic dose and a no observed adverse effect level (NOAEL). For some classes of 
products with little to no toxicity, it may not be possible to define a specific maximum dose. In 
these cases, a scientific justification of the rationale for the dose selection and projected 
multiples of human exposure should be provided. To justify high dose selection, consideration 
should be given to the expected pharmacological/physiological effects, availability of suitable 
test material, and the intended clinical use. Where a product has a lower affinity to or potency in 
the cells of the selected species than in human cells, testing of higher doses may be important. 
The multiples of the human dose that are needed to determine adequate safety margins may vary 
with each class of biotechnology-derived pharmaceutical and its clinical indication(s). 
 
1.2.2.5 Immunogenicity 
 
Many biotechnology-derived pharmaceuticals intended for humans are immunogenic in animals. 
Therefore, measurement of antibodies associated with administration of these types of products 
should be performed when conducting repeated dose toxicity studies in order to aid in the 
interpretation of these studies. Antibody responses should be characterized (e.g., titer, number of 
responding animals, neutralizing or non-neutralizing) and their appearance should be correlated 
with any pharmacological and/or toxicological changes. Specifically, the effects of antibody 
formation on pharmacokinetic/pharmacodynamic parameters, incidence and/or severity of 
adverse effects, complement activation, or the emergence of new toxic effects should be 
considered when interpreting the data. Attention should also be paid to the evaluation of possible 
pathological changes related to immune complex formation and deposition. 
In most cases, the immune response to biopharmaceuticals is variable, like that observed in 
humans. If the interpretation of the data from the safety study is not compromised by these 
issues, then no special significance should be ascribed to the antibody response. 
 
The induction of antibody formation in animals is not predictive of a potential for antibody 
formation in humans. Humans may develop serum antibodies against humanized proteins, and 
frequently the therapeutic response persists in their presence. The occurrence of severe 
anaphylactic responses to recombinant proteins is rare in humans. In this regard, the results of 
guinea pig anaphylaxis tests, which are generally positive for protein products, are not predictive 
for reactions in humans; therefore, such studies are considered of little value for the routine 
evaluation of these types of products. 
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1.2.3 Specific Considerations 
 
1.2.3.1 Safety Pharmacology 
 
It is important to investigate the potential for undesirable pharmacological activity in appropriate 
animal models and, where necessary, to incorporate particular monitoring for these activities in 
the toxicity studies and/or clinical studies. Safety pharmacology studies measure functional 
indices of potential toxicity. These functional indices may be investigated in separate studies or 
incorporated in the design of toxicity studies. The aim of the safety pharmacology studies should 
be to reveal any functional effects on the major physiological systems (e.g., cardiovascular, 
respiratory, renal, and central nervous systems). Investigations may also include the use of 
isolated organs or other test systems not involving intact animals. All of these studies may allow 
for a mechanistically-based explanation of specific organ toxicities, which should be considered 
carefully with respect to human use and indication(s). 
 
1.2.3.2 Exposure Assessment 
 1.2.3.2.1 Pharmacokinetics and Toxicokinetics 
 
It is difficult to establish uniform guidance for pharmacokinetic studies for biotechnology-
derived pharmaceuticals. Single and multiple dose pharmacokinetics, toxicokinetics, and tissue 
distribution studies in relevant species are useful; however, routine studies that attempt to assess 
mass balance are not useful. Differences in pharmacokinetics among animal species may have a 
significant impact on the productiveness of animal studies or on the assessment of dose-response 
relationships in toxicity studies. 
 
Pharmacokinetic studies should, whenever possible, utilize preparations that are representative of 
those intended for toxicity testing and clinical use and employ a route of administration that is 
relevant to the anticipated clinical studies. Patterns of absorption may be influenced by 
formulation, concentration, site, and/or volume. Whenever possible, systemic exposure should be 
monitored during the toxicity studies. 
 
When using radiolabeled proteins, it is important to show that the radiolabeled test material 
maintains activity and biological properties equivalent to that of the unlabeled material. Care 
should be taken in the interpretation of studies using radioactive tracers incorporated into 
specific amino acids because of recycling of amino acids into nondrug related proteins/peptides. 
 
Some information on absorption, disposition, and clearance in relevant animal models should be 
available prior to clinical studies in order to predict margins of safety based upon exposure and 
dose. 
 1.2.3.2.2 Assays 
 
The use of one or more assay methods should be addressed on a case-by-case basis and the 
scientific rationale should be provided. One validated method is usually considered sufficient. 
Ideally, the assay methods should be the same for animals and humans. The possible influence of 
plasma binding proteins and/or antibodies in plasma/serum on the assay performance should be 
determined. 
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1.2.3.2.3 Metabolism 
 
The expected consequence of metabolism of biotechnology-derived pharmaceuticals is the 
degradation to small peptides and individual amino acids. Therefore, the metabolic pathways are 
generally understood. Classical biotransformation studies as performed for pharmaceuticals are 
not needed. 
 
Understanding the behaviour of the biopharmaceutical in the biologic matrix (e.g., plasma, 
serum, cerebral spinal fluid) and the possible influence of binding proteins is important for 
understanding the pharmacodynamic effect. 
 
1.2.3.3 Single Dose Toxicity Studies 
 
Single dose studies may generate useful data to describe the relationship of dose to systemic 
and/or local toxicity. These data can be used to select doses for repeated dose toxicity studies. 
Information on dose-response relationships may be gathered through the conduct of a single dose 
toxicity study or as a component of pharmacology or animal model efficacy studies. The 
incorporation of safety pharmacology parameters in the design of these studies should be 
considered. 
 
1.2.3.4 Repeated Dose Toxicity Studies 
 
Repeated dose Toxicity studies should be designed considering the previous selection of animal 
species. The route and dosing regimen (e.g., daily versus intermittent dosing) should reflect the 
intended clinical use or exposure. When feasible, these studies should include toxicokinetics. 
 
A recovery period should generally be included in study designs to determine the reversal or 
potential worsening of pharmacological/toxicological effects, and/or potential delayed toxic 
effects. For biopharmaceuticals that induce prolonged pharmacological/toxicological effects, 
recovery group animals should be monitored until reversibility is demonstrated. The duration of 
repeated dose studies should be based on the intended duration of clinical exposure and disease 
indication. This duration of animal dosing has generally been 1-3 months for most biotechnology 
derived pharmaceuticals. 
 
For biopharmaceuticals intended for short-term use (e.g., < to 7 days) and for acute life-
threatening diseases, repeated dose studies up to 2 weeks duration have been considered 
adequate to support clinical studies as well as marketing authorization. For those 
biopharmaceuticals intended for chronic indications, studies of 6 months duration have generally 
been appropriate, although in some cases shorter or longer durations have supported marketing 
authorizations. For biopharmaceuticals intended for chronic use, the duration of long-term 
toxicity studies should be scientifically justified. 
 
1.2.3.5 Immunotoxicity Studies 
 
Many biotechnology-derived pharmaceuticals are intended to stimulate or suppress the immune 
system and, therefore, may affect not only humoral but also cell-mediated immunity. 
Inflammatory reactions at the injection site may be indicative of a stimulatory response. It is 
important, however, to recognize that simple injection trauma and/or specific toxic effects 
caused by the formulation vehicle may also result in toxic changes at the injection site. In 
addition, the expression of surface antigens on target cells may be altered, which has 
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implications for autoimmune potential. Immunotoxicological testing strategies may require 
screening studies followed by mechanistic studies to clarify such issues. Routine tiered testing 
approaches or standard testing batteries, however, are not recommended for biotechnology-
derived pharmaceuticals. 
 
1.2.3.6 Reproductive Performance and Developmental Toxicity Studies 
 
The need for reproductive/developmental toxicity studies is dependent upon the product, clinical 
indication and intended patient population. The specific study design and dosing schedule may 
be modified based on issues related to species specificity, immunogenicity, biological activity, 
and/or a long elimination half-life. For example, concerns regarding potential developmental 
immunotoxicity, which may apply particularly to certain monoclonal antibodies with prolonged 
immunological effects, could be addressed in a study design modified to assess immune function 
of the neonate. 
 
1.2.3.7 Genotoxicity Studies 
 
The range and type of genotoxicity studies routinely conducted for pharmaceuticals are not 
applicable to biotechnology-derived pharmaceuticals and therefore are not needed. Moreover, 
the administration of large quantities of peptides/proteins may yield uninterpretable results. It is 
not expected that these substances would interact directly with DNA or other chromosomal 
material. With some biopharmaceuticals, there is a potential concern about accumulation of 
spontaneously mutated cells (e.g., via facilitating a selective advantage of proliferation) leading 
to carcinogenicity. The standard battery of genotoxicity tests is not designed to detect these 
conditions. Alternative in vitro or in vivo models to address such concerns may have to be 
developed and evaluated. 
 
1.2.3.8 Carcinogenicity Studies 
 
Standard carcinogenicity bioassays are generally inappropriate for biotechnology-derived 
pharmaceuticals. However, product-specific assessment of carcinogenic potential may still be 
needed depending upon duration of clinical dosing, patient population, and/or biological activity 
of the product (e.g., growth factors, immunosuppressive agents, etc.). When there is a concern 
about carcinogenic potential, a variety of approaches may be considered to evaluate risk. 
 
Incorporation of sensitive indices of cellular proliferation in long-term repeated dose toxicity 
studies may provide useful information. Careful consideration should be given to the selection of 
doses. The use of a combination of pharmacokinetic and pharmacodynamic endpoints with 
consideration of comparative receptor characteristics and intended human exposures represents 
the most scientifically based approach for defining the appropriate doses. The rationale for the 
selection of doses should be provided. 
 
 
 
1.2.3.9 Local Tolerance Studies 
 
Local tolerance should be evaluated. The formulation intended for marketing should be tested; 
however, in certain justified cases, the testing of representative formulations may be acceptable. 
In some cases, the potential adverse effects of the product can be evaluated in single or repeated 
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dose toxicity studies, thus obviating the need for separate local tolerance studies. 
 
1.2.4 Addendum to S6 
 
This addendum has been incorporated in the parent Guideline at the end of June 2011. 
 
The purpose of the addendum is to complement, provide clarification on, and update the 
following topics discussed in ICH S6: species selection, study design, immunogenicity, 
reproductive and developmental toxicity, and assessment of carcinogenic potential. The 
recommendations of this addendum further harmonize the nonclinical safety studies to support 
the various stages of clinical development among the regions of European Union (EU), Japan, 
and the United States. 
This guidance should facilitate the timely conduct of clinical trials, reduce the use of animals in 
accordance with the 3Rs (reduce/refine/replace) principles and reduce the use of other drug 
development resources. Although not discussed in this guidance, consideration should be given 
to the use of appropriate in vitro alternative methods for safety evaluation. These methods, if 
accepted by all ICH regulatory authorities, can be used to replace current standard methods. 
This guidance promotes safe and ethical development and availability of new pharmaceuticals. 
This addendum does not alter the scope of the original ICH S6 guidance. For biotechnology-
derived products intended to be used in oncology the guidance S9 Nonclinical Evaluation for 
Anticancer Pharmaceuticals (ICH S9) should be consulted. 
 
1.2.4.1 Species Selection 
 1.2.4.1.1 General Principles 
 
A number of factors should be taken into account when determining species relevancy. 
Comparisons of target sequence homology between species can be an appropriate starting point, 
followed by in vitro assays to make qualitative and quantitative cross-species comparisons of 
relative target binding affinities and receptor/ligand occupancy and kinetics. 
Assessments of functional activity are also recommended. Functional activity can be 
demonstrated in species-specific cell based systems and/or in vivo pharmacology or toxicology 
studies. Modulation of a known biologic response or of a pharmacodynamic (PD) marker can 
provide evidence for functional activity to support species relevance. 
Consideration of species differences in target binding and functional activity in the context of the 
intended dosing regimen should provide confidence that a model is capable of demonstrating 
potentially adverse consequences of target modulation. When the target is expressed at very low 
levels in typical healthy preclinical species (e.g., inflammatory cytokines or tumor antigens), 
binding affinity and activity in cell-based systems can be sufficient to guide species selection. 
 
In specific cases (i.e., where the approaches described above cannot be used to demonstrate a 
pharmacologically relevant species) tissue cross-reactivity (TCR) studies can be used to guide 
selection of toxicology species by comparison of tissue binding profiles between those human 
and animal tissues where target binding is expected. 
As described in ICH S6, when no relevant species can be identified because the 
biopharmaceutical does not interact with the orthologous target in any species, use of 
homologous molecules or transgenic models can be considered. 
For monoclonal antibodies and other related antibody products directed at foreign targets (i.e., 
bacterial, viral targets etc.), a short-term safety study (see ICH S6) in one species (choice of 
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species to be justified by the sponsor) can be considered; no additional toxicity studies, including 
reproductive toxicity studies, are appropriate. Alternatively, when animal models of disease are 
used to evaluate proof of principle, a safety assessment can be included to provide information 
on potential target-associated safety aspects. Where this is not feasible, appropriate risk 
mitigation strategies should be adopted for clinical trials. 
 1.2.4.1.2 One or two species 
 
If there are two pharmacologically relevant species for the clinical candidate (one rodent and one 
non-rodent), then both species should be used for short-term (up to 1 month duration) general 
toxicology studies, then longer term general toxicity studies in one species are usually 
considered sufficient. The rodent species should be considered unless there is a scientific 
rationale for using non-rodents. Studies in two non-rodent species are not appropriate. The use of 
one species for all general toxicity studies is justified when the clinical candidate is 
pharmacologically active in only one species. 
 1.2.4.1.3  Use of Homologous Proteins 
 
Use of homologous proteins is one of the alternative approaches described in ICH S6. Studies 
with homologous proteins can be used for hazard detection and understanding the potential for 
adverse effects due to exaggerated pharmacology, but are generally not useful for quantitative 
risk assessment; it can be possible to conduct safety evaluation studies using a control group and 
one treatment group for the study design and dose selected (e.g., maximum pharmacological 
dose). 
 
1.2.4.2 Study Design 
 1.2.4.2.1 Dose Selection and application of PK/PD Principles 
 
The toxicity of most biopharmaceuticals is related to their targeted mechanism of action; 
therefore, relatively high doses can elicit adverse effects, which are apparent as exaggerated 
pharmacology. 
 
A rationale should be provided for dose selection taking into account the characteristics of the 
dose-response relationship. Pharmacokinetic-pharmacodynamic (PK-PD) approaches (e.g., 
simple exposure-response relationships or more complex modeling and simulation approaches) 
can assist in high dose selection by identifying: 
1. a dose that provides the maximum intended pharmacological effect in the preclinical 
species; 
2. a dose that provides an approximately 10-fold exposure multiple over the maximum 
exposure to be achieved in the clinic. 
 
 
The higher of these two doses should be chosen for the high dose group in preclinical toxicity 
studies unless there is a justification for using a lower dose (e.g., maximum feasible dose). 
 
Where in vivo/ex vivo PD endpoints are not available, the high dose selection can be based on 
PK data and available in vitro binding and/or pharmacology data. Corrections for differences in 
target binding and in vitro pharmacological activity between the nonclinical species and humans 
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should be taken into account to adjust the exposure margin over the highest anticipated clinical 
exposure. 
 1.2.4.2.2 Duration of Studies 
 
For chronic use products, repeat dose toxicity studies of 6 months duration in rodents or non-
rodents are considered sufficient; the principles for duration of toxicology studies are outlined in 
ICH S9. 
 1.2.4.2.3 Recovery 
 
Recovery from pharmacological and toxicological effects with potential adverse clinical impact 
should be understood when they occur at clinically relevant exposures. This information can be 
obtained by an understanding that the particular effect observed is generally reversible/non-
reversible or by including a non-dosing period in at least one study, to examine reversibility of 
these effects, not to assess delayed toxicity. The demonstration of complete recovery is not 
considered essential. The addition of a recovery period just to assess potential for 
immunogenicity is not required. 
 1.2.4.2.4 Exploratory Clinical Trials 
 
The flexible approaches to support exploratory clinical trials as outlined in the guidance M3(R2) 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals (ICH M3(R2)) can be applicable to biopharmaceuticals. It is 
recommended that these approaches be discussed and agreed upon with the appropriate 
regulatory authority. 
 
1.2.4.3 Immunogenicity 
 
Such analyses in nonclinical animal studies are not relevant in terms of predicting potential 
immunogenicity of human or humanized proteins in humans. 
Measurement of anti-drug antibodies (ADA) in nonclinical studies should be evaluated when 
there is: 
1. evidence of altered PD activity; 
2. unexpected changes in exposure in the absence of a PD marker; 
3. evidence of immune-mediated reactions (immune complex disease, vasculitis, 
anaphylaxis, etc.). 
 
Characterization of neutralizing potential is warranted when ADAs are detected and there is no 
PD marker to demonstrate sustained activity in the in vivo toxicology studies. Neutralizing 
antibody activity can be assessed indirectly with ex-vivo bioactivity assay or an appropriate 
combination of assay formats for PK-PD, or directly in a specific neutralizing antibody assay. 
 
 
1.2.4.4 Reproductive and Developmental Toxicity 
 
Reproductive toxicity studies should be conducted in accordance with the principles outlined in 
the guidance S5(R2) Detection of Toxicity to Reproduction for Medicinal Products and Toxicity 
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to Male Fertility (ICH S5). 
 
The evaluation of toxicity to reproduction should be conducted only in pharmacologically 
relevant species. When the clinical candidate is pharmacologically active in rodents and rabbits, 
both species should be used for embryo-fetal development (EFD) studies, unless embryo-fetal 
lethality or teratogenicity has been identified in one species. 
 
Developmental toxicity studies should only be conducted in nonhuman primates (NHPs) when 
they are the only relevant species. When the clinical candidate is pharmacologically active only 
in NHPs, there is still a preference to test the clinical candidate. However, an alternative model 
can be used in place of NHPs if appropriate scientific justification is provided. 
When no relevant animal species exists for testing the clinical candidate, the use of transgenic 
mice can be considered. For products that are directed at a foreign target such as bacteria and 
viruses, in general, no reproductive toxicity studies would be expected. 
 1.2.4.4.1 Fertility 
 
For products where mice and rats are pharmacologically relevant species, an assessment of 
fertility can be made in one of these rodent species (see ICH S5). 
 
It is recognized that mating studies are not practical for NHPs. However, when the NHP is the 
only relevant species, the potential for effects on male and female fertility can be assessed by 
evaluation of the reproductive tract (organ weights and histopathological evaluation) in repeat 
dose toxicity studies of at least 3 months’ duration using sexually mature NHPs. If there is a 
specific cause for concern based on pharmacological activity or previous findings, specialized 
assessments such as menstrual cyclicity, sperm count, sperm morphology/motility, and male or 
female reproductive hormone levels can be evaluated in a repeat dose toxicity study. 
 
If there is a specific concern from the pharmacological activity about potential effects on 
conception/implantation and the NHP is the only relevant species, the concern should be 
addressed experimentally. A homologous product or transgenic model could be the only practical 
means to assess potential effects on conception or implantation when those are of specific 
concern. However, it is not recommended to produce a homologous product or transgenic model 
solely to conduct mating studies in rodents. 
 1.2.4.4.2 Embryo-Fetal Development (EFD) and Pre/Post-Natal Development (PPND) 
 
Potential differences in placental transfer of biopharmaceuticals should be considered in the 
design and interpretation of developmental toxicity studies. For products pharmacologically 
active only in NHPs, several study designs can be considered based on intended clinical use and 
expected pharmacology. One well-designed study in NHPs that includes dosing from day 20 of 
gestation to birth (enhanced PPND; ePPND) can be considered, rather than separate EFD and/or 
PPND studies. 
 
For the single ePPND study design described above, no Caesarian section group is warranted, 
but assessment of pregnancy outcome at natural delivery should be performed. This study should 
also evaluate offspring viability, external malformations, skeletal effects (e.g., by X-ray) and, 
ultimately, visceral morphology at necropsy. Ultrasound is useful to track maintenance of 
pregnancy but is not appropriate for detecting malformations. These latter data are derived from 
postpartum observations. Because of confounding effects on maternal care of offspring, dosing 
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of the mother postpartum is generally not recommended. Other endpoints in the offspring can 
also be evaluated if relevant for the pharmacological activity. The duration of the postnatal phase 
will be dependent on which additional endpoints are considered relevant based on mechanism of 
action. 
 
The developmental toxicity studies in NHP as outlined above are just hazard identification 
studies; therefore, it might be possible to conduct these studies using a control group and one 
dose group, provided there is a scientific justification for the dose level selected. An example of 
an appropriate scientific justification would be a monoclonal antibody that binds a soluble target 
with a clinical dosing regimen intended to saturate target binding. 
 1.2.4.4.3 Timing of Studies 
 
If women of child-bearing potential are included in clinical trials prior to acquiring information 
on effects on embryo-fetal development, appropriate clinical risk management is appropriate, 
such as use of highly effective methods of contraception (see ICH M3(R2)). 
 
For biopharmaceuticals pharmacologically active only in NHPs, where there are sufficient 
precautions to prevent pregnancy (see ICH M3(R2), section XI.C (11.3), paragraph 2), an EFD 
or ePPND study can be conducted during Phase III, and the report submitted at the time of 
marketing application. 
 
If the rodent or rabbit is a relevant species, see ICH M3(R2) for timing of reproductive toxicity 
studies. ICH M3(R2) should also be followed for the timing of data on fertility for products 
where rodents are relevant species. 
 
For oncology products which fall within the scope of ICH S9, see that guidance for aspects 
relating to timing of study conduct. 
 
1.2.4.5 Carcinogenicity 
 
The need for a product-specific assessment of the carcinogenic potential for biopharmaceutical 
should be determined with regard to the intended clinical population and treatment duration (see 
the guidance S1A The Need for Carcinogenicity Studies of Pharmaceuticals). 
 
This strategy could be based on a weight of evidence approach, including a review of relevant 
data from a variety of sources. The data sources can include published data (e.g., information 
from transgenic, knock-out or animal disease models, human genetic diseases), information on 
class effects, detailed information on target biology and mechanism of action, in vitro data, data 
from chronic toxicity studies and clinical data. In some cases, the available information can be 
sufficient to address carcinogenic potential and inform clinical risk without additional 
nonclinical studies. 
 
For products where there is insufficient knowledge about specific product characteristics and 
mode of action in relation to carcinogenic potential, a more extensive assessment might be 
appropriate (e.g., understanding of target biology related to potential carcinogenic concern, 
inclusion of additional endpoints in toxicity studies). The product-specific assessment of 
carcinogenic potential is used to communicate risk and provide input to the risk management 
plan along with labeling proposals, clinical monitoring, post-marketing surveillance, or a 
combination of these approaches. 
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Rodent bioassays (or short-term carcinogenicity studies) with homologous products are generally 
of limited value to assess carcinogenic potential of the clinical candidate. Alternative approaches 
can be considered as new strategies/assays are developed. 
See references  [52] [53] [54] [55] [56] [57] and [58]. 
2. SELECTION OF THE RELEVANT ANIMAL SPECIES 
 
The cytokine IL-2 is synthetized and produced after antigenic stimulation of resting T cells. 
T cells use IL-2 for clonal expansion and cytokine production. IL-2 binds to its receptor, the IL- 
2 receptor (IL-2R). 
 
The high affinity IL-2 is a heterotrimeric cell surface receptor composed of α, β and γ-
polypeptide chains. The IL-2Rα chain (also known as TAC, CD25) is specific for the IL-2R, but 
β and γ chains are part of cytokine receptor superfamily and are also shared by other cytokine 
receptors [59]. The intermediate affinity receptor is a dimer composed of β  and γ  chains while 
the low affinity receptor consist of a monomeric α. Subunit that has no signal transduction 
capacity [67]. Resting T-cells, B-cells, and monocytes express few IL-2Rα-subunit but the 
receptor is rapidly transcribed and expressed upon activation [61]. Cells expressing the high 
affinity IL-2R express the IL-2Rα-subunits in excess, which leads to both high and low affinity 
IL-2 binding profiles  [62] [63]. 
 
IL-2Rα is highly expressed by T cells in some autoimmune diseases (e.g. rheumatoid arthritis, 
scleroderma, uveitis), skin disorders (psoriasis, atopic dermatitis), and a variety of lymphoid 
neoplasms (e.g. T-cell leukemia, Hodgkin’s disease) [64]. 
Moreover, IL-2Rα expression is associated with allograft rejection and graft-versus-host 
responses (GvHD) [65], [66] Error! Reference source not found.. 
 
Fully human monoclonal antibody against IL-2Rα was generated aiming of preventing the 
biological consequences of IL-2 binding to its receptor. 
 
Selection of the relevant animal species for preclinical safety studies was based on: 
• interspecies amino-acid sequence homology of CD25 extracellular domain as obtained 
from the NCBI Basic Local Alignment Search Tool (BLAST); 
• cross-reactivity of Anti-CD25 mAb, fully human anti-CD25 antibody (lead candidate), 
evaluated in Peripheral Blood Mononuclear Cells (PBMCs) from different animal 
species. 
2.1 Selection of the relevant animal species by amino-acid sequence homology 
 
The BLAST program revealed 91% sequence identity between human and macaque monkeys. In 
contrast, percentages of sequence identity drop down when comparing the human sequence with 
other species: dog (61%), pig (56%), mouse (60%) and rat (60%). 
 
Cross reactivity was therefore more likely to occur between human and the macaque monkey 
rather than with the other above-mentioned species. 
 
Moreover, published data [67] on comparative sequence analyses suggest that both human CD25 
and Rhesus CD25 share identity for most of the critical amino acids essential for viable folding 
and IL-2 ligand binding. 
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2.2 Characterization of relevant animal species by cross-reactivity 
 
Extensive laboratory work was conducted to comparatively evaluate the capacity of Anti- CD25 
mAb to bind monkey (Rhesus, Cynomolgus and marmoset), minipig, mouse, rat and rabbit CD25 
receptor expressed on CD3+ T cells using resting or activated Peripheral Blood Mononuclear 
Cells (PBMCs). 
 
PBMCs obtained from blood samples (purchased externally) from different animal species. 
The following animal species were used and suppliers are shown in brackets: 
 
• Macaca fascicularis (Cynomolgus monkey) (Hartelust, The Netherland); 
• Macaca mulatta (Rhesus monkey) (Hartelust, The Netherland); 
• Marmoset (Callithrix jacchus) (Covance Laboratories GmbH); 
• Minipigs (Ellegaard Göttingen); 
• New Zealand white rabbits (Charles River Italy); 
• Sprague Dawley Crl:CD(SD) BR rats (Charles River Italy); 
• Crl:CD-1 (ICR) BR mice (Charles River Italy). 
 
PBMCs are cells in which IL-2Rα is expressed after antigenic stimulation and this expression 
can be easily monitored. 
 
Resting and activated animal PBMCs were used for testing their expression of CD25 antigen. 
In addition, resting and activated human PBMCs were assayed in the same way as control of 
assay performance and to comparatively evaluate the binding capacity of test item to non-human 
blood cells. 
 
2.3 Commercial monoclonal anti-CD25 antibodies 
 
Daclizumab (Zenapax, Roche). A humanized IgG1 IL-2Rı. antagonist. 
Basiliximab (Simulect, Novartis). A chimeric human and mouse IgG1 IL-2Rı. antagonist. 
 
The above commercial therapeutic monoclonal antibodies were used in parallel with the test item 
to assess the cross-reactivity equivalence of Anti-CD25 mAb. 
The commercial monoclonal antibodies were tested at the same concentrations and in the same 
vehicle as the test item. 
 
2.4 Cross – reactivity evaluation: methods 
 
The binding ability of Anti-CD25 mAb to IL-2Rα, expressed on PBMCs obtained from whole 
blood samples of different animal species, were evaluated by indirect immunofluorescence 
method in flow cytometry. 
Blood samples from one human healthy donor, and two healthy animals from each species were 
tested. 
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2.4.1 PBMCs isolation 
 
Fresh heparinized peripheral blood was diluted with PBS at room temperature. The cell 
suspensions, well mixed, were added directly to Ficoll gradient and centrifuged at 1000 g for 20 
min at 20 °C. After centrifugation the mononuclear cells were harvested at the interface ring, 
washed once and suspended in complete medium at a concentration of 2x106 cells/mL. 
 
2.4.2 PBMCs stimulation 
 
Cell suspensions at the concentration of 2x106 cells/mL were transferred into culture flasks or 
24-well plates, depending on the amount of PBMCs recovered, to obtain the final concentration 
of 1x106 cells/mL. Cells were exposed to phytohemagglutinin (PHA : 5 μg/mL) for 3 days at 37 
°C in a humidified 5% CO2 incubator. 
 
2.4.3 Resting and activated PBMC staining for flow cytometry 
 
 
Resting PBMCs from all animal species tested were stained for flow cytometry on the day of 
PBMCs isolation. Cells were suspended at a concentration of 2x106 cells/mL. CD25 expression 
was evaluated using Anti-CD25 mAb (the test item), commercial monoclonal anti-CD25 
antibodies (Zenapax and Simulect) or isotype IgG control at the final concentrations of 100 and 
10 μg/mL. 
Initially, the concentrations of 100 and 10 μg/mL were also used to investigate the 
crossreactivity of the Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG 
control with stimulated PBMCs from marmosets, minipigs, rabbits, rats and mice. 
 
Activated PBMCs were harvested at the end of the stimulation period, centrifuged once (7 min at 
300 g), counted and suspended at the concentration of 2x106 cells/mL. 1x105 cells/50 μL of PBS 
+ 0.1% BSA were dispensed into plastic conical tubes and incubated with 50 μL of the primary 
antibodies (30 min, 4°C) at different concentrations. 
After washing twice in PBS, the cells were incubated for 30 min at 4°C with 50 μL of a second 
antibody mixture containing rabbit anti-human IgG-FITC or PE conjugated and anti species-
specific CD3 appropriately conjugated. 
The cells were washed once, suspended in 500 μL of PBS and cell-associated fluorescence was 
assessed by flow cytometry using FACSCanto and FACSDiva software (BD Biosciences) with a 
gate on CD3+ T-cells for all species with the exception of rabbits in which the gate was done on 
CD4+ T-cells. 
 
The binding capacity of the antibodies to IL-2Rα was expressed as MFI of CD3+ or CD4+ cells. 
MFI data obtained from Cynomolgus and Rhesus monkeys, and human donor were used to 
calculate EC50 (half maximal effective concentration) values with Graph Pad prism software 
(GraphPad Software, Inc. La Jolla, CA, USA). 
 
2.5 Cross- reactivity evaluation: results 
 
The ability of Anti-CD25 mAb to bind the CD25 receptor was assessed on resting and activated 
PBMCs and compared with two marketed therapeutic anti-CD25 antibodies, Zenapax 
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(Daclizumab) and Simulect (Basiliximab). 
The same experiment in each species was performed, for control and comparison, on resting and 
activated human PBMCs. 
In each assay the expression of CD25 antigen on resting and activated PBMCs was also 
evaluated with commercial mAbs for research use only, specific for each animal species used. 
 
Cynomolgus monkey was the only species where binding to CD25-bearing cells was shown at 
potentially relevant in vivo concentrations. Therefore the Cynomolgus monkey was considered a 
valuable candidate for the preclinical development program of Anti-CD25 mAb . 
 
Data subsequently obtained in the in vitro/ex-vivo functional assays (e.g. inhibition of anti-CD3-
stimulated PBMCs proliferation), coupled with the CD25 saturation data of the CD4+ T cells 
from the in vivo experiments collectively allowed to qualify the Cynomolgus monkey as a 
responsive animal species to Anti- CD25 mAb. 
 
The overall results indicated that the CD25 expression, evaluated as CD25+ cell percentage or 
MFI, was absent or very low on human or animal resting PBMCs, while it was expressed on 
activated PBMCs, indicating that the method used was suitable for the investigation purpose. 
 
2.5.1 Cynomolgus monkey 
 
Anti- CD25 mAb cross-reactivity was assessed on Cynomolgus monkey resting and activated 
PBMCs. 
 
Anti- CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG control were used at 
the concentrations of 100 and 10 μg/mL on resting PBMCs, while different concentrations were 
tested on activated PBMCs. 
 
The assays were performed on two animals (1 male and 1 female) and on one human being. 
 
No binding was observed on monkey and human resting PBMCs (Figures 4, 5 and 6). 
 
Regarding activated monkey PBMCs (Figures 7, 8 and 9), Anti-CD25 mAb binding capacity 
was relevant compared to that shown by the negative control (IgG1k), but was lower than the 
binding capacity shown by Zenapax and Simulect. 
 
Zenapax and Simulect binding was obtained at mAb concentrations from 1.5 to 100 ng/mL, 
while Anti-CD25 mAb bound primate PBMCs at antibody concentrations from 390 ng/mL to 
100000 ng/mL. 
 
On human cells, Anti-CD25 mAb bound IL-2Rα in a dose-dependent manner more efficiently 
than on monkey cells, and the binding capacity was almost comparable with Zenapax and 
Simulect tested in the same conditions. 
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Fig. 4: Cross reactivity evaluation in resting Cynomolgus Monkey PBMCs (male) 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to resting Cynomolgus monkey PBMCs (isotype control: light blue). 
 
 
 
 
Fig. 5: Cross reactivity evaluation in resting Cynomolgus Monkey PBMCs (female) 
Cross reactivity evaluation of Anti-CD25(violet), Simulect competitor 1(Yellow) and Zenapax competitor 2(purple) 
to resting Cynomolgus monkey PBMCs (isotype control: light blue). 
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Fig. 6: Cross reactivity evaluation in resting human PBMCs 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to resting human PBMCs (isotype control: light blue). 
 
 
 
 
Fig. 7: Cross reactivity evaluation in activated Cynomolgus Monkey PBMCs (male) 
Cross-reactivity evaluation of Anti-CD25 mAb (blue), Simulect competitor 1(Yellow) and Zenapax competitor 
2(pink) to activated Cynomolgus monkey PBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light 
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blue). 
 
 
 
Fig. 8: Cross reactivity evaluation in activated Cynomolgus Monkey PBMCs (female) 
Cross-reactivity evaluation of Anti-CD25 mAb (blue), Simulect competitor 1(Yellow) and Zenapax competitor 
2(pink) to activated Cynomolgus monkey PBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light 
blue). 
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Fig. 9: Cross reactivity evaluation in activated human PBMCs 
Cross-reactivity evaluation of Anti-CD25(blue), Simulect competitor 1(Yellow) and Zenapax competitor 2(pink) to 
activated human PBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light blue). 
 
Anti- CD25 mAb, Simulect (competitor 1) and Zenapax (competitor 2) highest concentrations 
were tested on activated monkey PBMCs in order to obtain a saturation curve and to calculate 
the EC50 values (Figures 10 and 11). 
 
PBMCs from 2 male monkeys were used, and the following concentrations were tested: 500000, 
250000, 125000, 20800, 3500, 580, 96, 16, 2.7, 0.45 ng/mL. As shown in Figures 6a and 6b, the 
full saturation curve was reached both for Anti-CD25 and the two competitors mAbs at the 
concentration of 125 and 250 μg/mL. The reduced binding at the concentration of 500 μg/mL 
was due to an antibody excess zone. On the basis of the results obtained, data from the cross- 
reactivity evaluation in activated PBMCs, were used to calculate EC50s of the three products 
since 100 μg/mL was also considered as a saturating concentration. 
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Fig. 10: Saturation curve in Cynomolgus monkey activated PBMCs (male 1) 
Saturation curve of the binding of Anti- CD25 mAb (blue), competitor 1(yellow) and competitor 2(pink) to 
Cynomolgus monkey activated PBMCs. (FITC MFI of Abs binding on CD3+ cells) 
 
Note: Competitor 2(pink) data from the 3 lowest concentrations are not shown (unreliable due to a technical error in 
sample dilution.) 
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Fig. 11: Saturation curve in Cynomolgus monkey activated PBMCs (male 2) 
Saturation curve of the binding of Anti- CD25 mAb (blue), competitor 1(yellow) and competitor 2(pink) to 
Cynomolgus monkey activated PBMCs. (FITC MFI of Abs binding on CD3+ cells) 
 
Note: Competitor 2(pink) data from the 3 lowest concentrations are not shown (unreliable due to a technical error in 
sample dilution.) 
 
The results obtained from Anti-CD25 mAb cross-reactivity evaluation in PBMCs showed that 
cross-reactivity with Cynomolgus monkey PBMCs was lower and the EC50 was higher than 
those determined for the two competitors. 
 
2.5.2 Rhesus monkeys 
 
Anti-CD25 mAb cross-reactivity was assessed on Rhesus monkey resting and activated PBMCs 
with the test procedure and reagents used for Cynomolgus monkeys. 
 
Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG control were used at 
the concentration range of 100000 to 0.38 ng/mL on activated monkey (1 male and 1 female) and 
human PBMCs. 
 
No binding was observed on monkey and human resting PBMCs (Figures 12, 13 and 14). 
 
Regarding activated monkey PBMCs (Figures 15, 16 and 17) Anti-CD25 mAb binding capacity 
was relevant compared to that shown by the negative control (IgG1k), but was lower than the 
binding capacity shown by Zenapax and Simulect. Zenapax and Simulect binding was obtained 
at mAb concentrations from 1.5 to 100 ng/mL, while Anti-CD25 mAb bound primate PBMCs at 
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antibody concentration from 390 ng/mL to 100000 ng/mL. 
 
The results obtained in this assay were used to calculate EC50s of the three products since 100 
μg/mL was considered as a saturating concentration due to the binding activity very similar to 
that observed in Cynomolgus PBMCs. 
 
On human cells, Anti-CD25 mAb bound IL-2Rα in a dose-dependent manner more efficiently 
than on monkey cells, and the binding capacity was almost comparable with Zenapax and 
Simulect tested in the same conditions, confirming the results obtained in the Cynomolgus assay. 
 
 
 
Fig. 12: Cross reactivity evaluation in resting Rhesus Monkey PBMCs (male) 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to Rhesus monkey resting PBMCs (isotype control: light blue). 
 
 
 
Fig. 13: Cross reactivity evaluation in resting Rhesus Monkey PBMCs (female) 
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Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to Rhesus monkey resting PBMCs (isotype control: light blue). 
 
 
Fig. 14: Cross reactivity evaluation in resting human PBMCs 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to human resting PBMCs (isotype control: light blue). 
 
 
 
 
Fig. 15: Cross reactivity evaluation in activated Rhesus Monkey PBMCs (male) 
Cross-reactivity evaluation of Anti-CD25(blue), Simulect competitor 1(Yellow) and Zenapax competitor 2(pink) to 
activated Rhesus monkey PBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light blue). 
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Fig. 16: Cross reactivity evaluation in activated Rhesus Monkey PBMCs (female) 
Cross-reactivity evaluation of Anti-CD25(blue), Simulect competitor 1(Yellow) and Zenapax competitor 2(pink) to 
activated Rhesus monkey PBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light blue). 
 
 
 
 
Fig. 17: Cross reactivity evaluation in activated human PBMCs 
Cross-reactivity evaluation of Anti-CD25(blue), Simulect competitor 1(Yellow) and Zenapax competitor 2(pink) to 
activated humanPBMCs (FITC MFI of Abs binding on CD3+ cells), (isotype control: light blue). 
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Note: The lack of Zenapax binding in the female animal at the concentration of 25000 ng/mL was due to a technical 
error. 
 
2.5.3  Anti-CD25 mAb, Zenapax and Simulect EC50 estimation on Cynomolgus and 
Rhesus monkey and human activated PBMCs 
 
MFI data obtained from Cynomolgus and Rhesus monkey, and human activated PBMCs in the 
various assays were used to calculate EC50 values. Individual and mean values are reported in 
Table 1 and 2, respectively. 
 
Anti-CD25 mAb bound to the Cynomolgus activated PBMCs with an EC50 value of about 18000 
ng/mL. Anti-CD25 mAb EC50 to Cynomolgus CD25 was about 90 times higher than Simulect 
(207 ng/mL) and 165 times higher than Zenapax (110 ng/mL), indicating a lower binding 
capacity than the commercial anti-CD25 mAbs. In comparison to human PBMCs, the Anti-CD25 
mAb EC50 to the Cynomolgus CD25 was 1000 times higher. 
Regarding Rhesus animals, Anti-CD25 mAb bound to the Rhesus PBMCs with an EC50 value of 
about 33000 ng/mL, indicating that the Anti-CD25 mAb binding ability to Rhesus CD25 receptor 
was about 2 times less than Cynomolgus in comparison to human PBMC. Zenapax EC50 (118 
ng/mL) was similar to that obtained in Cynomolgus, while the Simulect EC50 of 9634 ng/mL was 
about 50 times higher.  
Anti-CD25 mAb and Simulect bound to the human PBMCs with a mean EC50 of 17 and 18 
ng/mL respectively. Zenapax binding ability was 4 fold less than Anti-CD25 mAb with an EC50 
of 73 ng/mL. 
From the calculation of the EC50 values of the anti-CD25 antibodies against human CD25 it can 
be concluded that the binding capacity of Anti-CD25 mAb and Simulect are similar, and that 
Anti-CD25 mAb binds 4 times as much as Zenapax. 
 
Table 1: EC50 individual data (ng/mL) 
Binding of Anti-CD25 mAb, Simulect and Zenapax to activated PBMCs 
 EC50 individual values (ng/mL) 
Anti-CD25 mAb Simulect Zenapax 
Male Cynomolgus 21410 193.1 174.4 
Female Cynomolgus 17641 224.9 46.37 
Male 1 Cynomolgus  14460 325.0 - 
Male 2 Cynomolgus 18697 84.06 - 
Male Rhesus 34103 10875 74.15 
Female Rhesus 32800 8393 161.3 
Human donor 16.93 20.93 91.77 
Human donor 17.64 15.72 54.74 
 
Table 2: Mean EC50 (ng/mL) 
Binding of Anti-CD25 mAb, Simulect and Zenapax to activated PBMCs 
 Mean EC50 (ng/mL) 
Anti-CD25 mAb Simulect Zenapax 
Cynomolgus 
monkey 
18052 207 110 
Rhesus monkey 33452 9634 118 
Humans  17 18 73 
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The binding capacity of Anti-CD25 mAb and Simulect for human CD25 antigen were similar, 
with that of Anti-CD25 mAb being greater than that of Zenapax. 
The species cross-reactivity to Cynomolgus and Rhesus PBMCs showed lower binding for Anti-
CD25 mAb in comparison to human PBMCs, more evident in Rhesus species when the EC50s 
were compared. 
Due to the observed difference between Cynomolgus and Rhesus monkeys Anti-CD25 mAb 
cross-reactivity data, Cynomolgus monkeys can be considered suitable for use in toxicity safety 
studies. 
 
2.5.4 Marmoset Monkey 
 
Anti-CD25 mAb cross-reactivity was assessed on Marmoset monkey resting and activated 
PBMCs with the same test procedure and reagents used for Cynomolgus and Rhesus animal 
species. 
 
No binding was recorded for the 3 products on resting human PBMCs, while on activated cells 
the binding was 10 times higher, confirming the data obtained in previous experiments 
(Figures 18 and 19). 
 
Regarding Marmosets, no binding was obtained on resting PBMCs for the 3 products. On 
activated cells low binding activity was recorded in two out of four animals with Anti-CD25 mAb 
at 100 μg/mL only, while for Zenapax and Simulect relevant binding activity was recorded at 
both concentrations tested, 100 and 10 μg/mL (Figures 20 and 21). 
 
Data sets demonstrate that healthy Marmoset monkey is not the relevant species to be used in 
safety studies since very poor cross-reactivity of Anti-CD25 mAb mAb to PBMCs was obtained. 
 
 
 
 
Fig. 18: Cross reactivity evaluation in human resting PBMCs 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to human resting PBMCs (isotype control: light blue). 
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Fig. 19: Cross reactivity evaluation in human activated PBMCs 
Cross reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to human activated PBMCs (isotype control: light blue). 
 
 
Fig. 20: Cross reactivity evaluation in resting Marmoset Monkey PBMCs 
Cross-reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
2(purple) to Marmoset monkey resting PBMCs (isotype control: light blue). 
 
100 µg/mL Ab      10 µg/mL Ab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
0
500
1000
1500
2000
2500
3000
3500
Marmoset
1M
Marmoset
2M
Marmoset
3F
Marmoset
4F
M
FI
 C
D3
 p
os
iti
ve
 
ac
tiv
at
ed
 e
lls
0
500
1000
1500
2000
2500
3000
3500
Marmoset
1M
Marmoset
2M
Marmoset
3F
Marmoset
4F  
Fig. 21: Cross reactivity evaluation in activated Marmoset Monkey PBMCs 
Cross-reactivity evaluation of Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) and Zenapax competitor 
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2(purple) to Marmoset monkey activated PBMCs (isotype control: light blue). 
 
2.5.5 Minipig  
 
Anti-CD25 mAb cross-reactivity was assessed on healthy Goettingen minipig resting and 
activated PBMCs. 
Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG control were used at 
the concentrations of 100 and 10 μg/mL on resting and activated PBMCs from four animals (2 
males and 2 females) and one healthy human donor. 
 
No binding was recorded for the 3 products on resting human PBMCs, while on activated cells 
the binding was 60 times higher confirming the data obtained in previous experiments (Figures 
22 and 23). 
No binding was obtained for the 3 products on minipig resting and activated PBMCs (Figures 24 
and 25). 
 
These data sets demonstrate that healthy minipigs are not the relevant species to be used in safety 
studies since no cross-reactivity of Anti-CD25 mAb to PBMCs was obtained. 
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Fig. 22: Cross reactivity evaluation in resting humanPBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 23: Cross reactivity evaluation in activated human PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
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blue). 
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Fig. 24: Cross reactivity evaluation in resting Minipig PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 25:Cross reactivity evaluation in activated Minipig PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
 
 
2.5.6 Rabbit 
 
Anti-CD25 mAb cross-reactivity was assessed on healthy New Zealand White rabbit resting and 
activated PBMCs. 
 
Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG control were used at 
the concentrations of 100 and 10 μg/mL on resting and activated PBMCs from four male animals 
and one healthy human donor. 
 
No binding was recorded for the 3 products on resting human PBMCs, while on activated cells 
the binding was 60 times higher confirming the data obtained in previous experiments (Figures 
26 and 27). 
 
No binding was obtained for Simulect (competitor 1) and Zenapax (competitor 2) on rabbit 
resting and activated PBMCs at both concentrations tested, while slightly higher MFI values 
only at 100 μg/mL of Anti-CD25 mAb was recorded and it was considered due to a aspecific 
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binding since occurred in either resting or activated rabbit PBMCs, and only at the higher 
concentration used (Figures 28 and 29). 
 
These data sets demonstrate that healthy rabbits are not the relevant species to be used in safety 
studies since no cross-reactivity of Anti-CD25 mAb to PBMCs was obtained. 
 
 
 
 
Fig. 26: Cross-reactivity evaluation in resting human PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 27:Cross-reactivity evaluation in activated human PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 28: Cross-reactivity evaluation in  resting rabbit PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 29: Cross-reactivity evaluation in activated rabbit PBMCs. 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
 
2.5.7 Rat 
 
Anti-CD25 mAb cross-reactivity was assessed on healthy Sprague-Dawley rats resting and 
activated PBMCs. 
 
Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG control were used at 
the concentrations of 100 and 10 μg/mL on resting and activated PBMCs from four animals 
(2 males and 2 females) and one healthy human donor. 
These humans PBMCs have to be considered as control also for mice since these two animal 
species were tested together. 
As expected, low and similar binding was recorded for the 3 products on resting human PBMCs, 
while on activated cells the binding was higher, confirming the data obtained in previous 
experiments (Figures 30 and 31). 
 
In rats, no binding was obtained for the 3 products on resting PBMCs. 
 
On activated PBMCs low and similar binding was recorded for the 3 products at 100 μg/mL, 
while no binding was observed at the concentration of 10 μg/mL (Figures 32 and 33). 
 
These data sets demonstrate that healthy rats are not the relevant species to be used in safety 
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studies since no cross-reactivity of Anti-CD25 mAb to PBMCs was obtained. 
 
 
Fig. 30: Cross-reactivity evaluation in resting human PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 31:Cross-reactivity evaluation in activated human PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 32: Cross-reactivity evaluation on resting rat PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 33: Cross-reactivity evaluation on activated  rat PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
 
 
 
2.5.8 Mouse 
 
Anti-CD25 mAb cross-reactivity was assessed on healthy CD1mice in three different assays. 
 
In the first assay, Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype IgG 
control were used at the concentrations of 100 and 10 μg/mL on resting and activated PBMCs 
from four animals (2 males and 2 females) and one healthy human donor tested in parallel to 
mouse PBMCs (Figures 34 and 35). 
 
No binding was obtained on resting PBMCs for the 3 products. 
 
No binding was recorded for Simulect (competitor 1) and Zenapax (competitor 2), while a low 
binding was obtained with Anti-CD25 mAb at 100 μg/mL on activated PBMCs, even if a very 
poor CD25 expression was obtained on these cells. 
 
Therefore, to better clarify the result obtained, a second assay was carried out using spleen 
lymphocytes instead of PBMCs (hard to obtain due to the limited volume of blood that can be 
drawn from each animal). 
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In this second assay (Figure 36), Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or 
isotype IgG control were used at the concentrations of 100, 10, 1 and 0.1 μg/mL on resting and 
activated spleen lymphocytes from four animals (2 males and 2 females). 
 
No binding was obtained on resting PBMCs for the 3 products. 
 
As observed in the first assay, on activated PBMCs no binding was recorded for Simulect 
(competitor 1) and Zenapax (competitor 2), while a low binding was obtained with Anti-CD25 
mAb at 100 μg/mL and again a poor CD25 expression was obtained. 
 
Since the positive control used to evaluate the CD25 expression was unsatisfactory 
independently of the fluorocrome adopted (PE conjugated for PBMC and FITC conjugated for 
splenocytes) it was deemed necessary to optimize the procedure for mouse lymphocyte 
activation and to use it in a third assay (Figure 37) to define whether Anti-CD25 mAb is able to 
bind CD25 antigen expressed on mouse activated lymphocytes. 
 
Two mitogens (PHA and ConA), different mitogen concentrations (PHA 5 μg/mL; ConA: 2.5, 5, 
10 μg/mL), 3 differents activation times (24, 48, and 72 hours), two PE conjugated anti-mouse 
CD25 antibodies (BD Pharmingen and eBioscence) were tested on spleen cells. 
 
Also in this third asssay Anti-CD25 mAb, commercial mAbs (Zenapax and Simulect) or isotype 
IgG control were used at the concentrations of 100, 10, 1 and 0.1 μg/mL on resting and activated 
spleen lymphocytes from four animals (2 males and 2 females). 
 
As shown in Figure 38, no binding was obtained for the 3 products on CD1 mouse resting and 
activated spleen lymphocytes. 
 
These data sets demonstrate that healthy CD1mice are not the relevant species to be used in 
safety studies since no cross-reactivity of Anti-CD25 mAb to lymphocytes was obtained. 
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Fig. 34: Cross-reactivity evaluation in resting mouse PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 35:Cross-reactivity evaluation in activated mouse PBMCs 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 36: Cross-reactivity evaluation in resting and activated mouse spleen cells 
(FITC MFI of Abs binding on CD3+ cells) 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
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Fig. 37: Cross-reactivity evaluation in resting and activated mouse spleen cells 
(FITC MFI of Abs binding on CD3+ cells) 
Anti-CD25 mAb (violet), Simulect competitor 1(Yellow) , Zenapax competitor 2(purple) and (isotype control: light 
blue). 
 
 
Page 53 
2.6 Cross- reactivity evaluation: conclusion 
 
The aim of this investigation was to evaluate the cross-reactivity of Anti-CD25 mAb to PBMCs 
of the animal species most commonly used in toxicology investigations, in order to provide 
supportive data for selection of the most relevant one(s) to be used in safety studies. 
 
The results obtained in Marmoset monkeys, Goettingen Mini-pigs, New Zealand white rabbits, 
Sprague Dawley rats and CD1 mice showed the absence of Anti-CD25 mAb cross-reactivity to 
PBMCs, and none of these species are therefore eligible. 
 
Cross-reactivity with Rhesus PBMC was mild and lower than with Cynomolgus monkey 
PBMCs.  Although the EC50 of Anti-CD25 mAb for PBMCs of Cynomolgus was higher than 
those determined for the marketed anti-CD25 mAbs, this was the only species where binding to 
CD25-bearing cells was shown at potentially relevant in vivo concentrations. Therefore the 
Cynomolgus monkey was considered relevant for the preclinical development program of Anti-
CD25 mAb. 
 
Based on the above-summarized results it was considered the Cynomolgus monkey be a suitable 
species to evaluate the safety, kinetics, dynamics and toxicity resulting from Anti-CD25 mAb 
administration. 
It was also recognized that the extent of extrapolation of the monkey data to humans is 
somewhat limited by the lower capacity of Anti-CD25 mAb to bind monkey CD25. 
 
The high dose levels used in the pre-clinical development were intended to overcome this 
potential issue. From the experience gained to date the % of CD25+ cells within the CD4+ T cell 
population in healthy Cynomolgus monkeys averaged 4% (range of 1.8 to 6.1%); human data 
either from HVs (healthy volunteers) and MS (Multiple Sclerosis) patients are being collected. 
 
Data subsequently obtained in the in vitro/ex-vivo functional assays (e.g. inhibition of anti-CD3-
stimulated PBMCs proliferation), coupled with the CD25 saturation data of the CD4+ T cells 
from the in vivo experiments collectively allowed to qualify the Cynomolgus monkey as a 
responsive animal species to Anti-CD25 mAb. 
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3. AIM OF THIS THESIS 
 
Anti-CD25 mAb is a fully human IgG1 kappa monoclonal antibody (mAb) against the alpha 
subunit of the interleukin 2 receptor (IL2Rα, also known as CD25 or TAC antigen) of potential 
clinical interest in autoimmune diseases, including multiple sclerosis, uveitis, type 1 diabetes and 
psoriasis. 
 
Anti-CD25 mAb acts mainly by inhibiting the proliferation of T cells and by consequence T cell 
clonal expansion and cytokine production. IL-2 is a potent immunomodulator whose major 
function is the activation of various cells of the immune system, i.e. T cells (including CD4+ 
CD25+ regulatory T cells), B cells, NK cells and macrophages, which express CD25 upon 
antigen stimulation. 
 
The key to immunotherapeutic success with an anti-CD25 is to elicit the correct balance of 
effector and regulatory T cells. Nevertheless, the effects of an anti-CD25 antibody on the balance 
between pro-inflammatory T cells versus anti-inflammatory regulatory T cells are still unclear. 
 
The potential advantages of Anti-CD25 mAb are the high affinity for human CD25 and the fact 
that it is a fully humanized mAb, potentially less immunogenic, leading to longer duration of 
therapeutic effect. It is difficult to foresee which subpopulation of CD25 cells will be the most 
inhibited by blocking the IL-2Rα as a consequence of in vivo administration of Anti-CD25 mAb. 
Such aspects were investigated in healthy non-human primates. 
 
The purpose of the thesis is to assess the potential adverse effects resulting from the repeated 
administration of Anti-CD25 mAb in Cynomolgus monkeys, selected as the most relevant animal 
species for this preclinical safety study. 
 
Anti-CD25 mAb was given by intravenous route (IV) at doses of 5, 25, 125 mg/kg or 
subcutaneously (SC) at a dose of 75 mg/Kg to 22 males and 22 females once a week for 5 
consecutive weeks. 
 
During the study general clinical observations, clinical pathology, CD25 expression, CD25 
saturation and down-modulation on lymphocyte subsets, NK cell activity, cytokine release 
markers, T- cell proliferation and regulatory T cells number evaluation were determined. 
 
One week after the last treatment 3 monkeys/sex/group were sacrificed for pathology 
investigations, while the remaining animals were subjected to a 28-week recovery period. 
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4. MATERIALS and METHODS 
4.1 Test System 
4.1.1 Characterization of the test system 
 
Macaca fascicularis (Cynomolgus monkeys). 
 
4.1.2 Justification for selection of the test system 
 
The Cynomolgus monkey was chosen as non-rodent species since it has been found to be cross-
reactive to the test compound. 
 
4.1.3 Test system management 
 
4.1.3.1 Supply, acceptance and selection 
 
This study was performed on 22 male and 22 female bred Cynomolgus monkeys. 
 
At the start of the study (day 1) the Cynomolgus monkeys were about 3-5 years old and the 
males weighed between 2.04 and 4.53 kg and the females between 1.83 and 3.09 kg. 
 
Prior to their arrival at the test facility all monkeys had been quarantined and TB-tested with 
negative results. All animals were tested negative for Hepatitis B, Marburg and Ebola Viruses 
and were free from Salmonella/Shigella. Animals were also subjected to selected blood 
chemistry tests. During the pre-test period (3 weeks) preceding the start of treatment, all the 
animals were clinically examined by the test facility veterinarians to ascertain their fitness for the 
study. 
 
Before the start of treatment all the animals were subjected to body weight and food 
consumption recordings, ophthalmological examinations, ECG recordings, hematological and 
blood chemistry tests and urinalysis. 
 
The test-eligible animals were then randomly allocated to the different dose groups and the 
identification number of each animal was marked on its cage card. 
 
4.1.3.2 Housing 
 
The monkeys were caged singly in sheet stainless steel cages with front wall and bottom in 
stainless steel grill. The cages were hung on metal racks. The cages were housed in an air 
conditioned (24°C±2°C) room, with 15 – 20 air changes per hour, relative humidity of 55% ± 15, 
artificial lighting with a circadian cycle of 12 hours (7 a.m. - 7 p.m.). 
 
4.1.3.3 Diet and water supply 
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A diet coded "3KE25 GLP top certificate", produced for Charles River Italia by its licensee 
Mucedola S.r.l., Settimo Milanese, analyzed for nutrients, was used. 
 
With the diet, the producer supplied a Certificate of analysis in which it declared that the 
presence and the levels of contaminants in the diet were within the limits proposed by the EPA-
TSCA (44FR:44053- 44093, July 26, 1979). 
 
The animal feed is re-analyzed at least twice a year for bacterial contamination. The ration was 
distributed once a day in the total amount of about 200 g/monkey. Fruit or vegetables were 
distributed twice a day. Filtered water was distributed by means of an automatic watering valve 
system. The drinking water offered to the animals "ad libitum" came from the Ivrea regional 
water main. 
 
Periodically the drinking water is analyzed for microbiologic count, heavy metals, other 
contaminants (e.g. solvents, pesticides) and other chemical and physical characteristics. 
The acceptance limits of quality of the drinking water were those defined in EEC Directive 
80/778. Contaminants that might interfere with the objectives of this study were not expected to 
be present either in the diet or in the drinking water. 
 
4.2 Experymental Design 
 
4.2.1 Treatment schedule 
 
4.2.1.1 Doses, Volume, concentration 
 
The animals were randomly allocated to 4 dose groups plus 1 control group according to the 
scheme below: 
 
Group 
Doses 
(mg /kg/ week) 
[administr.Route] 
Volume 
of 
administr. 
(ml/Kg) 
Concentr. 
In 
vehicle 
(mg/ml) 
No. of 
males 
No. of 
females 
Group color 
identification 
1 0 (vehicle)  [IV] 2 0 4 4 white 
2 5 [IV] 2 2.5 4 4 yellow 
3 25 [IV] 2 12.5 4 4 green 
4 125 [IV] 2 62.5 5 5 red 
5 75 [SC] 2 37.5 5 5 blue 
 
The administration volume was 2 ml/kg and was adjusted on the basis of the most recently 
recorded body weight (individual values). During the study general clinical observations, ECG 
recordings, ophthalmoscopy, body temperature and body weight and food consumption 
measurements were carried out. 
 
Laboratory investigations (hematology, blood chemistry and urinalysis) were also performed. 
Samples for toxicokinetics purposes and additional evaluations were also collected. 
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One week after the last treatment 3 monkeys/sex/group were sacrificed for pathology 
investigations, while the remaining animals were subjected to a 29-week recovery period and 
then sacrificed. 
 
4.2.1.2 Administration regimen 
 
The test article was administered once a week. 
 
4.2.1.3 Administration route 
 
The intravenous [IV] and subcutaneous [SC] routes are the anticipated therapeutic routes. 
 
Intravenous route, injection in the right saphena vein. 
Subcutaneous route, in the subcutis of the right leg. 
 
4.2.2 Test system identification and grouping criteria 
 
The 44 test- eligible monkeys were randomly allocated to the experimental groups, as detailed 
below. 
 
All monkeys were identified using the last digits of the number tattooed by the Supplier. 
 
 
Group 1 
(white) 0 mg/kg/week (vehicle) 
 
Male No.s: 0311051 - 0311353 - 0312045 - 0406025(§) 
Females No.s: 0109042 - 0212152 - 0302670 - 0309164 (§) 
 
Group 2 
(yellow) 5 mg/kg/week (IV) 
 
Male No.s: 0212101 - 0309087 - 0311021 - 0401043 (§) 
Females No.s 0312224 - 0312342 - 0401126 - 0401208 (§) 
 
Group 3 
(green) 25 mg/kg/week (IV) 
 
Males No.s 0208097 - 0209075 - 0310153 - 0402027 (§) 
Females No.s 0109110 - 0304172 - 0312398 - 0312490 (§) 
 
Group 4 
(red) 125 mg/kg/week (IV) 
 
Males No.s 10103 - 0308363 - 0309073 - 0310411 (§) - 0404015 (§) 
Females No.s 0306520 - 0307610 - 0308074 - 0312210 (§) - 0402134 (§) 
 
Group 5 
(blue) 75 mg/kg/week (SC) 
 
Males No.s 0202205 - 0210253 - 0309365 - 0312003 (§) - 0401037 (§) 
Females No.s 0108190 - 0302688 - 0303226 - 0307140 (§) -0401222 (§) 
 
§: animals subjected to recovery period
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4.2.3 Experimental procedures 
 
4.2.3.1 Clinical observation 
 4.2.3.1.1 Mortality 
Animals were inspected twice a day for mortality (early in the morning and again in the 
afternoon). 
 4.2.3.1.2 Clinical Signs 
All monkeys were monitored for physical appearance, behaviour and general clinical signs 
before and after each administration. Moreover, frequent inspections were done after each 
dosing. 
 
During the recovery period the animals were inspected twice, early in the morning and again in 
the afternoon. 
 
Individual clinical observations were made in order to detect abnormalities related to the 
involvement of CNS, Tegumental, Digestive, Musculoskeletal, Respiratory and Genitourinary 
apparatus. 
 
All signs of ill health, together with any behavioural change or reaction to treatment, were 
recorded for each animal. Dated and signed records of clinical signs were kept on clinical history 
sheets for individual animals. 
 4.2.3.1.3 Body weight, food consumption, rectal temperature 
All the animals were weighed twice prior to the beginning of treatment and then weekly during 
the dosing and recovery periods. 
 
Food consumption was measured once pre-trial and during the treatment and recovery periods, 
when the body weight was recorded. At each of the scheduled times, the residual feed from that 
offered (2000 g gross weight, equivalent to about 1400 g net weight, subdivided into daily 
portions of about 200 g) was weighed; consumption of food was calculated and expressed as 
g/animal/day. 
 
Rectal temperature was measured twice pre-trial and then before and at 2, 6 and 24 hours after 
each treatment. Measurements were always performed before blood sampling. 
 4.2.3.1.4 Ophthalmological examinations 
Both eyes of all animals assigned to the study were examined once pre-trial. The same 
examination was repeated at the end of treatment (week 5) and during weeks 7 and 26/27 of the 
recovery period. 
 
Eyes were initially examined by macroscopic observation (naked eye); then conjunctiva, cornea, 
anterior chamber, iris, lens, vitreous body and fundus were examined with an Omega 100 
indirect ophthalmoscope (Heine), after instillation of 1% Tropicamide (Visumidriatic -
Visufarma). 
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4.2.3.1.5 Electrocardiography and heart rate 
ECG tracings were recorded on the animals according to Bailey’s lead system by a three-channel 
Bosch EKG 506 D electrocardiograph (amplification automatically adjusted according to R wave 
amplitude). 
 
Electrocardiogram spot tracings were recorded once pre-study and then on 2 animals/sex of 
groups 1, 2 and 3 (those with the highest identification number), and on 3 animals/sex of groups 
4 and 5 (those with the highest identification number). 
Heart rate was calculated on the basis of systolic complexes occurring in an ECG tracing within 
a period of 6 seconds. 
 
During the ECG recordings the animals were kept in right lateral recumbency and held with hind 
and forelegs at right angles to the body and parallel to each other by an assistant. Insulated 
alligator clips were used as electrodes. 
 
Electrocardiogram tracings were recorded at the following times: 
 
• Before the start of treatment (day -10 for males and day -7 for females) 
• On the animals treated by intravenous route: 
o 1 hour after the treatment performed in weeks 2 and 4 and in weeks 8 and 27/28 
of recovery. 
• On the animals treated by subcutaneous route: 
o 3 hours after the treatment performed in weeks 2 and 4 and in weeks 8and 27/28 
of recovery. 4.2.3.1.6 Laboratory investigations (Hematology, blood chemistry and urinalysis) 
In order to permit urine collection, the monkeys were kept in metabolism cages for about 16 
hours without food and water, after having received 20 mL/kg of tap water by gavage as water 
load, before the scheduled analysis day. 
 
Blood samples (3.0 mL/each sampling) were drawn in the morning from a cephalic vein of each 
fasted animal. Hematological examinations, blood chemistry tests (including IgG and IgM, 
Fibrinogen, alpha 1 antitrypsin (α1 AT), alpha 1 acid glycoprotein (α1 AGP), C-reactive protein 
(CRP) tests and urinalyses were performed in all the animals following the scheme below: 
 
Period Week Test 
Pre- trial - 2 Hematology (+Fibrinogen) Blood Chemistry (+ AT, AGP, CRP, IgG and IgM), urinalyses 
Treatment 1 Fibrinogen, APT, AGP, CRP.  
Treatment 3 Fibrinogen, APT, AGP, CRP. 
Treatment 5 Fibrinogen, APT, AGP, CRP. 
Treatment 6 Hematology (+Fibrinogen) Blood Chemistry (+ AT, G AGP, CRP, IgG and IgM), urinalyses 
Recovery 8 Hematology (+Fibrinogen) Blood Chemistry (+ AT, AGP CRP, IgG and IgM), urinalyses 
Recovery 13 Hematology (+Fibrinogen) Blood Chemistry (+ AT, AGP, CRP, IgG and IgM), urinalyses 
Recovery 28 Hematology (+Fibrinogen) Blood Chemistry (+ AT, AGP, CRP, IgG and IgM), urinalyses 
Legend: AGP = Alpha-1-acid glycoprotein, CRP = C-reactive protein, AT = alfa-1-antitrypsin 
 
Page 60 
4.2.3.1.7 Pathology (Necropsy and Histopathology) 
At the end of the treatment (week 5) and recovery (week 28) periods each animal was fasted 
overnight (about 16 hours); the fasted body weight was recorded before sacrifice. 
 
The animals were sacrificed after being anesthetized with an i.v. injection of an overdosage of 
barbiturate (50 mg/kg). Each anesthetized animal was bled to death through the femoral arteries 
and subjected to a complete necropsy. 
 
Organs and tissues were collected and the organs weighed in all animals as well as the fixative(s) 
used. Histological examination was performed on all animals sacrificed after 4 weeks of 
treatment and in the animals which underwent recovery. 
Individual organ weight/fasted body weight ratios were calculated. The organs to be examined 
were embedded in paraffin blocks, sectioned and stained with hematoxylin and eosin. Bone 
tissues were decalcified before being embedded. 
 4.2.3.1.8 Toxicokinetics 
Blood samples (about 0.5 mL/sample) were collected for toxicokinetic purposes from a cephalic 
vein of all animals following the schedule below: 
 
- In monkeys treated by intravenous route: 
• Basal time point =0 
• After the 1st treatment: 5 minutes, 30 minutes, 1, 2, 3, 6, 24, 96 and 168 hours. 
• From the 2nd to the 4th treatment: before treatment and after 30 minutes. 
• At the 5th treatment: before treatment and after 0, 5 minutes, 30 minutes, 1, 2, 3, 6, 24, 96 
and 168 hours. 
• During recovery period: once a week during W1, W2, W3, W4, W5, W6, W7, W10, 
W14, W23 W26 and W28 for the female, and during W1, W2, W4, W5, W6, W7, W8, 
W11, W14, W20, W27 and W28 for the male. 
 
- In monkeys treated by subcutaneous route: 
• Basal time point =0 
• After the 1st treatment: 30 minutes, 2, 6, 24, 96 and 168 hours. 
• From the 2nd to the 4th treatment: 4 hours. 
• At the 5th treatment: 0, 30 minutes, 2, 6, 24 and 96 hours. 
• During recovery period: once a week during W1, W2, W3, W4, W5, W6, W7, W10, 
W14, W23 W26 and W28 for the female, and during W1, W2, W4, W5, W6, W7, W8, 
W11, W14, W20, W27 and W28 for the male. 
The blood samples collected were allowed to clot for 50-60 minutes at room temperature. The 
clot was spun down by centrifugation at 3000 rpm for 15 minutes and the supernatant was 
collected and divided into two aliquots, which were stored frozen at –80°C until analysis. 
 
Serum samples were analyzed for Anti- CD25 quantification using the validated ELISA method. 
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4.2.3.1.9 PD markers: leukocyte and lymphocyte subsets; CD25 expression, saturation and down-modulation on lymphocyte subsets. 
Whole-blood samples were obtained for PD analysis at the following time points: 
 
• Pre- treatment - All animals (D1) 
• After 1st treatment - 3 h after treatment (D1), in monkeys treated by IV route 
 - 6 h after treatment (D1), in monkeys treated by SC route 
• From 2nd to 5th 
administration 
- All animals on the day before treatment (D7,D14, D21, D28) 
• Recovery period - all animals, in weeks 2, 4, 6, 8, 11, 14, 18, 23, 29 
 
At the time points listed above, the following parameters were recorded: 
 
• Total leukocytes and leukocyte subsets (lymphocytes and neutrophils, absolute count, 
monocyte percentage and absolute counts), as determined by hematological analysis. 
 
• Lymphocyte subsets (percentage and absolute values) of total T-cells (CD3+), helper T-cells 
(CD3+CD4+), cytotoxic T-cells (CD3+CD4-), B-cells (CD3-CD20+) and Natural Killer (NK) 
cells (CD3-CD16+), determined by flow cytometry (FACS) analysis. 
 
• CD25 expression/saturation/down-modulation (cell percentage) on the following lymphocyte 
subsets: total T-cells, helper T-cells, cytotoxic T-cells, as determined by FACS analysis. 
 
• CD25 expression/saturation was determined using anti-human CD25 PE-conjugated 
monoclonal antibody (mAb) (clone ACT-1; Dako Cytomation). Clone ACT-1 binds to an 
epitope similar to that used by Anti- CD25 and therefore binds only to free CD25 antigen. 
 
• CD25 down-modulation was determined using anti-human CD25 PE-conjugated mAb (clone 
7G7B6; Ancell). Clone 7G7B6 binds to a CD25 epitope different from that bound by Anti- 
CD25 and therefore it can bind to all the CD25 molecules expressed on the cell surface. This 
antibody recognizes the human IL-2 receptor but binds to an epitope distinct from that 
recognised by either IL- 2 or Anti-CD25 mAb. 
Therefore the ability of Anti-CD25 to bind to and saturate IL-2Rα sites on lymphocytes was 
assessed indirectly by loss of anti-CD25/ACT-1 binding relative to 7G7/B6 binding. 
 
• Anti-CD25 mAb (test item) bound to the cell surface, as determined by FACS analysis using 
an anti-human IgG PE-conjugated mAb; this parameter was recorded as follows: 
- in all animals undergoing recovery starting from week 4 or 2 of withdrawal for males and 
females respectively, to monitor the reduction in Anti-CD25 and, consequently CD25 
desaturation. 
- in some animals sacrificed at the end of treatment at various analytical time points. 
 
Low monocyte counts (percentage and absolute values) were recorded in some animals at 
various sampling times. These monocyte values were flagged as outliers and, for the statistical 
evaluation, they were replaced with the mean value of all animals of the same group at the time 
point considered. 
 
Immunophenotyping analysis and CD25 expression/saturation/down-modulation were performed 
on peripheral blood collected in EDTA (0.5 mL blood/sampling time) and analyzed by flow 
cytometry using direct immunofluorescence and lyse-no-wash techniques. 
Commercially available human mAbs that crossreact with Cynomolgus monkey antigens were 
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used at the concentrations recommended by the manufacturer or the best applicable dilutions 
tested in a preliminary study. 
 
ANTIBODY PANEL 
 
MoAb Clone Source 
Mouse IgG1k PE isotype control MOPC-21 BD Pharmingen 
Mouse IgG2a PE isotype control G155-178 BD Pharmingen 
Mouse anti-human CD3-APC-Cy7 SP34-2 BD Pharmingen 
Mouse anti-human CD4-APC L200 BD Pharmingen 
Mouse anti-human CD20-FITC 2H7 BD Pharmingen 
Anti-human CD16-FITC 3G8 BD Pharmingen 
Mouse anti-human CD45-PerCP D058/1283 BD Pharmingen 
Mouse anti-human CD25-PE (IgG1k) ACT-1 Dako Cytomation 
Mouse anti-human CD25-PE (IgG2ak) 7G7B6 Ancell 
Anti-human IgG Fcγ fragment specific-PE N.A. eBioscience 
 
Lymphocyte subsets and CD25 expression/saturation/down-modulation were detected with the 
following combinations of markers diluted with PBS/0.1% BSA and appropriately pooled: 
 
IMMUNOPHENOTYPING – CD25 EXPRESSION/SATURATION 
 
Pool Markers Cell Population 
A CD45PerCP/CD4APC/CD20FITC/CD3APCCy7/ CD25PE (Dako) 
CD3+: TotalT lymphocytes 
CD3+CD4+: T helper cells 
CD3+CD4-: T cytotoxic cells 
CD3-CD20+: Total B cells 
CD3+CD25+ 
CD3+CD4+CD25+ 
CD3+CD4-CD25+ 
B CD45PerCP/CD16FITC/CD3APC-Cy7 CD3-CD16+: NK cells 
 
CD25 DOWN-MODULATION 
 
Pool Markers Cell Population 
A CD45PerCP/CD4APC/CD20FITC/CD3APCCy7/ CD25PE (Ancell) 
CD3+CD25+ 
CD3+CD4+CD25+ 
CD3+CD4-CD25+ 
 
For each individual sample 25 or 15 μL of antibody pool A and pool B, respectively, were added 
to 25 μL of whole blood. 
 
Isotype controls in each combination were run to assess the presence of non-specific staining and 
to set quadrants for dot plot analysis of either CD25 expression (Dako mAb) or CD25 down-
modulation (Ancell mAb). They were used for staining the blood samples from the first animal 
(in numerical order) in each group, and were dispensed in the tubes as follows: 
 
Tube 1: mouse IgG1k PE, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD20 FITC, anti-CD45 
PerCP 
Tube 2: mouse IgG2a PE, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD20 FITC, anti-CD45 
PerCP 
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The tubes were mixed and incubated in the dark for 15 min at room temperature. 
 
1 mL of ammonium chloride lysing solution was added and, after mixing, the tubes were kept in 
the dark for 15 min. at room temperature. The tubes were run on a FACSCanto instrument within 
one hour of the end of preparation. 
 
A FACSCanto flow cytometer (BD Biosciences) equipped with 488 nm and 633 nm laser lines 
and FACSDiva software (BD Biosciences) was used for acquisition and analysis of all samples. 
BD FACS 7-color setup beads (BD Biosciences) were run in order to check proper instrument 
setting and detector linearity. 
 
The lymphocyte acquisition gate was set on CD45 fluorescence/side scatter plot and a minimum 
of 5000 events were acquired within the lymphocyte gate. 
Each lymphocyte subpopulation was analyzed and referred to a lymphocyte gate set on 
forward/side scatter parameters, and expressed as number of events as well as percentage of cells 
within the lymphocyte gate. 
 
Estimates of the absolute cell counts of lymphocyte subsets were obtained using dual-platform 
counting technologies, calculated from the percentage of cells in each subset obtained by flow 
cytometry and the absolute lymphocyte cell count obtained by automated hematology analyzer. 
 
CD25 expression/down-modulation on Total, CD4+ and CD8+ T-cells, was referred to the 
appropriate lymphocyte subpopulation and expressed as percentage of CD25-positive cells. 
 
Statistical analysis was performed in GraphPad Prism considering males and females together. 
 
The following parameters were analyzed: 
 
- CD25 expression, saturation and down modulation on CD4+ T-cells (cells %); 
- lymphocyte subsets and monocytes (absolute counts); 
- Hematological parameters: lymphocytes, neutrophils and white blood cells (WBC) (cells/μL 
of blood). 
 
For each parameter, data obtained at the different time points were compared with pre-treatment 
values; a control group of untreated animals was included. 
 
A repeated measurements one-way ANOVA per group, across time, for each parameter was 
used. It was then followed by a post-hoc test (Dunnett’s multiple comparison test of each time 
point against the pre-dose value). 
 
Statistical analysis of the parameters obtained during the recovery period was not performed due 
to the limited number of animals/group: 1 male + 1 female in groups 1, 2 and 3; 2 males + 
2 females in groups 4 and 5. 4.2.3.1.10 Other Biomarkers 
4.2.3.1.10.1 Natural killer (NK) cell activity 
NK activity was measured by the ability of effector cells (PBMC) to kill the target cells (human 
K562 cell line). 
 
Heparinized blood samples were obtained from the blood collected through the saphena vein 
from all animals at the following time point: pre-dose, at the end of treatment (on week 5) and at 
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three timepoints during the recovery period (in weeks 13, 25 and 28). 
 
Orpegen Pharma NKTEST kit for the quantification of the cytotoxic activity of natural killer 
cells was used following the manufacturer’s instructions. 
 
PBMCs were separated by Ficoll procedure and incubated with pre-stained (green fluorescence) 
K562 target cells for 2 hours at an effector/target ratio of 25:1. 
Each sample was prepared in triplicate. 
 
Moreover, positive control samples were prepared adding IL2 prior to incubation and control 
samples with target cells alone to measure spontaneous cell death (6 replicates). 
Cells were stained for 5 min with a DNA staining solution, to label killed cells, and immediately 
analyzed with FACSCanto (FACSDiva software). 
 
Target cells were gated and the percentage of dead target cells was obtained. 
Results were expressed as % of NK specific activity, determined by subtracting the percentage of 
dead cells in the control tubes from the percentage of killed target cells in the test samples. 
 
4.2.3.1.10.2 CRS MARKERS (TNFα, IL-6, IFNγ, IL-1β, IL-2, IL-4, IL-10, IL-8, MCP-1) 
In order to perform cytokine profiling investigations, blood samples were collected from 
animals at the following time points: 
 
 
 
 
At each selected time point 0.5 mL of blood were collected in tubes with Na-Citrate as 
anticoagulant and centrifuged at 2500g at +4°C for 10 min. The supernatant (plasma) was 
collected and divided into three aliquots, of at least 60 μL each, which were stored frozen at -
80°C until analysis. 
 
The Luminex100 system, a flow cytometer with two lasers able to perform the simultaneous 
detection of several cytokines/chemokines, was used in this study. 
 
The principle of the test is based on a regular sandwich ELISA where the primary antibody is 
coated onto a fluorescent polystyrene bead. 
These beads can be detected and sorted univocally by the first laser (635 nm) while the 
fluorochrome reporter (phycoerythrin), can be quantified by the second laser (523 nm). Different 
bead sets were combined in a single well to allow multiplex assays using a small amount of 
biological sample. 
 
The concentrations of the following cytokines/chemokines were determined: 
A) IFNγ, IL-2, IL-4, IL-10, TNFα, MCP-1, IL8 (kit for monkey cytokines/chemokines); 
B) IL-6 kit for human IL-6); 
C) IL1β (kit for monkey IL-1β). 
Group Route No. of animal 
Dose 
mg/ Kg 
Dosage 
regimen 
 
Time Points 
Day 0 Day 1 Day 28 
1 IV 4M+4F Vehicle Once a week 
 
Predose 2h 6h 24h 2h 6h 24h 
2 IV 4M+4F 5 Once a week 
 
Predose 2h 6h 24h 2h 6h 24h 
3 IV 4M+4F 25 Once a week 
 
Predose 2h 6h 24h 2h 6h 24h 
4 IV 5M+5F 125 Once a week 
 
Predose 2h 6h 24h 2h 6h 24h 
5 SC 5M+5F 75 Once a week 
 
Predose 2h 6h 24h 2h 6h 24h 
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Two commercial Luminex kits (Monkey Cytokines 5-plex – Cat # LPC0001 and Monkey 
Chemokines 5-plex – Cat # LPC0002, BioSource International Inc., Camarillo, CA) were mixed 
and used with their own reagents, buffers and standards, according to the leaflet (Figure 38) 
upon an optimization phase. 
 
A) The two kits included 10 analytes (IFNγ, IL-2, IL-4, IL-10, TNFα, MCP-1, MIP-1α, MIP-
1β, RANTES, IL8) but MIP-1α, MIP-1β and RANTES were not analyzed since of no 
interest for this study. 
 
Fig. 38: Determination of IFNγ, IL-2, IL-4, IL-10, TNFα, MCP-1, IL8 
 
Washing steps were performed in 1.2 μm filter membrane 96-well microtiter plates (Millipore 
Corp., Billerica, MA) with a multiscreen vacuum manifold for 96-well plates (Millipore). 
Incubations were done on a plate shaker Mini OrbitalShaker (Bellco Glass, In) at room 
temperature. The plates were read using the above-mentioned Luminex100 System (Luminex 
Corp., Austin, TX). 
 
B) A commercial Luminex kit (Human IL-6 single-plex – Cat # 171-B10719, Bio-Rad 
Laboratories, Hercules, CA) was used with its own reagents, buffers and standards, 
according to the leaflet (see figure below) upon an optimization phase. In particular, the 
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standard curve was run in a pool of monkey plasma (Na-Citrate) instead of using the buffer 
provided by the vendor. 
 
 
Fig. 39: Determination of IL-6 
 
Washing steps were performed in 1.2 μm filter membrane 96-well microtiter plates (Millipore 
Corp., Billerica, MA) with a multi-screen vacuum manifold for 96-well plates (Millipore). 
Incubations were done on a plate shaker Mini OrbitalShaker (Bellco Glass, In) at room 
temperature. The plates were read using the above mentioned Luminex100 System (Luminex 
Corp., Austin, TX). 
 
C) A commercial ELISA kit (Monkey IL-1β – Cat # CMK039, Cell Sciences, Canton, MA) was 
used with its own reagents, buffers and standards, according to the leaflet upon an 
optimization phase. In particular, the standard curve was run in a pool of monkey plasma 
(Na-Citrate) instead of using the buffer provided by the vendor. 
 
Data analysis: 
A-B) Data were generated and analyzed using the Luminex dedicated software: these data 
were arranged in an Excel spreadsheet and subsequently visualized in GraphPad. 
C) Data were generated using the Spectrophotometer dedicated software: these data were 
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analyzed and arranged in an Excel spreadsheet and subsequently visualized in 
GraphPad. 
 
Statistical analysis was performed on GraphPad: a two-way ANOVA test with Bonferroni post-
test (when necessary) was applied to evaluate both dose-effect along with time and time-effect 
within each experimental group. Due to the variability of the cytokine basal levels among 
animals, data were normalized versus the predose values. 
 
4.2.3.1.10.3 Functional test: T-cell Proliferation assay and Treg cells number evaluation 
Functional tests were set to evaluate the antiproliferative and immunomodulatory effect of Anti-
CD25 mAb. 
 
CD25 is present at low levels in resting human T cells (with the exception of T regulatory cells) 
but is significantly up-regulated on activated T cells, enabling them to receive a high-affinity IL-
2 signal [68]. 
 
Therefore, it is believed that the blockade of CD25 will result in selective functional inhibition of 
activated T cells [69]. Although it has been demonstrated that Daclizumab (or the original 
murine anti-Tac mAb) inhibits early IL-2R signal transduction events and blocks T cell 
activation and expansion in vitro [70], a comprehensive characterization of its in vivo effects is 
still lacking. 
 
T-cell proliferation assay and FoxP3 staining were performed at the following time point: pre-
dose, 24h after the last administration and at 3 recovery time-points (8, 18, 25 weeks after the 
last treatment). 
 
Blood samples (3 ml/monkey) were collected in tubes with Na Heparin for PBMCs separation. 
 
PBMCs from monkey were obtained by Ficoll gradient separation and 5x106 cells were stained 
with CSFE 5 μM and 2x106 unstained. Then cells were plated in a 96 well plate (0.2x106 
cells/well) in complete medium (RPMI 10%FBS, 1%PS, 1%L-Gln, 1% NEN, 1‰ Hepes, 50 μM 
β- mercaptoethanol) in presence and absence of stimuli as IL2, PHA and CD3 and left at 37°C in 
a cell incubator. After 72h cell proliferation was analyzed by FACS analysis. 
 
In parallel, PBMCs have been harvested immediately after blood collection for FoxP3 staining, 
in order to evaluate if the administration of Anti-CD25 mAb could affect T regulatory cells 
percentage. 
 
Data from literature showed that in MS patients FoxP3 levels were diminished, indicating that an 
impaired immunoregulation by T regulatory cells could contribute to MS exacerbation [71]. 
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4.2.3.1.10.4 Antibody determination 
Antibody determination (i.e. the presence of host-anti-drug antibodies) was done using residual 
serum samples obtained pre-study, at the end of treatment and during the recovery period. 
Collected blood samples were allowed to clot for 50-60 minutes at room temperature. 
 
The clot was spun down by centrifugation at 3000 rpm for 15 minutes and the supernatant was 
collected and divided into two aliquots, which were stored frozen at –80°C until analysis. 
Samples were analyzed using the validated ELISA method. 
 
4.2.4 Statistical methods and data analysis 
 
All raw data were recorded on appropriate forms bound in registers numbered, stored and 
processed by a computer system. All units of measure of the input data were selected so that the 
third decimal place would not be determinant. The computer rounds off figures at the second 
decimal place (except for the S.D.). 
 
By Internal definition, “day 0” is the day immediately preceding the start of treatment (day 1). 
 
The days of the experiment, both for pre-trial and experimental phases, are numbered according 
to this definition. In order to gather together the observations carried out on different calendar 
dates a “nominal day”, associated to each single observation, has been introduced. 
 
This day, coincides with the actual treatment day (defined as the difference between the date of 
the event and the date relative to “day 0”, previously defined) only for body weight and food 
consumption measurements. 
 
The “day”, is the actual day. The “week”, is calculated automatically on the basis of the 
“nominal day”, according to the following formula: 
 
week = integer part [(nom. day + 6)/7] if nom. day greater or equal to 0 
week = integer part [(nom. day - 6)/7] if nom. day less than 0 
 
Recordings were expressed both in absolute figures and as mean and standard deviation 
(M. ± S.D.). All the data were compared according to following decision tree. 
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Fig. 40: Statistical methods 
 
If one transformation was successfully applied, ANOVA and Dunnett’s test (when necessary) 
were applied on transformed data. 
 
Levels of significance were indicated by asterisks: 
* P <0.05 (all tests) 
** P <0.01 (all tests) 
*** P <0.001 (all tests except Dunnett’s test) 
 
Statistical analysis was performed using Graphpad Prism 4.3. The analysis applied was a 2-way 
ANOVA with repeated measurements (matching by subject), considering the 2 factors Time and 
Dose, followed by Bonferroni as post hoc test. 
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4.2.5 Regulatory Compliance 
 
The study design was in accordance with International Conference on Harmonization (ICH) 
Guidelines. 
 
Procedures followed during the study were those documented in the test facility Standard 
Operating Procedures collection. 
 
The Institute is fully authorized by Competent Veterinary Health Authorities. 
 
4.2.6 Ethics 
 
Protection of animals used in the experiment is in accordance with Directive 86/609/EEC, 
enforced by the Italian D. L. No. 116 of January 27, 1992. 
 
Physical facilities and equipment for accommodation and care of animals are in accordance with 
the provisions of EEC Council Directive 86/609.
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5. RESULTS   
5.1 CLINICAL OBSERVATIONS 
 
5.1.1 Mortality 
 
No animals died during the study. 
 
5.1.2 Clinical signs 
 
No clinical signs (general and local) or behavioural changes were observed in any monkey. 
 
5.1.3 Body Weight, Food Consumption, Rectal temperature 
 
Statistical analysis of mean data did not reveal significant changes from the control group at any 
of the doses tested. 
 
Treatment period - Males (monkeys) 
 
Fig. 41: Body weight – Treatment period – All the animals: Males (monkeys) 
Gr1:0mg/kg IV;Gr2:5 mg/kg IV;Gr3: 25mg/kg IV;Gr4:125 mg/kg IV;Gr5: 75mg/kg SC 
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Treatment period - Females (monkeys) 
 
Fig. 42: Body weight – Treatment period – All the animals: Females (monkeys) 
Gr1:0mg/kg IV; Gr2:5 mg/kg IV;Gr3: 25mg/kg IV;Gr4:125 mg/kg IV;Gr5: 75mg/kg SC 
 
 
No adverse effects were seen on mean food consumption of animals treated with the test item at 
any dose.  
No adverse effects were seen on body temperature. The differences highlighted by statistical 
analysis are without toxicological relevance. 
 
5.1.4 Ophthalmological Examination 
 
No eye changes were detected in any animal at any time. 
5.1.5 Electrocardiography and heart rate 
 
The subcutaneous and intravenous administration of Anti-CD25 mAb at all doses tested did not 
induce modifications in heart rate or in the electrocardiographic parameters. The morphological 
pattern of ECG complexes recorded at the scheduled times were comparable to those recorded 
pre-trial (basal) and no disturbances of cardiac rhythm were found at any dose. 
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5.2 LABORATORY INVESTIGATIOS 
 
5.2.1 Hematology 
 
No treatment-related hematological changes were seen in any animal treated at the various 
dosages by either intravenous or subcutaneous route at the end of the treatment or at any test 
point of the recovery period (Tables 3and 4). 
 
A slight statistically significant decrease in fibrinogen was noted in males treated at 
5 mg/kg/week pre-trial and at the end of the treatment period. However, it was considered 
incidental, being dose-unrelated. 
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Table 3: Hematologic parameters - Males (monkeys) 
(Mean, S.D., n) 
 
                                                            Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Erythrocytes ........................(x10E6/mcL)       -2     5.87     5.58     5.98     5.62     5.99 
                                                             0.568    0.558    0.121    0.507    0.333 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     5.02     4.70     5.01     4.95     5.12 
                                                             0.555    0.464    0.347    0.356    0.305 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     5.04     5.74     4.91     5.11     6.12 
                                                                                        0.120    0.092 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     5.34     6.02     5.55     5.54     6.49 
                                                                                        0.064    0.198 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     4.68     5.94     5.47     5.29     5.97 
                                                                                        0.057    0.212 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Hemoglobin ...............................(g/dL)       -2    14.00    13.35    14.72    13.60    13.94 
                                                             0.638    0.465    0.550    0.704    0.868 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    11.90    11.60    12.38    12.06    12.14 
                                                             0.678    0.577    0.568    0.288    0.385 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    12.70    12.40    12.80    12.50    13.90 
                                                                                        0.424    0.000 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    13.50    13.20    14.30    13.60    14.90 
                                                                                        0.707    0.424 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    12.20    13.00    14.00    13.25    13.90 
                                                                                        0.212    0.566 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Hematocrit ..................................(%)       -2    44.35    41.60    46.05    42.76    44.14 
                                                             2.403    2.211    1.318    2.180    2.924 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    37.85    35.97    38.48    37.64    37.46 
                                                             2.024    1.305    1.852    1.184    1.282 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    41.10    39.10    39.30    38.85    44.50 
                                                                                        2.475    0.141 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    43.10    40.40    44.30    42.05    47.15 
                                                                                        2.333    2.475 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    38.90    40.40    43.90    41.35    44.10 
                                                                                        0.919    2.263 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Leukocytes ..........................(x10E3/mcL)       -2    14.20    11.21    13.18    12.47    10.02 
                                                             2.846    3.038    5.162    3.404    3.003 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6    12.78    10.39    11.06    11.73     9.15 
                                                             1.928    2.191    4.424    1.819    0.474 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     8.31     9.21     7.01    11.75     9.63 
                                                                                        0.778    1.930 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    16.20    11.00    10.60    11.35     8.48 
                                                                                        1.202    0.106 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    15.80    10.60    15.10    14.45     8.88 
                                                                                        1.485    0.884 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Neutrophils .................................(%)       -2    49.88    40.17    48.43    41.24    46.24 
                                                             7.229   14.748   17.643   15.299   13.855 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    47.98    38.65    50.65    41.53    50.86 
                                                            10.364   13.126    9.956   23.409   13.906 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    35.60    26.70    49.00    52.65    37.80 
                                                                                       22.132   17.961 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    27.80    28.90    32.20    42.35    31.05 
                                                                                        4.172   10.536 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    21.70    20.50    47.00    38.75    27.05 
                                                                                        7.990   13.506 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Lymphocytes .................................(%)       -2    46.38    56.25    47.63    54.50    48.38 
                                                             7.433   16.155   18.578   15.188   13.504 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    47.70    55.92    44.62    52.42    44.84 
                                                             9.487   12.515   11.383   21.875   13.175 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    61.20    67.90    46.50    41.10    55.40 
                                                                                       18.102   15.698 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    68.10    67.60    65.50    54.05    62.90 
                                                                                        0.071   10.041 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    72.60    74.10    47.70    55.15    70.00 
                                                                                        6.718   16.688 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Monocytes ...................................(%)       -2     3.18     3.12     2.30     3.33     4.34 
                                                             1.520    1.900    0.964    1.199    1.329 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6     3.28     4.53     3.41     4.68     3.21 
                                                             0.670    2.461    1.133    2.831    0.388 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Monocytes ...................................(%)        8     2.66     4.70     2.45     5.51     6.08 
                                                                                        3.210    1.739 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     3.47     2.99     0.38     3.22     5.53 
                                                                                        4.356    0.445 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     4.29     4.84     2.62     4.92     2.39 
                                                                                        0.905    3.272 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Eosinophils .................................(%)       -2     0.50     0.34     1.57     0.64     0.82 
                                                             0.253    0.159    1.285    0.539    0.628 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
Eosinophils .................................(%)        6     0.87     0.55     1.08     0.98     0.98 
                                                             0.647    0.378    0.375    0.904    0.727 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.31     0.38     1.87     0.23     0.43 
                                                                                        0.267    0.109 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.64     0.43     1.93     0.31     0.45 
                                                                                        0.202    0.081 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     1.32     0.28     2.65     0.92     0.49 
                                                                                        0.486    0.178 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Basophils ...................................(%)       -2     0.10     0.14     0.07     0.27     0.19 
                                                             0.128    0.128    0.035    0.179    0.132 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6     0.20     0.32     0.20     0.40     0.11 
                                                             0.083    0.350    0.275    0.588    0.059 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.23     0.35     0.12     0.51     0.33 
                                                                                        0.543    0.390 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.06     0.06     0.00     0.10     0.07 
                                                                                        0.134    0.020 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.12     0.32     0.06     0.31     0.06 
                                                                                        0.062    0.078 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Neutrophils .........................(x10E3/mcL)       -2     7.14     4.58     7.02     5.16     4.86 
                                                             2.039    2.302    5.394    2.651    2.640 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     6.20     4.17     5.87     5.00     4.64 
                                                             1.996    1.956    3.475    3.173    1.258 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     2.96     2.46     3.44     6.27     3.80 
                                                                                        2.998    2.447 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     4.49     3.17     3.42     4.79     2.63 
                                                                                        0.049    0.863 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Neutrophils .........................(x10E3/mcL)       32     3.44     2.17     7.11     5.54     2.35 
                                                                                        0.601    0.969 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Lymphocytes .........................(x10E3/mcL)       -2     6.53     6.23     5.58     6.77     4.61 
                                                             1.460    2.382    0.662    2.396    0.840 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     6.04     5.66     4.65     6.03     4.12 
                                                             1.250    0.952    1.192    2.475    1.301 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     5.09     6.25     3.26     4.77     5.18 
                                                                                        1.831    0.460 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    11.00     7.42     6.97     6.13     5.34 
                                                                                        0.672    0.919 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    11.50     7.86     7.21     8.01     6.29 
                                                                                        1.768    2.100 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Monocytes ...........................(x10E3/mcL)       -2     0.44     0.35     0.32     0.45     0.45 
                                                             0.212    0.229    0.248    0.229    0.221 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6     0.42     0.48     0.41     0.53     0.29 
                                                             0.106    0.341    0.292    0.332    0.030 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.22     0.43     0.17     0.64     0.57 
                                                                                        0.337    0.052 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.56     0.33     0.04     0.39     0.47 
                                                                                        0.535    0.044 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.68     0.51     0.40     0.72     0.20 
                                                                                        0.202    0.270 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Eosinophils .........................(x10E3/mcL)       -2     0.07     0.04     0.22     0.07     0.08 
                                                             0.048    0.021    0.196    0.032    0.075 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     0.12     0.06     0.12     0.12     0.09 
                                                             0.096    0.049    0.048    0.103    0.067 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.03     0.04     0.13     0.03     0.04 
                                                                                        0.030    0.002 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.10     0.05     0.21     0.03     0.04 
                                                                                        0.019    0.008 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.21     0.03     0.40     0.14     0.04 
                                                                                        0.083    0.020 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Basophils ...........................(x10E3/mcL)       -2     0.01     0.02     0.01     0.04     0.02 
                                                             0.019    0.015    0.005    0.027    0.019 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Basophils ...........................(x10E3/mcL)        6     0.03     0.03     0.03     0.05     0.01 
                                                             0.009    0.044    0.048    0.071    0.006 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.02     0.03     0.01     0.06     0.03 
                                                                                        0.060    0.031 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.01     0.01     0.00     0.01     0.01 
                                                                                        0.016    0.001 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.02     0.03     0.01     0.04     0.00 
                                                                                        0.005    0.006 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular Volume ....................(fL)       -2    75.90    74.92    77.00    76.24    73.62 
                                                             4.745    6.912    2.340    4.279    2.226 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    75.95    77.03    77.00    76.20    73.30 
                                                             5.429    7.198    2.736    3.750    2.564 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
Mean Corpuscular Volume ....................(fL)        8    81.40    68.10    80.00    76.05    72.60 
                                                                                        3.041    0.849 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    80.70    67.20    79.80    75.80    72.55 
                                                                                        3.394    1.626 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    83.00    68.00    80.30    78.25    73.85 
                                                                                        2.475    1.202 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular HGB Conc. ...............(g/dL)       -2    31.57    32.12    32.00    31.84    31.62 
                                                             0.591    0.655    0.510    0.619    0.698 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6    31.40    32.23    32.25    32.00    32.38 
                                                             0.082    0.427    0.705    0.778    0.370 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    30.90    31.80    32.50    32.15    31.30 
                                                                                        1.061    0.000 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    31.40    32.60    32.30    32.35    31.60 
                                                                                        0.071    0.849 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    31.30    32.10    31.90    32.10    31.45 
                                                                                        0.141    0.354 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular HGB .......................(pg)       -2    23.98    24.05    24.65    24.32    23.28 
                                                             1.452    2.179    1.008    1.801    1.006 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    23.85    24.85    24.85    24.42    23.72 
                                                             1.654    2.339    1.363    1.647    1.055 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    25.20    21.70    26.00    24.45    22.70 
                                                                                        0.212    0.283 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Mean Corpuscular HGB .......................(pg)       13    25.40    21.90    25.80    24.55    22.95 
                                                                                        1.061    0.071 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    26.00    21.90    25.60    25.15    23.25 
                                                                                        0.636    0.071 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Platelets ...........................(x10E3/mcL)       -2   264.75   323.00   353.50   312.20   320.80 
                                                            30.391   54.522   79.910   64.794   98.594 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6   283.25   306.00   409.25   342.00   341.40 
                                                            43.146   51.088   67.638   40.927  103.057 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8   275.00   325.00   420.00   355.00   324.50 
                                                                                       77.782   71.418 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13   342.00   381.00   446.00   370.50   369.00 
                                                                                      106.773   39.598 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32   418.00   389.00   444.00   383.50   339.50 
                                                                                      120.915   75.660 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Prothrombin Time ..........................(sec)       -2     9.89     9.75     9.11     9.25     9.62 
                                                             1.567    0.733    0.295    0.391    2.731 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    10.18    10.60    10.18    10.34    10.38 
                                                             0.859    0.572    0.544    0.391    0.415 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    10.90    13.50    13.70    13.25    12.65 
                                                                                        1.909    0.919 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     9.90    10.20     9.60     9.98    10.15 
                                                                                        0.318    0.071 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     8.85     9.30     9.30     9.45     9.68 
                                                                                        0.000    0.106 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                         **                               P   * 
Fibrinogen ..............................(mg/dL)       -2   272.25   195.50   249.50   252.40   244.20 
                                                            31.742    9.469   26.489   36.060   34.967 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        1   271.50   234.00   296.00   284.25   288.60 
                                                            58.666   26.981   63.003   49.284   45.357 
                                                               (4)      (4)      (4)      (4)      (5) 
 
                                                                                                          P 
                                                        3   254.75   226.25   251.25   271.60   247.40 
                                                            11.587   17.858   13.623   22.367   33.687 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3   267.50   247.50   280.25   290.60   264.80 
                                                             9.000   27.887   24.432   20.157   45.263 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5   261.25   240.00   291.00   298.40   240.20 
                                                            25.734   21.710   36.092   62.035   36.711 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Fibrinogen ..............................(mg/dL)        5   295.50   255.50   311.25   355.00   308.80 
                                                            30.512   35.940   33.896   60.092   47.819 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                         **                               P  ** 
                                                        6   306.25   202.25   253.00   276.20   273.20 
                                                            28.418   12.868   22.465   33.064   41.656 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8   241.00   238.00   251.00   275.00   268.50 
                                                                                       52.326   38.891 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13   207.00   207.00   212.00   223.00   241.00 
                                                                                        0.000   18.385 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32   245.00   224.00   254.00   262.00   276.00 
                                                                                       49.497    7.071 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Activated Partial Thromboplastin Time .....(sec)       -2    17.77    19.38    18.27    18.98    18.84 
                                                             0.914    1.788    1.873    1.137    1.345 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    19.08    21.62    19.80    21.10    19.24 
                                                             0.991    0.613    1.467    1.202    2.638 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    18.00    23.20    20.40    24.55    20.30 
                                                                                        3.323    2.828 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Activated Partial Thromboplastin Time .....(sec)       13    17.50    16.60    16.00    17.65    15.50 
                                                                                        1.202    1.273 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    16.00    15.90    15.10    18.00    15.90 
                                                                                        0.849    0.707 
                                                               (1)      (1)      (1)      (2)      (2) 
 
ANOVA: "P" = Parametric; "N" = Non Parametric; "-" = Not processed 
Significance Level: * p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
 
Table 4: Hematologic parameters - Famales (monkeys) 
(Mean, S.D., n) 
 
                                                            Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Erythrocytes ........................(x10E6/mcL)       -2     5.60     5.60     5.67     5.59     5.61 
                                                             0.419    0.292    0.505    0.464    0.303 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     4.65     4.66     4.64     4.76     4.96 
                                                             0.382    0.260    0.436    0.556    0.316 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     5.40     5.40     5.45     5.75     5.36 
                                                                                        0.438    0.064 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     5.53     5.68     5.59     6.12     5.66 
                                                                                        0.177    0.163 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
                                                       32     5.50     5.73     5.56     5.95     5.64 
                                                                                        0.523    0.495 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Hemoglobin ...............................(g/dL)       -2    13.28    13.50    13.65    13.34    13.24 
                                                             1.239    0.812    1.201    0.805    0.513 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    11.10    11.28    11.30    11.32    11.62 
                                                             0.876    0.340    0.757    0.753    0.653 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    13.60    12.70    13.30    13.25    12.45 
                                                                                        1.061    0.354 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    14.10    13.40    13.60    13.80    12.95 
                                                                                        0.424    0.354 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    13.90    13.40    13.60    13.90    13.25 
                                                                                        1.131    0.495 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Hematocrit ..................................(%)       -2    41.92    42.30    42.85    41.64    41.82 
                                                             4.155    2.667    4.007    2.460    1.232 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    35.28    35.58    35.60    36.04    37.10 
                                                             3.099    1.072    3.058    2.801    1.789 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    42.30    39.70    40.90    41.15    39.25 
                                                                                        2.475    1.202 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    42.80    41.70    41.60    44.00    41.15 
                                                                                        0.566    0.354 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    43.50    42.70    42.70    43.35    41.85 
                                                                                        3.182    2.475 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Leukocytes ..........................(x10E3/mcL)       -2    12.69    12.15    13.08    13.83    16.32 
                                                             2.952    2.344    4.025    5.053    5.777 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    14.41    15.39    11.72    13.84    11.88 
                                                             6.895    4.312    1.884    7.589    2.480 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    12.50    10.80     9.57    10.11    13.75 
                                                                                        1.683    3.889 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Leukocytes ..........................(x10E3/mcL)       13    12.80     9.69    15.10    12.26    14.40 
                                                                                        4.306    2.970 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    17.60    11.80     9.45    13.70    16.30 
                                                                                        0.424    1.556 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Neutrophils .................................(%)       -2    27.73    33.80    29.57    37.84    31.00 
                                                            10.338    8.722    9.534   23.541    4.741 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Neutrophils .................................(%)        6    44.10    56.65    38.20    50.22    35.00 
                                                            16.371   14.776   18.122   22.159   10.050 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    38.90    41.40    30.60    34.50    33.25 
                                                                                       28.284    3.182 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    31.80    19.80    27.10    39.05    20.50 
                                                                                       19.163    2.687 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    51.30    28.80    37.90    45.95    24.70 
                                                                                       24.678    8.061 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Lymphocytes .................................(%)       -2    65.10    56.98    64.25    56.18    63.92 
                                                            10.120    5.324    9.750   25.094    3.770 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    47.98    38.33    55.75    44.62    58.44 
                                                            12.167   13.738   17.803   22.012    7.966 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    55.20    52.30    60.90    55.85    60.40 
                                                                                       34.153    2.828 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    65.40    72.80    66.30    53.35    73.55 
                                                                                       20.153    0.495 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    43.90    67.10    61.80    48.40    70.70 
                                                                                       27.294    7.637 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Monocytes ...................................(%)       -2     4.73     6.66     4.66     4.21     3.68 
                                                             1.043    2.751    0.709    2.636    2.023 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     5.93     3.97     4.71     4.26     4.90 
                                                             3.458    2.642    1.777    1.123    2.253 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     4.75     5.04     7.03     7.84     4.74 
                                                                                        6.173    0.997 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     1.54     5.19     4.93     5.84     3.94 
                                                                                        2.376    1.450 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     3.70     3.32     0.08     3.53     3.15 
                                                                                        4.472    0.000 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Eosinophils .................................(%)       -2     2.21     2.07     1.16     1.52     1.20 
                                                             3.173    1.950    0.869    1.157    0.496 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     1.58     0.70     1.12     0.76     1.32 
                                                             1.479    0.733    1.223    0.594    0.926 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     1.06     1.24     1.41     1.59     1.43 
                                                                                        0.354    1.299 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Eosinophils .................................(%)       13     0.97     2.23     1.62     1.68     1.64 
                                                                                        1.319    1.386 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     1.01     0.74     0.21     2.03     1.25 
                                                                                        1.907    0.537 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Basophils ...................................(%)       -2     0.24     0.47     0.34     0.21     0.20 
                                                             0.157    0.470    0.316    0.200    0.165 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        6     0.42     0.37     0.22     0.16     0.36 
                                                             0.424    0.293    0.167    0.121    0.347 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
Basophils ...................................(%)        8     0.14     0.07     0.10     0.28     0.14 
                                                                                        0.084    0.081 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.24     0.00     0.11     0.12     0.38 
                                                                                        0.027    0.299 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.07     0.08     0.00     0.03     0.16 
                                                                                        0.039    0.105 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Neutrophils .........................(x10E3/mcL)       -2     3.59     4.17     3.91     5.48     4.88 
                                                             1.685    1.522    1.973    4.947    1.006 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     7.16     8.59     4.55     7.55     4.05 
                                                             5.798    3.088    2.697    6.854    0.986 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     4.87     4.48     2.93     3.25     4.51 
                                                                                        2.284    0.870 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
Neutrophils .........................(x10E3/mcL)       13     4.07     1.92     4.09     4.36     2.91 
                                                                                        0.679    0.219 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     9.05     3.39     3.58     6.34     3.96 
                                                                                        3.578    0.926 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Lymphocytes .........................(x10E3/mcL)       -2     8.14     6.92     8.38     7.50    10.58 
                                                             1.770    1.467    2.874    3.198    4.425 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     6.31     6.05     6.50     5.57     7.02 
                                                             1.445    3.389    2.433    2.459    2.098 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     6.92     5.66     5.83     5.92     8.35 
                                                                                        4.377    2.758 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     8.37     7.05    10.00     6.95    10.59 
                                                                                        4.738    2.128 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     7.74     7.89     5.84     6.56    11.56 
                                                                                        3.521    2.319 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Monocytes ...........................(x10E3/mcL)       -2     0.60     0.77     0.63     0.54     0.63 
                                                             0.210    0.216    0.246    0.312    0.487 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     0.68     0.57     0.53     0.55     0.59 
                                                             0.157    0.382    0.115    0.207    0.319 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.59     0.55     0.67     0.74     0.63 
                                                                                        0.487    0.050 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.20     0.50     0.74     0.66     0.59 
                                                                                        0.041    0.325 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.65     0.39     0.01     0.49     0.51 
                                                                                        0.627    0.048 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Eosinophils .........................(x10E3/mcL)       -2     0.33     0.23     0.13     0.25     0.19 
                                                             0.507    0.190    0.105    0.248    0.094 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     0.21     0.11     0.12     0.13     0.17 
                                                             0.229    0.129    0.130    0.157    0.130 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.13     0.13     0.14     0.16     0.22 
                                                                                        0.062    0.235 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.12     0.22     0.24     0.23     0.26 
                                                                                        0.233    0.247 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.18     0.09     0.02     0.27     0.21 
                                                                                        0.252    0.107 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Basophils ...........................(x10E3/mcL)       -2     0.03     0.05     0.05     0.03     0.04 
                                                             0.024    0.046    0.048    0.025    0.044 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     0.05     0.06     0.03     0.02     0.04 
                                                             0.030    0.055    0.021    0.021    0.043 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.02     0.01     0.01     0.03     0.02 
                                                                                        0.004    0.017 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.03     0.00     0.02     0.02     0.06 
                                                                                        0.008    0.054 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.01     0.01     0.00     0.00     0.03 
                                                                                        0.006    0.015 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular Volume ....................(fL)       -2    74.92    75.60    75.50    74.66    74.56 
                                                             3.035    2.041    3.093    2.967    1.988 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    75.92    76.50    76.78    75.96    74.92 
                                                             2.939    2.146    2.024    3.250    2.799 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Mean Corpuscular Volume ....................(fL)        8    78.30    73.50    75.00    71.60    73.40 
                                                                                        1.131    3.111 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    77.50    73.40    74.50    71.95    72.85 
                                                                                        1.202    2.758 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    79.20    74.50    76.70    72.90    74.25 
                                                                                        1.131    2.051 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular HGB Conc. ...............(g/dL)       -2    31.63    31.93    31.90    32.08    31.60 
                                                             0.310    0.411    0.775    0.342    0.583 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    31.53    31.73    31.80    31.42    31.40 
                                                             0.723    0.287    0.698    0.841    0.612 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    32.10    32.10    32.50    32.20    31.75 
                                                                                        0.566    0.071 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    32.90    32.30    32.60    31.45    31.40 
                                                                                        0.636    0.566 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    32.00    31.50    31.90    32.15    31.65 
                                                                                        0.212    0.636 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Mean Corpuscular HGB .......................(pg)       -2    23.68    24.12    24.05    23.94    23.56 
                                                             0.900    0.486    0.719    1.092    0.688 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    23.95    24.27    24.40    23.90    23.52 
                                                             1.258    0.660    0.753    1.622    0.918 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    25.10    23.50    24.40    23.05    23.30 
                                                                                        0.071    0.990 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    25.50    23.70    24.30    22.55    22.85 
                                                                                        0.071    1.344 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    25.30    23.50    24.50    23.45    23.50 
                                                                                        0.212    1.131 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Platelets ...........................(x10E3/mcL)       -2   325.00   301.25   339.75   400.80   283.00 
                                                            30.463   44.131   84.721   49.160   85.121 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6   354.00   347.25   329.75   413.00   340.80 
                                                           110.686   44.925   80.769   24.970   65.473 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8   279.00   233.00   395.00   369.00   280.00 
                                                                                        5.657  113.137 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13   314.00   234.00   373.00   386.50   313.50 
                                                                                       12.021  137.886 
                                                               (1)      (1)      (1)      (2)      (2) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Platelets ...........................(x10E3/mcL)       32   317.00   302.00   452.00   422.00   362.50 
                                                                                       26.870  116.673 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Prothrombin Time ..........................(sec)       -2     9.95     9.97    10.38    10.14    10.22 
                                                             0.858    0.806    0.189    0.416    0.550 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    10.25     9.95    10.83    10.04    10.18 
                                                             0.332    0.603    0.512    0.230    0.502 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    10.50    10.50    13.60    10.07    10.65 
                                                                                        0.460    0.354 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    12.40    10.30    11.30    10.10     9.85 
                                                                                        0.424    0.636 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     9.00    10.50    10.60     9.38    10.03 
                                                                                        1.167    0.813 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Fibrinogen ..............................(mg/dL)       -2   219.00   232.75   227.25   219.60   242.20 
                                                            72.392   28.395   38.012   19.680   19.422 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        1   271.75   261.25   275.00   330.80   387.40 
                                                            20.549   39.204   49.173   89.438  102.810 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3   275.25   252.75   226.25   226.40   252.60 
                                                            53.922   54.402   28.312   26.633   17.516 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3   282.25   262.50   237.75   240.80   249.80 
                                                            62.591   44.918   18.786   16.664   12.716 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5   283.50   334.75   222.00   234.00   246.80 
                                                            79.685  219.505   67.562   21.668   28.683 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        5   250.50   334.25   237.75   278.00   248.60 
                                                            82.075  219.922   71.955   49.188   15.258 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6   250.75   263.50   222.50   233.20   225.00 
                                                            48.965   89.161   81.193   37.772   11.554 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8   184.00   160.00   209.00   167.00   189.00 
                                                                                       15.556    1.414 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13   178.00   163.00   188.00   211.50   165.50 
                                                                                        3.536   20.506 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32   248.00   188.00   229.00   225.00   216.00 
                                                                                       32.527    4.243 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Activated Partial Thromboplastin Time .....(sec)       -2    20.70    21.75    21.25    21.46    20.32 
                                                             2.825    0.545    3.131    2.844    3.283 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Activated Partial Thromboplastin Time .....(sec)        6    19.10    21.27    19.95    20.08    19.08 
                                                             1.421    2.081    3.025    2.158    2.179 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    18.00    22.50    26.10    21.00    18.95 
                                                                                        0.000    2.051 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    19.60    21.00    22.60    19.95    18.85 
                                                                                        0.919    3.041 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    15.60    20.30    20.10    17.80    16.10 
                                                                                        0.424    1.697 
                                                               (1)      (1)      (1)      (2)      (2) 
 
ANOVA: "P" = Parametric; "N" = Non Parametric; "-" = Not processed 
Significance Level: * p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
5.2.2 Blood Chemistry 
 
Compared to the control group, some treatment-related changes in blood chemistry tests 
appeared in the animals treated by either intravenous or subcutaneous route at the end of the 5-
week treatment (Tables 5 and 6).  
 
Minor decreases in IgG and IgM were detected at the two higher IV doses and in the group 
treated by SC route at the end of the dosing period but of no biological meaning. 
 
Several changes were observed in both sexes treated by either intravenous or subcutaneous (only 
for one female animal) route. However, all the findings in alpha 1 glycoprotein acid and C-
reactive protein were considered transient changes, being dose-unrelated or time-unrelated. 
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Table 5: Blood chemistry relevant parameters - Males (monkeys) 
(Mean, S.D., n) 
 
                                                            Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          N 
Alpha 1 Glycoprotein Acid ...............(mg/dL)       -2    34.00     n.d.    23.00    22.00    24.50 
                                                            10.739                      0.000    2.646 
                                                               (4)               (1)      (2)      (4) 
                                                                                                          P 
                                                        1    30.75    23.67    25.25    36.20    30.50 
                                                             8.421    6.351    3.202   23.317    6.557 
                                                               (4)      (3)      (4)      (5)      (4) 
 
                                                                                                          P 
                                                        3    35.50    26.50    25.00    28.00    26.75 
                                                             4.950    0.707    2.828    9.644    7.890 
                                                               (2)      (2)      (2)      (3)      (4) 
 
                                                                                                          P 
                                                        3    33.50    28.00    24.50    26.00    28.00 
                                                             4.950    6.557    0.707    6.377    7.165 
                                                               (2)      (3)      (2)      (4)      (4) 
 
                                                                                                          P 
                                                        5    35.00    26.50    24.67    28.67    30.00 
                                                             4.243    7.778    6.429   10.786    1.414 
                                                               (2)      (2)      (3)      (3)      (2) 
 
                                                                                                          P 
                                                        5    28.50    27.67    27.75    32.00    33.33 
                                                             7.506   11.590    7.411   13.323    9.713 
                                                               (4)      (3)      (4)      (5)      (3) 
 
                                                                                                          P 
                                                        6    36.00    24.50    24.00    27.60    28.25 
                                                            11.518    6.364    5.292    8.204    8.655 
                                                               (4)      (2)      (3)      (5)      (4) 
 
                                                                                                          N 
Alpha 1 Glycoprotein Acid ...............(mg/dL)        8    20.00    23.00     n.d.    29.50    32.50 
                                                                                       12.021    0.707 
                                                               (1)      (1)               (2)      (2) 
 
                                                                                                          - 
                                                       13     n.d.     n.d.     n.d.     n.d.    27.00 
                                                                                                 2.828 
                                                                                                   (2) 
 
                                                                                                          N 
                                                       32    57.00     n.d.    21.00    20.00    26.00 
                                                                                                 2.828 
                                                               (1)               (1)      (1)      (2) 
 
                                                                                                          P 
Immunoglobulin G ........................(mg/dL)       -2  1231.50  1284.75  1006.00  1230.00  1149.60 
                                                            67.456  278.620  127.088  147.907  155.146 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6  1227.50  1278.50   957.75  1113.40   948.00 
                                                           124.551  253.728  171.165  240.242  205.359 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8  1087.00  1478.00   720.00  1216.00  1135.50 
                                                                                      642.053  327.390 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13  1065.00  1198.00   791.00  1201.00  1161.50 
                                                                                      200.818  184.555 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32   970.00  1055.00   831.00  1019.00  1046.00 
                                                                                      101.823  114.551 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Immunoglobulin M ........................(mg/dL)       -2   101.50    91.25    91.75    88.40    94.80 
                                                            30.946   38.483   26.538   26.159   22.499 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Males - continue)                                          Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Immunoglobulin M ........................(mg/dL)        6   100.50    71.50    89.25    63.40    60.00 
                                                            33.491    9.883   31.009   28.059   10.607 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    95.00    57.00    75.00    43.50    59.50 
                                                                                        6.364    4.950 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    83.00    55.00    71.00    53.00    66.00 
                                                                                       14.142   21.213 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32    80.00    48.00    52.00    36.00    53.00 
                                                                                        7.071    1.414 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
C-Reactive protein .......................(mg/L)       -2     2.30     2.27     0.71     0.84     1.08 
                                                             2.706    1.854    0.364    0.567    1.010 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        1     2.06     3.59     1.84     6.53     1.06 
                                                             1.461    3.104    2.049   11.277    0.475 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3     1.20     4.00     1.19     1.22     1.03 
                                                             0.753    2.882    0.971    0.583    0.512 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        3     1.24     6.15     1.39     1.17     1.08 
                                                             0.289    6.956    1.180    0.407    0.562 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5     1.12     2.87     1.48     2.17     0.88 
                                                             0.508    2.331    0.950    2.149    0.526 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5     1.32     4.35     1.41     2.45     1.08 
                                                             0.598    4.888    0.579    1.240    0.460 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     1.30     1.37     0.88     1.42     0.92 
                                                             1.281    0.744    0.863    1.054    0.753 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.87     2.46     0.89     1.94     0.97 
                                                                                        1.690    0.566 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.65     2.85     0.56     1.35     0.98 
                                                                                        0.516    0.912 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     0.40     1.99     2.67     1.52     0.95 
                                                                                        0.064    0.863 
                                                               (1)      (1)      (1)      (2)      (2) 
 
 
ANOVA: "P" = Parametric; "N" = Non Parametric; "-" = Not processed 
Significance Level: * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 6: Blood chemistry relevant parameters - Females (monkeys) 
(Mean, S.D., n) 
 
                                                            Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                                          P 
Alpha 1 Glycoprotein Acid ...............(mg/dL)       -2    31.67    26.00    25.75    23.67    25.75 
                                                            14.154    7.211    7.136    1.155    6.551 
                                                               (3)      (3)      (4)      (3)      (4) 
 
                                                                                                          P 
                                                        1    30.75    32.00    35.50    38.20    47.60 
                                                            11.587   11.916   13.916    9.731   35.872 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3    32.67    31.33    27.67    25.00    30.50 
                                                            17.616    8.622    4.041    2.345    9.815 
                                                               (3)      (3)      (3)      (5)      (4) 
 
                                                                                                          P 
                                                        3    35.67    29.75    28.25    25.60    30.50 
                                                            14.154    8.057    6.238    2.966    7.188 
                                                               (3)      (4)      (4)      (5)      (4) 
 
                                                                                                          N   * 
                                                        5    37.75    88.00    27.33    26.60    24.75 
                                                            14.245   97.041    1.528    3.286    1.708 
                                                               (4)      (3)      (3)      (5)      (4) 
 
                                                                                                          P 
                                                        5    37.75   107.75    29.75    37.20    26.60 
                                                            15.019  154.957    7.588    4.817    5.079 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6    35.50    51.50    29.33    29.80    24.50 
                                                            17.464   48.473    7.572    4.970    2.380 
                                                               (4)      (4)      (3)      (5)      (4) 
 
                                                                                                          N 
                                                        8    20.00    21.00    26.00    21.00    25.00 
                                                                                        0.000    1.414 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    24.00     n.d.    22.00    24.00    23.50 
                                                                                                 0.707 
                                                               (1)               (1)      (1)      (2) 
 
                                                                                                          N 
                                                       32    32.00     n.d.    25.00    20.00    22.50 
                                                                                                 0.707 
                                                               (1)               (1)      (1)      (2) 
 
                                                                                                          P 
Immunoglobulin G ........................(mg/dL)       -2  1342.25  1172.75  1151.75  1140.20  1179.80 
                                                            65.688   83.252  256.904  107.855  122.757 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6  1219.00  1087.50   930.75   836.20   912.60 
                                                            91.240   73.822  268.891  202.355  237.596 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8  1227.00  1201.00   839.00   960.50   949.00 
                                                                                      253.851  113.137 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13  1308.00  1305.00   872.00  1165.00  1142.50 
                                                                                      164.049   27.577 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32  1298.00  1182.00   813.00  1085.50  1105.00 
                                                                                      228.395   96.167 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
Immunoglobulin M ........................(mg/dL)       -2   116.75    89.00    78.75    78.80    93.20 
                                                            24.171   14.810   27.256   18.660   41.746 
                                                               (4)      (4)      (4)      (5)      (5) 
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(Females - continue)                                        Gr# 1    Gr# 2    Gr# 3    Gr# 4    Gr# 5     ANOVA 
Dose (mg/kg/week)                                                0        5       25      125       75 
---------------------------------------------------------   ------   ------   ------   ------   ------ 
                                                     Week 
                                                                                   *       **        *    P  ** 
Immunoglobulin M ........................(mg/dL)        6   104.75    77.50    53.25    37.60    61.40 
                                                            24.865   16.523   18.715    8.503   31.230 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8    97.00    94.00    41.00    31.50    41.50 
                                                                                        0.707    0.707 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13    96.00    94.00    52.00    44.50    48.50 
                                                                                        7.778    9.192 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32   102.00    72.00   173.00    52.50    56.50 
                                                                                        2.121    2.121 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          P 
C-Reactive protein .......................(mg/L)       -2     1.14     1.11     2.50     0.98     1.73 
                                                             0.668    0.408    3.488    0.451    1.582 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        1     1.19     1.43     2.61     5.49     7.61 
                                                             0.638    0.989    3.171    2.867    9.231 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3     1.24     1.08     1.32     1.60     1.42 
                                                             0.691    0.654    1.006    0.873    1.041 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        3     1.36     1.40     1.81     1.56     1.37 
                                                             0.443    0.589    1.200    0.819    1.017 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5     2.78     7.97     1.27     2.30     1.36 
                                                             3.200   13.700    0.880    1.758    1.001 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        5     1.37     7.11     1.98     4.19     1.97 
                                                             0.622   11.025    1.228    3.999    1.469 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          P 
                                                        6     1.54     1.33     1.26     1.49     1.16 
                                                             0.815    0.565    1.215    0.740    1.004 
                                                               (4)      (4)      (4)      (5)      (5) 
 
                                                                                                          N 
                                                        8     0.51     0.56     0.28     0.63     0.65 
                                                                                        0.523    0.028 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       13     0.41     0.27     0.11     0.83     1.18 
                                                                                        0.905    1.195 
                                                               (1)      (1)      (1)      (2)      (2) 
 
                                                                                                          N 
                                                       32     4.89     0.62     0.18     1.84     1.48 
                                                                                        0.813    1.435 
                                                               (1)      (1)      (1)      (2)      (2) 
 
ANOVA: "P" = Parametric; "N" = Non Parametric; "-" = Not processed 
Significance Level: * p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
5.2.3 Urinalysis 
 
No treatment-related variations in urinalyses were noted in any animal treated at various dosages 
by either intravenous or subcutaneous route at the end of the 5-week treatment period or at any 
test point during the recovery period. 
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5.3 PATHOLOGY 
 
5.3.1 Organ weights 
 
No organ weight variations related to treatment were seen at either sacrifice. 
 
5.3.2 Macroscopic Findings 
 
No treatment-related changes were noted at either sacrifice. 
 
At final killing, sporadic cases of perivascular hemorrhage were seen at the injection site of 
control and treated animals and considered to be caused by needle trauma. 
 
5.3.3 Microscopic Findings 
 
No systemic changes were seen in animals treated with Anti-CD25 by intravenous or 
subcutaneous routes at the final sacrifice. 
At the injection site, treatment-related changes were seen only in animals injected 
subcutaneously with 75 mg/kg/day (group 5) of the test item. Such changes consisted of minimal 
or mild perivascular mononuclear cell infiltration. 
A range of lesions was seen in several organs, all considered as incidental and of no relation to 
treatment. In fact, such changes had a comparable incidence in control and treated groups, or are 
characteristically seen in control Cynomolgus monkeys used in our laboratory. In particular, 
presence of hemorrhage, subcutaneous and vascular hemorrhage at the injection sites had a 
comparable incidence in control and treated animals and were considered to be related to needle 
trauma. After the withdrawal period, local changes induced by subcutaneous treatment had 
recovered completely. 
 
5.4 TOXICOKINETICS 
 
Anti-CD25 mAb was administered once a week for 5 consecutive weeks to Cynomolgus 
monkeys. Three groups were treated by intravenous route at 5 mg/kg (4 males and 4 females), at 
25 mg/kg (4 males and 4 females) and at 125 mg/kg (5 males and 5 females). The fourth group 
was treated by subcutaneous route at 75 mg/kg (5 males and 5 females). The control group (4 
males and 4 females) received 0 mg/kg dose (vehicle) by intravenous route. 
 
Complete toxicokinetic profiles were monitored after the first (Day 1) and the last treatment 
(Day 29). The following samplings were carried out also during the intermediate period: at all 
doses IV: 2nd, 3rd and 4th treatment, times 0 and 0.5 hours; SC 2nd, 3rd and 4th treatment, times 
0 and 4 hours. Sampling was performed also in recovery animals (1 male and 1 female at 5 and 
25 mg/kg IV doses; 2 males and 2 females at 125 mg/kg IV dose and 75 mg/kg SC dose). All the 
animals were exposed to the test item for the entire treatment periods. No test item amounts were 
found in animals at pre-dose sampling. 
The main PK parameters are reported in the following table as mean ± S.D. values (Table 7). 
Page 93 
Table 7: PK parameters - (Mean ± S.D.) 
 
Dose (mg/kg) 5 25 125 
Dose ratio 1 5 25 
INTRAVENOUS  ADMINISTRATION 
Day 1 
Cmax                      (µg/mL) 132.0 ± 39.5 522.2 ± 92.3 3120 ± 1954 
tmax   
(1)                         (h) 0.083 (0.083-3) 0.083 (0.083-0.5) 0.29 (0.083-3) 
AUC0-168             (h⋅µg/mL) 5853 ± 789 25511 ± 4185 141243 ± 22434 
AUC                     (h⋅µg/mL) 8675 ± 1529 39850 ± 11861 231234 ± 60164 
MRT168                           (h) 64.3 ± 1.6 66.1 ± 5.0 65.9 ± 3.4 
t1/2                                    (h) 100.9 ± 21.7 106.1 ± 40.1 121.9 ± 55.7 
Cl                          ( mL/h/kg) 0.60 ± 0.12 0.67 ± 0.17 0.57 ± 0.13 
Vz                             ( mL/kg) 84.36 ± 13.52 97.05 ± 30.81 92.81 ± 21.13 
Vss                           (mL/kg) 84.58 ± 10.81 99.31 ± 23.58 93.45 ± 19.78 
DP AUC 0-168 ratio  4.4 24.1 
 
Day 29 
  **  **  ** 
Cmax                       (µg/mL) 207.2 ± 79.4  898.8 ± 304.9  4752 ± 4277  
tmax   
(1)                          (h) 0.5 (0.083-24)  0.5 (0.083-4)  0.5 (0.083-3)  
AUC0-168             (h⋅µg/mL) 12849 ± 3710  46887 ± 23191  230391 ±51877  
AUCz                    (h⋅µg/mL)  27178  99093  559334 ± 140592 
AUC                     (h⋅µg/mL) 17689 ± 3784 27245 86682 ± 48017 99106 342852±59303 559414 ± 140634 
MRT168                            (h) 68.6 ± 2.1  67.7 ± 4.7  65.7 ± 3.2  
MRTz                                (h)  218. 3  221.4  371.9 ± 35.0 
t1/2                                    (h) 118.5 ± 35.6 201.3 120.6 ± 40.3 180.5 103.7 ± 15.1 265.0 ± 40.4 
Cl                          ( mL/h/kg) 0.30 ± 0.06 0.19 0.34 ± 0.13 2.33 0.38 ± 0.07 0.24 ± 0.07 
Vz                            ( mL/kg) 47.91 ± 5.36 52.60 53.71 ± 9.43 109.30 55.29 ± 8.23 91.41 ± 34.68 
Vss                           (mL/kg) 48.19 ± 3.42 39.97 55.07 ± 9.00 87.16 55.13 ± 8.82 89.50 ± 35.45 
DP AUC 0-168 ratio   3.7  17.9  
Rac 2.3 ± 1.0  1.8 ± 0.8  1.6 ± 0.3  
AUCτ-AUC∞ ratio 1.58 1.15 1.04 
 
Dose (mg/kg) 75 
SUBCUTANEOUS  ADMINISTRATION 
 Day 1 Day 29 
   ** 
Cmax                                    (µg/mL) 980.7 ± 913.7 1965 ± 2249  
tmax   
(1)                                       (h) 24 (24-24) 24 (6-432)  
AUC0-168                         (h⋅µg/mL) 82589 ± 33529 157484 ± 43862  
AUCz                                 (h⋅µg/mL)   401483 ± 106974 
AUC                                  (h⋅µg/mL) 157682 ± 46128 323820 ± 106009 401509 ± 106998 
t1/2                                                 (h) 153. 0 ± 83.4 165.1 ± 43.4 236.6 ± 114.0 
MRT168                                        (h) 74.2 ± 7.6 72.9 ± 6.2  
MRTz                                            (h)   375.6 ± 95.4 
Rac  2.1 ± 0.8  
F 1.08 1.12  
AUCτ-AUC∞  ratio  1.08 
* As regards Day 29, group 2, subject no. 311021M was excluded from mean ± SD calculation 
** Values derived from animals undergoing recovery period 
(1) Median and range are indicated for tmax 
DP AUC0-168 ratio = Dose proportionality, calculated by AUC0-168h (Dose 25 or 125 mg/kg)/ AUC0-168 (Dose 5 mg/kg) 
values 
Rac = Accumulation ratio, calculated by AUC0-168h (Day 29)/ AUC0-168 (Day 1) values 
F= Absolute bioavailability calculated by AUC0-168h (s.c) vs. AUC0-168h (i.v., dose 25 mg/kg) values 
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Absorption rate: 
Serum levels were seen to increase after IV doses 
 
Dose proportionality: 
The compound was quantifiable at all sampling times in all groups, with good dose 
proportionality. On Day 29 the increase in exposure remained still roughly proportional with the 
dose. As expected, AUC values were higher in animals following recovery period, confirm the 
acceptable dose proportionality. After subcutaneous dose, it was showed an increased exposure 
between the first and the last, 5th, administration. 
 
Mean residence time: 
MRT values (after IV doses till 168 h) were comparable between sampling days and overall were 
about 3 days. Longer MRT were observed in recovery animals (range 10-15 days). MRT values 
found after SC administrations were similar to those after IV treatments, being about 3 days on 
both Day 1 and Day 29 and about 15 days in the animals under recovery monitoring. 
 
Half-life values: 
Animals treated by IV route showed a very slow elimination rate in the 0- 168 h interval; half-
life values, on Day 1 ranging from 101 h (about 4 days) to122 h (about 5 days) and 104–121 h 
(about 4-5 days) on Day 29. A longer half–life was observed after the last dose in recovery 
animals, ranging from 180 to 265 h (about 7.5-11 days). Also SC administration showed slow 
compound elimination. Half-life was 153 h (about 6 days) and 165 h (about 7 days) when 
calculated until 168 h on Day 1 and Day 29 and 237 h (about 10 days) in recovery animals. 
These values are similar to those obtained after IV treatments. 
 
Clearance and Distribution volume: 
PK profiles followed until 168 h showed low clearance values (range 0.57-0.67 mL/h/kg) on 
Day 1. Distribution volume values at steady state, Vss, were in general low at all doses and 
sampling periods. On Day 1 they ranged 84.6-99.3 mL/kg and on Day 29 ranged 48.2-55.1 
mL/kg. As regard recovery animals, they showed low Vss values, namely in the range from 40.0 
to 89.5 mL/kg. 
 
The results suggested compound distribution limited to the volume of the extracellular space, 
due to high molecular weight and therefore low ability to cross membranes. 
 
Accumulation ratio: 
Compound accumulation was estimated by Rac values, calculated as the AUC0-168h Day 
29/AUC0-168h Day 1 ratio. As general trend, at low doses there was higher accumulation, but 
also higher data variability (as expected). Accumulation was not overall noticed by either IV or 
IV treatments, with the exception of group 2 (ratio=1.6 and Rac=2.3), anyway the values were 
not however statistically significant (Student T test= 0.06). 
 
To better clarify the matter, concentration at steady state was calculated using WinNonLin 
(nonparametric superposition tool), the results are reported in the following table (Table 8) and 
are consistent with the above conclusions. 
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Table 8: Compound accumulation ratio 
Animal n° AUC0-168 (5th adm) AUCinf (1st adm) Ratio Animal n° AUC0-168 (5th adm) AUCinf (1st adm) Ratio
212101M 11660 9731 1.20 208097M 35163 31414 1.12
309087M 10684 6646 1.61 209075M 42885 37880 1.13
401043M 20336 6299 3.23 310153M 45806 36678 1.25
312224F 12113 10255 1.18 402027M 5469 31495 0.17
312342F 10367 8278 1.25 109110F 82667 64900 1.27
401126F 9811 10240 0.96 304172F 49243 42980 1.15
401208F 14974 9303 1.61 312398F 42667 27425 1.56
Mean 1.58 p=0.059§ 312490F 71199 46029 1.55
SD 0.77 Mean 1.15 p=0.233§
CV 49% SD 0.43
CV 38%
Animal n° AUC0-168 (5th adm) AUCinf (1st adm) Ratio Animal n° AUC0-168 (5th adm) AUCinf (1st adm) Ratio
10103M 264142 209180 1.26 202205M 169485 191191 0.89
308363M 199081 229522 0.87 210253M 155849 198028 0.79
309073M 182567 337959 0.54 309365M 159328 113267 1.41
310411M 213797 280011 0.76 312003M 202331 131099 1.54
404015M 205143 210721 0.97 401037M 130459 131293 0.99
306520F 264044 192889 1.37 108190F 148423 86972 1.71
307610F 224675 191894 1.17 302688F 107179 160352 0.67
308074F 238638 172798 1.38 303226F 254907 168332 1.51
312210F 176587 168998 1.04 307140F 122713 150033 0.82
402134F 337677 318366 1.06 401222F 124162 246251 0.50
Mean 1.04 p=0.979§ Mean 1.08 p=0.993§
SD 0.27 SD 0.42
CV 26% CV 39%
§ Student t-test, paired data.
Group 5 (SC, 75 mg/kg)
Group 2 (IV, 5 mg/kg) Group 3 (IV, 25 mg/kg)
*: Animal 311021M excluded due to a possible administration error.
Group 4 (IV, 125 mg/kg)
 
 
Absolute subcutaneous bioavailability: 
The F values, calculated from the ratio of AUC0-168h on Day 1 or Day 29 vs. the AUC0-168h 
found at 25 mg/kg IV, were 1.08 after the first administration and 1.12 after the last (5th) 
treatment, indicating a good compound bioavailability by this route at 75 mg/kg. No gender 
difference was found. 
 
Toxicokinetics evaluation: 
Serum level increased between the first and the last treatment at all doses by both administration 
routes. Evaluations were carried out on data from all animals on Day 1 (first treatment) and on 
Day 29 (last, 5th treatment) until the 168 h sampling time after both administration routes, then 
extended to recovery animal data. After intravenous doses, concentrations peaked at 0.083-0.5 h, 
increasing between the sampling periods. Acceptable dose proportionality was found. 
Compound residence in the body, evaluated as MRT, was long, about 3 days on both Day 1 and 
Day 29, increasing to 10- 15 days in animals during the recovery period. Therefore and as 
expected, also elimination occurred at very slow rate, in general recording a half-life of about 4-5 
days on Day 1 and Day 29 or longer, 10-15 days, in the profiles of animals that completed 
kinetics during the recovery period. Low clearance and small distribution volume at steady-state 
were found. In general their values were seen to decrease from Day 1 to Day 29 and to recovery 
weeks, suggesting compound distribution in the extracellular fluids. Accumulation was not 
observed at any dose after intravenous dosing. 
Subcutaneous treatment attained their maxima levels usually within 24 h and concentrations 
increased between the first (Day 1) and the last (Day 29) administration. Exposure increased 
with time. The long mean residence time, about 3 days on Day 1 and Day 29, was still longer, 
about 15 days, in recovery animals. Similar values were recorded after IV doses. Half-life values 
were 6-7 days on Day 1 - Day 29 and about 10 days in recovery animals. No significant 
compound accumulation was found after multiple SC administration. Bioavailability was 108% 
after the first treatment and 112% after the last treatment. 
 
Page 96 
5.5 PD MARKERS: LEUKOCYTE AND LYMPHOCYTE SUBSETS; CD25 
EXPRESSION, SATURATION AND DOWN-MODULATION ON LYMPHOCYTE 
SUBSETS 
 
CD25 expression, saturation and down modulation  
 
CD25 expression on T cytotoxic cells was lower than 1% over time. 
 
Therefore, data related to this lymphocyte subpopulation were not reported. Because CD25 
expression was limited to CD4+ T-cells, the analyses of CD25 expression, saturation by Anti-
CD25 (Figure 43 and 44) and CD25 down-modulation were focused on this population only. 
 
CD25 expression, saturation 
 
Spontaneous expression of CD25 antigen in untreated healthy Cynomolgus monkey was detected 
on about 4% of CD4+ T-cells (mean from pre-trial data of 44 animals, 22M + 22F). 
 
IL-2Rα saturation was recorded at 3 and 6 h after Anti-CD25 administered by iv route at 5, 25, 
125 mg/kg and by sc route at 75 mg/kg, respectively, confirming data obtained in previous 
experiments. 
This parameter was evaluated once a week, before each treatment until the end of Anti-CD25 
administration (Day 29). 
 
CD25 saturation was observed in all dosed animals until the end of treatment (Day 28) with the 
exception of two male animals (Group 2 and (Group 3) in which CD25 expression near to pre-
treatment value (2.1 and 3.2%, respectively), started to show from Day 14 and at the end of 
treatment, respectively. 
 
CD25 desaturation 
 
CD25 desaturation, detected by anti-CD25/ACT-1 binding, was measured at biweekly intervals 
in the first 6 weeks after treatment and at monthly intervals until complete desaturation was 
reached in 1 animal/sex in groups 2 and 3, and 2 monkeys/sex in groups 4 and 5. 
 
CD25 desaturation was defined for each treated animal as return to a percentage of CD25+ cells 
similar to the pre-treatment value, as well as maintenance of constant values of CD25+ cell 
percentage. 
 
Moreover, for all animals undergoing recovery, CD25 desaturation was assessed as absence of 
Anti-CD25 bound to CD4+ T-cells detected with an anti-human IgG PE-conjugated mAb able to 
bind Anti-CD25 on the cell surface. 
 
CD25 desaturation was reached in a dose-dependent manner with the exception of the animal 
dosed at 25 mg/kg by IV route, in which the recovery of CD25 was observed on Day 28. 
 
Moreover the period to achieve the CD25 expression in female animals was longer than in male 
animals as reported below: 
 
Male animals 
- at week 6 of recovery in animals dosed at 5 mg/kg by IV route; 
- at Day 28 of treatment in animals dosed at 25 mg/kg by IV route; 
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- between weeks 11-18 of recovery in animals dosed at 125 and 75 mg/kg by iv and SC route, 
respectively. 
 
Female animals 
- at week 14 of recovery in animals dosed at 5 mg/kg by IV route; 
- at week 23 of recovery in animals dosed at 25 mg/kg by IV route; 
- at week 29 of recovery in animals dosed at 125 and 75 mg/kg by IV and SC route, 
respectively. 
 
 
Fig. 43: CD25 expression and saturation on CD4+ T cells - Males (monkeys) 
 
 
Fig.44: CD25 expression and saturation on CD4+ T cells - Females (monkeys) 
 
 
CD25 down-modulation 
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A trend toward CD25 down-modulation was observed at all doses (Figures 45 and 46). 
 
A statistically significant reduction in CD25+ cell % was recorded from Day 7 to Day 28 in 
animals dosed at 125 mg/kg by IV route and on Days 14 and 28 in animals dosed at 75 mg/kg by 
SC route. 
 
 
Fig. 45:CD25 down modulation on CD4+ T cells – Males (monkeys) 
 
 
Fig.46: CD25 down modulation on CD4+ T cells – Females (monkeys) 
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Total leukocytes, leukocyte subsets and lymphocyte subsets 
 
Individual data of leukocytes, leukocyte subsets (lymphocytes and neutrophils, absolute count) 
monocytes and lymphocyte subpopulations absolute counts are reported (Table 9). 
No treatment-related effects were seen on total leukocytes and leukocyte subsets, on total Tcells, 
helper T cells, cytotoxic T-cells, B-cells and NK-cells over time. 
A statistically significant increase in leukocyte and neutrophils absolute counts (Table 10), 
observed 3-6 hours after the beginning of treatment, seems to be related to the frequent blood 
sampling performed during the study to carry out the different analyses scheduled. 
Other statistically significant variations observed in some lymphocyte subsets reported as 
absolute counts, were considered treatment-unrelated and without any biological relevance. 
 
Table 9: Lymphocyte subsets and Monocytes absolute values - (Mean ± S.D.) 
 
Group 1 (IV) - 0 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 4352 2505 4344 4847 4557 3799 
S.D. 990 424 1936 3274 3268 1189 
N 4 4 4 4 4 4 
T helper cells 
Mean 2270 1403 2021.75 2235 2124.25 1855 
S.D. 665 392 702 1147 1522 465 
N 4 4 4 4 4 4 
T cytotoxic cell 
Mean 2095 1100 2346 2597 2420 1945 
S.D. 788 47 1556 2459 2260 994 
N 4 4 4 4 4 4 
B cells 
Mean 2228 1866 2134 2365 1924 2129 
S.D. 1170 1300 836 609 491 1058 
N 4 4 4 4 4 4 
NK cells 
Mean 875 339 540 447 442 773 
S.D. 79 177 347 325 462 285 
N 4 4 4 4 4 4 
Monocyte 
Mean 640 841 595 596 471 468 
S.D. 81 155 164 376 265 216 
N 4 4 4 4 4 4 
 
Group 1 (IV) - 0 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 5167 3802 3739 4183 3784 4454 
S.D. 2062 1910 2182 1667 1359 1884 
N 4 4 4 4 4 4 
T helper cells 
Mean 2687 2269 2095 2186 2082 2309 
S.D. 721 846 892 629 587 675 
N 4 4 4 4 4 4 
T cytotoxic cell 
Mean 4548.3 1534.5 1648.5 2011.5 1711.3 2131.3 
S.D. 3584 1118 1280 1042 774 1149 
N 4 4 4 4 4 4 
B cells 
Mean 1364 1608 1250 1268 1236 1247 
S.D. 358 431 366 243 250 364 
N 4 4 4 4 4 4 
NK cells 
Mean 798 431 565 672 603 926 
S.D. 727 484 466 398 297 408 
N 4 4 4 4 4 4 
Monocyte 
Mean 865 915 586 568 395 984 
S.D. 96 587 247 321 153 947 
N 4 4 4 4 4 4 
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Group 2 (IV) - 5 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 3962 2994 3803 3551 3983 4092 
S.D. 1447 1851 1567 1684 2031 770 
N 4 4 4 4 4 4 
T helper cells 
Mean 2233 1720 2089 2056 2260 2260 
S.D. 730 895 784 867 1130 154 
N 4 4 4 4 4 4 
T cytotoxic cell 
Mean 1719 1262 1709 1491 1715 1837 
S.D. 735 944 792 835 891 650 
N 4 4 4 4 4 4 
B cells 
Mean 1491 1278 1380 1283 1329 1519 
S.D. 751 781 661 729 458 551 
N 4 4 4 4 4 4 
NK cells 
Mean 900 462 834 688 724 762 
S.D. 112 154 145 166 118 226 
N 4 4 4 4 4 4 
Monocyte 
Mean 461 702 555 799 394 627 
S.D. 221 370 228 603 228 451 
N 4 4 4 4 4 4 
 
 
 
Group 2 (IV) - 5 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 6384 3312 4342 4507 3480 4253 
S.D. 2326 472 1642 1301 1341 2632 
N 3 4 4 4 4 4 
T helper cells 
Mean 3795 2046 2554 2769 2149 2628 
S.D. 1874 300 1520 1203 1039 1941 
N 3 4 4 4 4 4 
T cytotoxic cell 
Mean 2577 1262 1623 1729 1335 1636 
S.D. 443 323 566 147 308 709 
N 3 4 4 4 4 4 
B cells 
Mean 1595 1333 1312 1300 1109 1185 
S.D. 538 303 700 491 406 786 
N 3 4 4 4 4 4 
NK cells 
Mean 1104 406 785 723 835 1049 
S.D. 993 175 268 260 395 355 
N 3 4 4 4 4 3 
Monocyte 
Mean 900 1043 1027 713 688 1380 
S.D. 212 617 365 112 318 1494 
N 3 4 4 4 4 4 
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Group 3 (IV) - 25 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 2817 2451 2519 2455 2483 2695 
S.D. 663 572 546 391 255 934 
N 4 4 4 4 4 4 
T helper cells 
Mean 1787 1521 1582 1542 1479 1625 
S.D. 465 240 348 220 158 589 
N 4 4 4 4 4 4 
T cytotoxic cell 
Mean 1032 932 945 918 1011 1070 
S.D. 249 338 257 268 213 397 
N 4 4 4 4 4 4 
B cells 
Mean 1196 1205 1198 1135 1205 1326 
S.D. 457 434 385 357 392 493 
N 4 4 4 4 4 4 
NK cells 
Mean 971 504 899 804 825 768 
S.D. 487 301 254 240 188 219 
N 4 4 4 4 4 4 
Monocyte 
Mean 807 748 356 395 236 535 
S.D. 309 414 198 201 175 409 
N 4 4 4 4 4 4 
 
 
Group 3 (IV) - 25 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 5925 2705 4790 4670 4337 5214 
S.D. 2684 1454 2629 1774 1769 1964 
N 4 4 4 4 4 4 
T helper cells 
Mean 3167 1638 2555 2560 2254 2700 
S.D. 1115 806 1252 1227 684 796 
N 4 4 4 4 4 4 
T cytotoxic cell 
Mean 2778 1066 2223 2105 2052 2453 
S.D. 1868 826 1779 951 1228 1397 
N 4 4 4 4 4 4 
B cells 
Mean 2217 1948 2064 1994 2269 2289 
S.D. 1583 1576 1472 1240 1718 1511 
N 4 4 4 4 4 4 
NK cells 
Mean 803 266 673 671 721 782 
S.D. 455 174 387 412 378 432 
N 4 4 4 4 4 4 
Monocyte 
Mean 727 1028 934 860 628 605 
S.D. 413 467 242 356 292 338 
N 4 4 4 4 4 4 
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Group 4 (IV) - 125 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 3836 2848 4486 3899 4041 4016 
S.D. 1541 1304 1826 1601 2087 2841 
N 5 5 5 5 5 5 
T helper cells 
Mean 1983 1687 2363 2142 2055 1689 
S.D. 793 878 979 861 908 657 
N 5 5 5 5 5 5 
T cytotoxic cell 
Mean 1851 1159 2116 1754 1980 1370 
S.D. 970 452 1020 833 1351 391 
N 5 5 5 5 5 5 
B cells 
Mean 2482 2353 2567 2366 2611 2331 
S.D. 1499 1749 1732 1465 1436 1363 
N 5 5 5 5 5 5 
NK cells 
Mean 978 462 922 717 826 733 
S.D. 377 325 339 304 177 255 
N 5 5 5 5 5 5 
Monocyte 
Mean 715 858 641 706 506 786 
S.D. 353 527 204 268 442 447 
N 5 5 5 5 5 5 
 
Group 4 (IV) - 125 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
T cells 
Mean 3434 2693 6753 5915 5678 6377 6751 7519 5332 
S.D. 1350 1628 3516 1175 1909 1896 2583 2924 1126 
N 2 2 2 2 2 2 2 2 2 
T helper cells 
Mean 1564 1407 3095 2666 2545 2922 3131 3523 2788 
S.D. 576 646 1276 185 421 257 414 540 98 
N 2 2 2 2 2 2 2 2 2 
T cytotoxic cell 
Mean 1772 1264 3766 3267 3152 3431 3670 3972 2507 
S.D. 726 951 2393 989 1470 1640 2131 2384 975 
N 2 2 2 2 2 2 2 2 2 
B cells 
Mean 1875 1610 1995 1569 1784 1509 1881 1526 1231 
S.D. 455 78 270 245 109 64 294 260 281 
N 2 2 2 2 2 2 2 2 2 
NK cells 
Mean 653 380 691 739 608 598 698 623 622 
S.D. 366 249 69 366 173 148 135 127 322 
N 2 2 2 2 2 2 2 2 2 
Monocyte 
Mean 482 635 728 599 370 439 650 509 718 
S.D. 104 337 342 64 272 45 63 80 202 
N 2 2 2 2 2 2 2 2 2 
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Group 4 (IV) - 125 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
T cells 
Mean 5384 2550 4398 3922 3496 4260 
S.D. 2679 1846 2109 1927 2194 2178 
N 5 5 5 5 5 5 
T helper cells 
Mean 2875 1529 2470 2135 1907 2334 
S.D. 1207 1031 1089 905 1095 1081 
N 5 5 5 5 5 5 
T cytotoxic cell 
Mean 2515 1021 1955 1784 1583 1925 
S.D. 1566 819 1074 1079 1174 1203 
N 5 5 5 5 5 5 
B cells 
Mean 1165 1033 1013 983 1014 1251 
S.D. 656 838 722 555 659 783 
N 5 5 5 5 5 5 
NK cells 
Mean 892 273 694 692 553 965 
S.D. 346 147 448 354 248 543 
N 5 5 5 5 5 5 
Monocyte 
Mean 781 840 649 407 646 609 
S.D. 39 321 292 167 340 208 
N 5 5 5 5 5 5 
 
Group 4 (IV) - 125 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
T cells 
Mean 3110 3554 4754 4143 4463 4474 4457 4591 4351 
S.D. 2195 2720 3424 2701 3055 3454 2883 3177 2203 
N 2 2 2 2 2 2 2 2 2 
T helper cells 
Mean 1775 1937 2419 2149 2332 2324 2338 2374 2416 
S.D. 1406 1526 2015 1604 1741 1959 1590 1755 1162 
N 2 2 2 2 2 2 2 2 2 
T cytotoxic cell 
Mean 1336 1628 2341 2016 2112 2139 2186 2168 1858 
S.D. 846 1208 1415 1129 1315 1505 1199 1346 1129 
N 2 2 2 2 2 2 2 2 2 
B cells 
Mean 1083 1496 1225 1243 980 1003 1018 1170 1245 
S.D. 824 1258 936 949 725 812 690 993 975 
N 2 2 2 2 2 2 2 2 2 
NK cells 
Mean 754 765 802 675 708 731 694 763 691 
S.D. 515 409 166 332 171 428 372 376 241 
N 2 2 2 2 2 2 2 2 2 
Monocyte 
Mean 692 736 684 975 793 831 710 589 936 
S.D. 158 487 86 149 139 151 203 155 0 
N 2 2 2 2 2 2 2 2 2 
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Group 5 (SC) - 75 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time D1(pre-treat) D1(after 6 hrs) D7 D14 D21 D28 
T cells 
Mean 3519 2596 3162 3274 2595 3193 
S.D. 1250 745 777 880 1616 984 
N 5 5 5 5 5 5 
T helper cells 
Mean 2065 1543 1759 1888 1525 1732 
S.D. 1290 734 771 983 1112 974 
N 5 5 5 5 5 5 
T cytotoxic cell 
Mean 1464 1046 1397 1391 1078 1466 
S.D. 585 125 678 493 614 660 
N 5 5 5 5 5 5 
B cells 
Mean 1156 1712 1083 1160 1200 1094 
S.D. 494 417 657 588 710 631 
N 5 5 5 5 5 5 
NK cells 
Mean 892 314 715 555 678 702 
S.D. 685 255 547 408 647 413 
N 5 5 5 5 5 5 
Monocyte 
Mean 334 768 487 454 346 491 
S.D. 238 301 237 181 99 174 
N 5 5 5 5 5 5 
 
Group 5 (SC) - 75 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Males 
Sampling Time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
T cells 
Mean 3171 2875 4514 3909 3721 4323 4767 6175 4611 
S.D. 1276 540 1223 903 506 742 907 512 2057 
N 2 2 2 2 2 2 2 2 2 
T helper cells 
Mean 1818 1527 2513 2012 1861 2195 2632 3080 2734 
S.D. 1800 1288 1990 1505 1440 1639 1788 2151 2384 
N 2 2 2 2 2 2 2 2 2 
T cytotoxic cell 
Mean 1350 1366 2022 1916 1860 2119 2136 3083 1900 
S.D. 540 756 754 603 928 898 962 1665 264 
N 2 2 2 2 2 2 2 2 2 
B cells 
Mean 1842 1665 1568 1201 1138 898 1226 849 857 
S.D. 255 263 158 417 168 237 237 102 192 
N 2 2 2 2 2 2 2 2 2 
NK cells 
Mean 537 640 532 539 505 399 450 799 547 
S.D. 264 140 91 96 146 185 153 213 115 
N 2 2 2 2 2 2 2 2 2 
Monocyte 
Mean 464 568 575 622 393 470 574 315 198 
S.D. 153 52 40 216 158 4 9 413 270 
N 2 2 2 2 2 2 2 2 2 
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Group 5 (SC) - 75 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time D1(pre-treat) D1(after 6 hrs) D7 D14 D21 D28 
T cells 
Mean 6574 5966 6638 5318 4423 5280 
S.D. 2352 2719 2707 1156 883 875 
N 5 5 5 5 5 5 
T helper cells 
Mean 3797 3467 3944 3130 2656 3072 
S.D. 1073 1409 1428 606 591 551 
N 5 5 5 5 5 5 
T cytotoxic cell 
Mean 2787 2495 2692 2171 1751 2189 
S.D. 1315 1324 1287 548 324 359 
N 5 5 5 5 5 5 
B cells 
Mean 1340 2297 1706 1354 1348 1474 
S.D. 557 726 1088 476 532 730 
N 5 5 5 5 5 5 
NK cells 
Mean 1136 753 1027 824 800 950 
S.D. 650 454 527 367 375 418 
N 5 5 5 5 5 5 
Monocyte 
Mean 1309 966 663 748 451 832 
S.D. 1160 964 174 485 254 347 
N 5 5 5 5 5 5 
 
 
Group 5 (SC) - 75 mg/kg - Lymphocyte subsets and Monocytes (cells/µL of blood) - Females 
Sampling Time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
T cells 
Mean 5780 4945 7676 8465 8615 8354 10388 7699 7954 
S.D. 2406 1732 2541 3164 3827 2581 2843 746 1316 
N 2 2 2 2 2 2 2 2 2 
T helper cells 
Mean 3342 2929 3878 4580 4557 4574 5501 4236 4666 
S.D. 1501 1307 1365 1690 1894 1245 1230 238 998 
N 2 2 2 2 2 2 2 2 2 
T cytotoxic cell 
Mean 2454 2003 3805 3927 4042 3717 4870 3425 3297 
S.D. 902 432 1223 1503 1990 1447 1558 629 406 
N 2 2 2 2 2 2 2 2 2 
B cells 
Mean 1652 1955 2120 2607 2576 2205 2459 2180 2383 
S.D. 1168 1223 1456 1864 1962 1462 1201 1143 1168 
N 2 2 2 2 2 2 2 2 2 
NK cells 
Mean 1123 1427 1422 1373 1342 1355 1266 1186 875 
S.D. 19 248 196 23 66 190 17 74 51 
N 2 2 2 2 2 2 2 2 2 
Monocyte 
Mean 623 632 777 467 722 521 1045 785 512 
S.D. 9 50 499 421 383 11 120 19 48 
N 2 2 2 2 2 2 2 2 2 
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Table 10: Hematological parameters - (Mean ± S.D.) 
 
Group 1 (IV) - 0 mg/kg - Hematological parameters (cells/µL of blood) – Males 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 7562.5 4797.5 7072.5 7675.0 6995.0 6917.5 
S.D. 1282.0 1416.7 1382.9 3105.6 3551.8 1596.9 
N 4 4 4 4 4 4 
Neutrophils 
Mean 8081.3 15025.0 4610.0 5527.5 5727.5 6697.5 
S.D. 2753.4 5336.9 2064.4 3256.9 3223.1 4076.4 
N 4 4 4 4 4 4 
WBC 
Mean 16425.0 20725.0 12437.5 13925.0 13400.0 14225.0 
S.D. 2093.4 5736.7 2150.0 2035.3 2353.7 3214.9 
N 4 4 4 4 4 4 
 
Group 1 (i.v.) - 0 mg/kg - Hematological parameters (cells/µL of blood) - Females 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 7527.5 5950.0 5610.0 6297.5 5872.5 6672.5 
S.D. 2122.2 2113.4 2210.1 1540.8 1462.2 1886.4 
N 4 4 4 4 4 4 
Neutrophils 
Mean 4485.0 12892.5 4847.5 3925.0 3905.0 5540.0 
S.D. 974.0 4602.5 1475.1 652.8 1242.4 5766.4 
N 4 4 4 4 4 4 
WBC 
Mean 13250.0 19675.0 11227.5 10920.0 10330.0 13475.0 
S.D. 2074.4 3082.6 2586.0 1492.7 1693.7 5385.4 
N 4 4 4 4 4 4 
 
 
Group 2 (IV) - 5 mg/kg - Hematological parameters (cells/µL of blood) - Males 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 6290.0 4752.5 6022.5 5535.0 6095.0 6525.0 
S.D. 1500.6 2309.3 1546.4 1705.9 2049.2 892.0 
N 4 4 4 4 4 4 
Neutrophils 
Mean 4862.5 12750.0 5832.5 8440.0 5087.5 6627.5 
S.D. 3128.3 6281.6 2709.1 4878.2 4209.7 3829.1 
N 4 4 4 4 4 4 
WBC 
Mean 11665.0 18250.0 12535.0 14875.0 11667.5 14000.0 
S.D. 2737.1 4636.4 2297.2 4006.1 4190.2 2942.8 
N 4 4 4 4 4 4 
 
Group 2 (IV) - 5 mg/kg - Hematological parameters (cells/µL of blood) - Females 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 9230.0 5180.0 6440.0 6700.0 5712.5 6435.0 
S.D. 3808.3 704.1 2447.0 1849.2 2079.0 3850.4 
N 3 4 4 4 4 4 
Neutrophils 
Mean 4750.0 11812.5 6687.5 4837.5 7145.0 5135.0 
S.D. 1669.1 5562.4 2243.1 2299.2 4591.6 2389.4 
N 3 4 4 4 4 4 
WBC 
Mean 15066.7 18175.0 14450.0 12472.5 13547.5 13097.5 
S.D. 5564.5 6260.1 4221.0 2518.8 6414.1 5293.9 
N 3 4 4 4 4 4 
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Group 3 (IV) - 25 mg/kg - Hematological parameters (cells/µL of blood) - Males 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 4700.0 4057.5 4365.0 4215.0 4397.5 4712.5 
S.D. 920.4 900.6 670.8 540.7 297.4 1324.1 
N 4 4 4 4 4 4 
Neutrophils 
Mean 9605.0 14475.0 5992.5 6185.0 3505.0 8450.0 
S.D. 4985.7 3796.8 2456.8 3996.0 1682.4 5087.4 
N 4 4 4 4 4 4 
WBC 
Mean 16912.5 19350.0 10837.5 10945.0 8255.0 13852.5 
S.D. 5343.6 4805.9 2914.7 3684.6 2009.0 5736.7 
N 4 4 4 4 4 4 
 
Group 3 (IV) - 25 mg/kg - Hematological parameters (cells/µL of blood) - Females 
 
Sampling Time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Lymphocytes 
Mean 9047.5 4965.0 7555.0 7445.0 7542.5 8315.0 
S.D. 4034.2 2991.2 4065.4 3049.2 3096.4 3113.7 
N 4 4 4 4 4 4 
Neutrophils 
Mean 4552.5 13150.0 4480.0 4607.5 4762.5 2625.0 
S.D. 1245.7 2200.8 596.2 2723.3 2904.7 1312.8 
N 4 4 4 4 4 4 
WBC 
Mean 14485.0 19225.0 12877.5 12860.0 13087.5 11710.0 
S.D. 5502.6 4377.5 4612.0 5779.4 4856.9 3659.0 
N 4 4 4 4 4 4 
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Group 4 (IV) - 125 mg/kg - Hematological parameters (cells/µL of blood)  
 
Lymphocytes 
Sampling time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Males 
Mean 7194.0 5696.0 7898.0 6904.0 7482.0 6210.0 
S.D. 2794.4 3088.5 3580.6 2943.3 3253.3 2104.9 
N 5 5 5 5 5 5 
Females 
Mean 7520.0 3928.0 6212.0 5754.0 5200.0 6476.0 
S.D. 3162.5 2735.3 2781.2 2404.5 2703.2 2852.9 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 6135.0 4765.0 9830.0 8465.0 8615.0 8820.0 9830.0 10190.0 7510.0 
S.D. 473.8 1831.4 4058.8 530.3 2100.1 1810.2 2786.0 2984.0 1060.7 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 4940.0 5925.0 6980.0 6250.0 6625.0 6470.0 6405.0 6815.0 6560.0 
S.D. 3380.0 4377.0 4553.8 3988.1 4065.9 4780.0 3867.9 4645.7 3521.4 
N 2 2 2 2 2 2 2 2 2 
 
Neutrophils 
Sampling time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Males 
Mean 7362.0 14120.0 4190.0 5272.0 2384.0 7065.6 
S.D. 4136.1 3428.8 1007.4 1948.6 604.2 4048.7 
N 5 5 5 5 5 5 
Females 
Mean 5316.6 12524.0 5740.0 3582.0 4230.0 3458.0 
S.D. 5763.4 4551.5 1799.9 1849.6 2142.3 2432.7 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 2560.0 6270.0 4205.0 2935.0 2730.0 2055.0 3690.0 3810.0 5545.0 
S.D. 1088.9 2998.1 1506.1 502.0 240.4 346.5 1527.4 749.5 601.0 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 1940.0 3245.0 3150.0 4050.0 3732.0 3885.0 3190.0 2260.0 6340.0 
S.D. 523.3 2284.0 1979.9 919.2 3914.5 700.0 2121.3 297.0 3578.0 
N 2 2 2 2 2 2 2 2 2 
 
WBC 
Sampling time D1(pre-treat) D1(after 3 hrs) D7 D14 D21 D28 
Males 
Mean 15370.0 20680.0 12888.0 13040.0 10522.0 14260.0 
S.D. 6315.8 3476.6 3891.2 2133.8 3194.6 3617.0 
N 5 5 5 5 5 5 
Females 
Mean 13784.0 17360.0 12780.0 9850.0 8242.0 10788.0 
S.D. 5995.7 3592.1 1351.7 2617.3 4254.6 3858.1 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 9280.0 11750.0 15000.0 12200.0 11900.0 11550.0 14400.0 14700.0 14450.0 
S.D. 495.0 777.8 5798.3 989.9 2687.0 1343.5 1272.8 3818.4 1484.9 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 7700.0 10110.0 11100.0 11495.0 11505.0 11495.0 10860.0 10155.0 13700.0 
S.D. 4101.2 1682.9 6646.8 5239.7 8478.2 4532.6 6279.1 5579.1 424.3 
N 2 2 2 2 2 2 2 2 2 
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Group 5 (SC) - 75 mg/kg - Hematological parameters (cells/µL of blood)  
 
Lymphocytes 
Sampling time D1(pre-treat) D1(after 6 hrs) D7 D14 D21 D28 
Males 
Mean 5484.0 4722.0 4942.0 5002.0 5030.0 4486.0 
S.D. 1967.2 1106.0 1413.2 1085.5 1532.6 2017.0 
N 5 5 5 5 5 5 
Females 
Mean 9080.0 9044.0 9368.0 7590.0 6748.0 7636.0 
S.D. 2953.4 3430.4 3787.0 1598.6 1351.0 1699.7 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 5585.0 5175.0 6730.0 5725.0 5625.0 5900.0 6810.0 8220.0 6295.0 
S.D. 770.7 459.6 1173.8 601.0 544.5 806.1 806.1 565.7 2100.1 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 8605.0 8350.0 11350.0 12820.0 13045.0 12285.0 14550.0 11400.0 11560.0 
S.D. 3528.5 2757.7 3747.7 5204.3 6017.5 4122.4 4030.5 1838.5 2319.3 
N 2 2 2 2 2 2 2 2 2 
 
Neutrophils 
Sampling time D1(pre-treat) D1(after 6 hrs) D7 D14 D21 D28 
Males 
Mean 4768.0 6736.0 5312.0 4224.0 3938.0 6680.0 
S.D. 2913.3 1715.0 1606.0 2243.3 1820.4 3761.5 
N 5 5 5 5 5 5 
Females 
Mean 5202.0 7394.0 5002.0 5594.0 4042.0 3986.0 
S.D. 1162.7 567.8 2779.0 2470.7 1777.3 1951.9 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 3735.0 3800.0 3140.0 3200.0 3940.0 2290.0 2735.0 2650.0 2345.0 
S.D. 1534.4 2446.6 735.4 989.9 2644.6 1202.1 1718.3 1711.2 968.7 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 4815.0 4515.0 3520.0 4470.0 3075.0 3610.0 5145.0 2400.0 3955.0 
S.D. 2481.9 869.7 1032.4 876.8 1605.1 1583.9 1520.3 551.5 926.3 
N 2 2 2 2 2 2 2 2 2 
 
WBC 
Sampling time D1(pre-treat) D1(after 6 hrs) D7 D14 D21 D28 
Males 
Mean 10624.0 12360.0 10846.0 9828.0 9468.0 11576.0 
S.D. 3261.3 1569.4 2052.1 1411.9 709.8 2656.3 
N 5 5 5 5 5 5 
Females 
Mean 15840.0 17560.0 15260.0 14108.0 11458.0 12720.0 
S.D. 5122.8 4733.2 6325.6 4306.9 2309.2 3766.6 
N 5 5 5 5 5 5 
 
Sampling time W2 rec W4 rec W6 rec W8 rec W11 rec W14 rec W18 rec W23 rec W29 rec 
Males 
Mean 9885.0 9635.0 10600.0 9755.0 10070.0 8780.0 10255.0 11300.0 8885.0 
S.D. 586.9 1930.4 424.3 120.2 2305.2 367.7 912.2 1555.6 883.9 
N 2 2 2 2 2 2 2 2 2 
Females 
Mean 14385.0 13750.0 16100.0 18200.0 17100.0 16700.0 21500.0 14950.0 16300.0 
S.D. 6385.2 3889.1 5798.3 6929.6 8202.4 5939.7 2404.2 2474.9 1555.6 
N 2 2 2 2 2 2 2 2 2 
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5.6 OTHER BIOMARKERS 
 
5.6.1 Natural killer (NK) cell activity 
 
Mean and SD values of NK cell activity as obtained at the various time of analysis are 
graphically reported in Figure 47. 
 
No treatment-related effects were appreciable among the dosed groups. 
The lower values observed in animals dosed at 25 mg/kg at week 5 of treatment was considered 
incidental, and therefore without any biological relevance. 
 
 
 
Fig. 47: Natural Killer cell activity – Males & Females (monkeys) 
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5.6.2 CRS MARKERS (TNFα, IL-6, IFNγ, IL-1β, IL-2, IL-4, IL-10, IL-8, MCP-1) 
 
IL-1β, IL-2 and IFN-γ (Figure 48) as well as TNF-α, IL-4 and IL-10 (Figure 49) did not show 
any significant change over time. 
 
Nor was any effect seen with IL-8. MCP-1 showed a time-effect but this was not statistically 
significant (Figure 50). 
 
The modulation was similar both in the control group and in the treated groups. 
 
Of note, IL-6 level showed a rise at 2h and 6h after the administration of the two higher i.v.doses 
of Anti-CD25. 
This was observed both after the 1st and the 5th administration with the female animals showing 
a slightly higher response (Group 4) (Figure 51). 
The increase in IL6 was also seen once time as clearly reported in (Figure 52). 
This effect indicates the need to evaluate further such possibility at clinically relevant doses 
before any exposure. 
 
 
 
 
Fig. 48: IL-1β, IL-2 and IFN-γ effect over time - control group and all treated groups (monkeys) 
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Fig. 48: TNF-α, IL-4 and IL-10 effect over time - control group and all treated groups (monkeys) 
 
 
 
 
 
 
Fig. 49: IL-8, MCP-1, lL-6 effect over time - control group and all treated groups (monkeys) 
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Fig. 50: lL-6 time- effect within each group  - Males & Females (monkeys) 
 
 
 
 
Fig. 51: lL-6 dose- effect over time within each group  - Males & Females (monkeys) 
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5.7 ANTIBODY DETERMINATION 
 
The method used for the analysis showed that a concentration of 500 ng/mL of Anti-CD25 in the 
sample interfere with the assay. 
Only male animals of all the treated groups (from group 2 to group 5) were found positives for 
the presence of binding antibodies to Anti-CD25 (Table 11). 
Antibodies were revealed starting from week 6 of the recovery period with a mean titer of >100. 
They were detected till the last week of recovery. The positivity remained until the last week of 
the recovery. 
 
Table 11: Antibodies determination – Individual values 
 
Group 1 (0 mg/Kg - IV) Period 2 Period 3 
 time An. 0406025M rec An.0309164F rec 
 Pre-dose Neg. Neg. 
recovery w1 Neg. Neg. 
recovery w4 Neg. Neg. 
recovery w6 Neg. Neg. 
recovery w8 Neg. Neg. 
recovery w27M - w26F Neg. Neg. 
recovery w32 Neg. Neg. 
 
Group 2 (5 mg/Kg - IV) Period 2 Period 3 
 time An. 0401043M rec An.0401208F rec 
 Pre-dose Neg. Neg. 
recovery w1 Neg. Neg. 
recovery w4 Neg. Neg. 
recovery w6 Neg. Neg. 
recovery w8 Neg. Neg. 
recovery w27M - w26F Pos. >1000 Neg. 
recovery w32 Pos. >100 Neg. 
 
Group 3 (25 mg/Kg -IV) Period 2 An. 0402027M rec Period 3 An.0312490F rec 
 time Result Titer Result Titer 
recovery Pre-dose Neg. === Neg. === 
recovery W1 Neg. === Neg. === 
recovery w4 Neg. === Neg. === 
recovery w6 Pos. >>1000 Neg. === 
recovery w8 Pos. >>1000 Neg. === 
recovery w27M - w26F Pos. >>1000 Neg. === 
recovery w32 Pos. >>1000 Neg. === 
 
Group 4 (125 mg/Kg - IV) Period 2  Period 3  
 time An. 0310411M rec An.0404015M rec An.0312210F rec An.0402134F rec 
 Pre-dose Neg. Neg. Neg. Neg. 
recovery w1 Neg. Neg. Neg. Neg. 
recovery w4 Neg. Neg. Neg. Neg. 
recovery w6 Neg. Neg. Neg. Neg. 
recovery w8 Neg. Neg. Neg. Neg. 
recovery w27M - w26F Pos.>100 Neg. Neg. Neg. 
recovery w32 Neg. Pos >100 Neg. Neg. 
 
Group 5 (75 mg/Kg - SC) Period 2  Period 3  
 time An. 0312003M rec An.0401037M rec An.0307140F rec An.0401222F rec 
 Pre-dose Neg. Neg. Neg. Neg. 
recovery w1 Neg. Neg. Neg. Neg. 
recovery w4 Neg. Neg. Neg. Neg. 
recovery w6 Neg. Neg. Neg. Neg. 
recovery w8 Neg. Neg. Neg. Neg. 
recovery w27M - w26F Pos >1000 Pos.>1000 Neg. Neg. 
recovery w32 Pos. >100 Pos. >1000 Neg. Neg. 
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5.8 FUNCTIONAL TEST: T-cell Proliferation assay and Treg cells number 
evaluation 
 
The functional tests were set to evaluate the anti-proliferative and immunomodulatory effect of 
Anti-CD25 mAb. 
 
T cell proliferation assay and FoxP3 evaluation assay were performed at the following time 
point: pre-dose, 24h after the last administration and at 3 recovery time-points (8, 18, 25 weeks 
after the last treatment). 
 
T cell proliferation assay 
 
As shown in Figure53, 24 h after the last administration of 5 mg/kg IV, Anti-CD25 mAb did not 
affect the proliferation rate of anti-CD3, LPS, PHA and IL-2 stimulated cells, except a slight 
decrease (p<0.05, Student’s t test vs predose) in the proliferation index of cells stimulated with 
IL-2 and LPS respectively in the group 3 and group 5 24h after the last treatment. 
 
The recovery periods restored the initial values of proliferation. 
 
The evaluation of T cell proliferation has been performed after each time point (predose and 24h 
after the last treatment), immediately after the bleeding, without any stimulation. 
 
Anti-CD25 mAb administration for 5 weeks in a tox study IV and SC followed by 25 weeks 
recovery period in monkey demonstrated no effect on ex vivo T cell proliferation induced by 
anti-CD3 (0.1-1 μg/ml), IL-2 and LPS. 
 
 
 
Fig. 52: PBMCs proliferation over time - Males & Females (monkeys) 
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FoxP3 evaluation assay: 
 
Anti-CD25 mAb administration significantly decreased T regulatory cell percentage 
(CD4+CD25+FoxP3+). 
In Figure 54, representative dot-plots of two monkeys from group 1 (vehicle) and group 4 (125 
mg/kg IV) are shown. 
PBMCs have been stained for the surface markers CD4 and CD25, and subsequently 
intracellularly for FoxP3. After gating CD4+ cells, CD25+FoxP3+ cells percentages have been 
determined. 
As shown in Figure 55, T regulatory cell percentage was significantly decreased 24 h after Anti-
CD25 mAb administration at 125 mg/kg IV (group 4) and 75 mg/kg SC (group 5) (p<0.05 
Student’s t test vs predose). 
In Figure 56, Treg cells (CD4+CD25+FoxP3+, in light blue) are shown together with 
CD4+CD25+ (yellow), CD4+FoxP3+ (red) and CD25+FoxP3+ cell (orange) percentages. 
The group 4 (125 mg/kg IV) and group 5 (75 mg/kg IV) demonstrated the same decrease of 
CD25+FoxP3+ cells 24 after the last treatment vs the pre-dose time point. 
This evidence strengthen the detected effect of Anti-CD25 mAb on the Treg cells frequency. 
On the other hand, in the group 5 (75 mg/kg SC) a significant decrease of CD4+CD25+ cells has 
been observed. This could be associated to the CD25 receptor down-regulation that occurs 
during Anti-CD25 mAb administration. Notably in the group 5, the recovery periods were not 
able to restore the initial Treg cell rate and, 25 week after treatment Treg cell percentage is still 
lower than the predose value. 
In conclusion, Anti-CD25 mAb significantly decreased the percentage of T regulatory cells 24h 
after the last administration of 125 mg/kg IV and 75 mg/kg SC. 
This effect seems to correlate with the CD25 receptor down-regulation that occurs after 
administration of Anti-CD25 mAb for the 125 mg/kg IV group. 
On the other hand the decrease of Treg cells in the group treated with 75 mg/kg SC seems to be 
closely linked to the decrease of the FoxP3 transcription factor. 
 
 
Fig. 53:FoxP3 staining - dot plots -  Males & Females (monkeys) 
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Fig. 54: FoxP3 evaluation  over time within each group  - Males & Females (monkeys) 
 
 
 
Fig.55: FoxP3 evaluation  over time within each group  - Males & Females (monkeys) 
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6. DISCUSSION  
 
In this study the effects of repeated weekly administration of the test item Anti-CD25 on 
Cynomolgus monkeys were evaluated. 
 
The test item was given by subcutaneous or intravenous route to 22 males and 22 females 
(4 animals/sex for groups 1, 2 and 3 and 5 animals/sex for groups 4 and 5) every week for 5 
consecutive weeks as shown below: 
 
Group 
Doses 
(mg /kg/ week) 
[administr. route] 
Volume of 
administr. 
(ml/Kg) 
Concentr. 
in vehicle 
(mg/ml) 
No. of 
males 
No. of 
females 
Group color 
identification 
1 0 (vehicle)  [IV] 2 0 4 4 white 
2 5 [IV] 2 2.5 4 4 yellow 
3 25 [IV] 2 12.5 4 4 green 
4 125 [IV] 2 62.5 5 5 red 
5 75 [SC] 2 37.5 5 5 blue 
 
During the study general clinical observations, ophthalmological examination, ECG recordings, 
body temperature, body weight and food consumption measurements were carried out. 
 
Laboratory investigations (hematology, blood chemistry and urinalysis), PD markers, NK cell 
activity, CRS markers, antibody determination and toxicokinetic evaluations were also 
performed. 
 
One week after the last treatment 3 monkeys/sex/group were sacrificed for pathology 
investigations, while the remaining animals were subjected to a 28-week recovery period and 
then sacrificed. 
 
 
At 5 mg/kg/week by intravenous route: 
 
No clinical signs were found in any animal. ECG and ophthalmoscopy did not show changes 
versus basal and/or versus control group. 
 
The histological investigations did not reveal any treatment-related variations in any animal as 
well as clinical pathology evaluations. 
 
 
At 25 mg/kg/week by intravenous route: 
 
No clinical signs were found in any animal. ECG and ophthalmoscopy did not show changes 
versus basal and/or versus control group. 
 
The histological investigations did not reveal any treatment-related variations in any animal as 
well as clinical pathology evaluations. 
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At 125 mg/kg/week by intravenous route: 
 
No clinical signs were found in any animal. ECG and ophthalmoscopy did not show changes vs 
basal and/or vs control group. 
 
The histological investigations did not reveal any treatment-related variations in any animal as 
well as clinical pathology evaluations.  
 
 
At 75 mg/kg/week by subcutaneous route: 
 
No clinical signs were found in any animal. ECG and ophtalmoscopy did not show changes vs 
basal and/or vs control group. 
 
The histological investigations did not reveal any systemic treatment-related variations in any 
animal as well as clinical pathology evaluations. The local, subcutaneous and mild reactive 
changes were considered due to the subcutaneous treatment procedure (needle trauma). 
 
The antibodies determination did show that only male animals of all the treated groups (from 
group 2 to group 5) were found positives for the presence of binding antibodies to Anti- CD25. 
The antibodies presence was detected starting from week 6 of the recovery period with a mean 
titer of >100. The positiveness stay until the last week of the recovery. 
 
 
Toxicokinetics evaluation: 
 
Serum level increased between the first and the last treatment at all doses by both administration 
routes. Evaluations were carried out on data from all animals on Day 1 (first treatment) and on 
Day 29 (last, 5th treatment) until 168 hours after both administration routes, then extended to 
recovery animals. 
 
After intravenous doses, concentrations peaked at 0.083-0.5 h, increasing between the sampling 
periods. Acceptable dose proportionality was found. Compound residence in the body, evaluated 
as MRT, was long, about 3 days on both Day 1 and Day 29, with extent to 10-15 days in animals 
of the recovery period. Therefore and as expected, also elimination occurred at very slow rate, 
recording in general half-life of about 4-5 days on Day 1 and Day 29 or longer, 10-15 days, in 
the profiles of the animals that completed the kinetics during the recovery period. Low clearance 
and small distribution volume at the steady-state were found. 
 
In general their values were seen to decrease from Day 1 to Day 29 and to recovery weeks, 
suggesting compound distribution in the extracellular fluids. Accumulation after intravenous 
route was not observed at any doses. 
 
Subcutaneous treatments attained their maxima levels usually within 24 h and showed 
concentrations increased between the first (Day 1) and the last (Day 29) administration. 
Exposure increased with time. The long mean residence time, about 3 days on Day 1 and Day 
29, was still longer, about 15 days, in recovery animals. Similar values were recorded after IV 
doses. Half-life values were 6-7 days on Day1-Day29 and about 10 days in recovery animals. No 
significant compound accumulation was found after multiple SC administration. Bioavailability 
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was 108% after the first treatment and after the last treatment was 112%. 
 
In conclusion, the Anti-CD25 mAb when administered by intravenous or subcutaneous route, did 
not result in any adverse toxicological effect neither regarding clinical observations nor clinical 
and morphological pathology. 
 
However, treatment-related effects, not considered as toxicologically relevant, were observed as 
transient increases in serum IL-6 and reduction in serum immunoglobulins and in the percentage 
of blood Treg-cells were observed. 
 
 
7. CONCLUSION 
 
The overall non clinical development program conducted so far in a pharmacologically 
responsive animal species, the cynomolgus monkey, did not reveal any overt toxicity deriving 
either from on-target or off-target effects of the  Anti-CD25 mAb drug candidate.  
 
There were some modulations of the pharmacodynamics observed and consistent with the 
molecule mode of action such as the binding and saturation of the membrane-bound ligand 
expressed on a minor portion of circulating CD4+cells. The down-modulation of the CD25 
expression was marginal as was the production of host-anti drug antibodies, thus evaluation of 
the safety of the compound was not hindered. There was no evidence of any rebound effects in 
the recovery period.   
 
A safety signal was however detected in the study since an increase in the plasma levels of some 
cytokines involved in the acute phase reaction, i.e.  IL-6, was consistently observed. 
This finding strongly suggests the need to evaluate further the cytokine release potential of 
antiCD25mAb in validated in vitro models with PBMC and whole blood from human subjects, 
either from healthy subjects and patients,  across the putative range of therapeutically significant 
concentrations before investing in any clinical development program.  
 
Results from these in vitro studies together with the data coming from receptor occupancy with 
patient blood cells and  kinetic simulation will help in assessing a provisional benefit-risk for the 
drug candidate and defining the most likely starting dose in "first-in -human clinical trials  " 
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9. LIST OF ABBREVIATION  
 
• IL-2: interleukin-2  
• IL-2R: interleukin-2 receptor 
• MS: multiple sclerosis 
• Treg: regulatory T cell 
• NK: natural killer 
• PTKs: protein tyrosine kinases 
• TCRs: T cell receptors 
• AICD: activation-induced cell death 
• TNF: tumor-necrosis factor 
• DNA: deoxyribonucleic acid 
• ICH: international conference on harmonization  
• GLP: good laboratory practice 
• NOAEL: no observed adverse effect level 
• IV: intravenous 
• SC: subcutaneous 
• PD: pharmacodynamic 
• PK: pharmacokinetic 
• TCR: tissue cross-reactivity 
• ADA: anti-drug antibodies 
• NHPs: nonhuman primates 
• EFD: embryo-fetal development 
• PPND: pre/post-natal development 
• PHA: phytohemagglutinin 
• MFI: mean fluorescence intensity 
• AT: antitrypsin 
• AGP: acid glycoprotein 
• CRP: c-reactive protein 
• PBMC: peripheral blood mononuclear cell 
• IgG: immunoglobulin G 
• IgM: immunoglobulin M 
• i.e.: idem est  
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